







Impact of health warning messages on 













presented to the University of Waterloo 
in fulfillment of the 
thesis requirement for the degree of 
Master of Science 
in 





















I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including 
any required final revisions, as accepted by my examiners. 
 




Tobacco remains the leading preventable cause of death in the world, and 5 million people 
worldwide continue to smoke. Further adding to the problem is the fact that smoking cessation 
rates are very low, and there are some smokers for whom quitting smoking is extremely difficult. 
Many smokers find nicotine replacement therapy (NRT) products unappealing, and even when 
used as directed NRTs only achieve modest cessation rates. Smokeless tobacco (ST) may be 
more appealing than NRT and deliver nicotine in a more palatable way to cigarette smokers. ST 
is also far less harmful than smoking. It is for these reasons that many scientists and health 
professionals have suggested the use of ST as a substitute for smoking to reduce tobacco-related 
harm. 
 
Although the health risk posed by ST appears to be much less than conventional cigarettes, the 
extent to which ST may serve as a harm reduction product is highly contentious. Furthermore, 
although ST products are legal and widely available, it remains unclear whether conventional 
cigarette smokers in Canada will use ST products as a substitute for cigarettes or as a cessation 
aid, if at all. And despite the strong evidence for the effectiveness of cigarette warning labels, 
there is little research on ST health warning labels. 
 
The current study investigated perceptions of ST products with and without HWLs and relative 
health risk messages among 611 young adult Canadian smokers aged 18-30. The study sought to 
examine the impact of ST health warning labels (HWLs) on appeal, willingness to use, and 
perceived health risk and addictiveness. Participants completed a survey during which they were 
asked to view and provide their opinions on a series of ST packages that were digitally altered 
according to each of six experimental conditions: (1) "standard" packages of leading ST brands, 
(2) "standard" packages + a relative risk message about the harm of cigarettes compared to ST 
added, (3) "Standard" packages + text HWL, (4) "Standard" packages + text HWL and relative 
risk message, (5) "Standard" packages + picture HWL, and (6) "Standard" packages + picture 
HWL and relative risk message. 
 
The findings indicate that many smokers are unaware that ST is less harmful to health compared 
to smoking. Despite this, approximately half of young adult Canadian smokers indicated that 
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they were willing to try ST as a substitute for smoking and to help quit smoking. Picture 
warnings increased misperceptions about the health risk of ST and decreased smokers‘ 
willingness to try ST, whereas text warnings did not. Similarly, adding a relative health risk 
message to the warning label that communicates the lower risk of ST compared to cigarettes 
increased willingness to try ST when added to text warnings, and decreased willingness to try ST 
even further when added to picture warnings. This study is among the first to examine ST 
warning labels, and is the first to examine the impact of picture warning labels on ST. Overall, 
the findings suggest picture warnings may make it more difficult to communicate the differences 
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1.0 INTRODUCTION & OVERVIEW 
 
Smokeless tobacco (ST) products have received increasing attention by the tobacco industry and 
public health community. In May, 2007 the Swedish-style ST known as snus was introduced on 
the Canadian market by BAT-Imperial Tobacco Canada using the popular ―du Maurier‖ name 
and brand imagery. Other types of ST have been widely available on the Canadian market, 
including Skoal, Copenhagen, Access, and no legal barriers to their market introduction exist 
(PSC, 2007). 
 
ST comes in various forms that are either placed in the mouth or inhaled, including a finely 
ground or shredded tobacco known as snuff that may be sold loose or in ‗spitless‘ pouches, in 
dry and moist forms; compressed twist and plug forms, and loose leaf forms known as chewing 
tobacco; and newer dissolvable compressed powdered tobacco tablets (Hatsukami et al., 2007). 
All ST products pose significant health risks; however, ST products pose less risk than cigarettes. 
Some types of ST products, such as the ―low-nitrosamine‖ Swedish style of snuff known as snus, 




Although the health risk posed by ST appears to be much less than conventional cigarettes, the 
extent to which ST may serve as a harm reduction product is highly contentious (Hatsukami et 
al., 2007; PSC, 2007). It remains unclear whether conventional cigarette smokers in Canada will 
use ST products as a substitute for cigarettes or as a cessation aid. There are also concerns that 
the use of ST products will increase in the absence of any reduction in combustible product use. 
Increases in the prevalence of ST products also have the potential to serve as ―starter‖ products 
from which young people may transition to cigarettes and other ―higher risk‖ products.  
  
The current study investigated perceptions of ST products with and without health warning 
labels (HWLs) and relative health risk messages among young adult smokers aged 18-30 in 
Canada. Participants completed a survey during which they were asked to view and provide their 
opinions on a series of ST packages that were purchased and digitally altered according to each 
of six experimental conditions: (1) "standard" packages of leading ST brands, (2) "standard" 
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packages of leading ST brands with a relative health risk message about the harm of cigarettes 
compared to ST added, (3) "Standard" packages with text HWLs added, (4) "Standard" packages 
with text HWLs and a relative risk message added, (5) "Standard" packages with picture HWLs 
added, and (6) "Standard" packages with picture HWLs and a relative health risk message added.  
 
The study sought to examine the impact of ST HWLs on cigarette smokers: (1) ST product 
appeal; (2) Intentions to use ST as well as openness to trying ST for a variety of reasons 
including use as a cessation aid, as a long-term replacement, a product for temporary abstinence, 
and in response to smoke-free policies; (3) Perceptions of the relative health risk of different 
types of ST, conventional cigarettes, and nicotine replacement therapy, (4) Beliefs about the 
relative addictiveness of ST, NRT, and cigarettes, and (5) Support for each of picture HWLs and 
relative health risk information on ST packages.  
  
Overall, this study sought to expand the evidence base and address research gaps in this critical 
area, and has the potential to inform initiatives on the development of ST health warning labels 
in Canada, and elsewhere. The findings also provide important information on perceptions of ST 
products with respect to their potential use as a cessation, substitution or replacement product 
among young adult cigarette smokers. 
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2.0  LITERATURE REVIEW 
 
Tobacco is the leading preventable cause of death in the world (WHO, 2008). Twenty-two 
percent of the world‘s adults smoke. By 2030, tobacco-attributable deaths are estimated to 
increase from 5.4 million in 2004 to 8.3 million, and comprise 10% of deaths globally. 
Developing nations will bear 80% of these deaths (WHOWHS, 2008). 
 
Just less than 5 million Canadians, or about 19% of the population, were current smokers in 2006 
(Health Canada, 2006). In 1998, smoking accounted for 22% of all deaths in Canada (47,581 
deaths per year) (Makomaski & Kaiserman, 2004). In 2003, about 26% of Canadians above 15 
years of age were former smokers (Health Canada, 2003). 
 
2.1 Smokeless Tobacco 
2.1.1 Background 
 
Smokeless tobacco (ST) is a product that is receiving increased attention by both the public 
health community and the tobacco industry. There is general consensus that ST use is much less 
harmful to health than smoking cigarettes (Stratton, Shetty, Wallace & Bondurant, 2001; 
Tobacco Advisory Group of the Royal College of Physicians [TAGRCP], 2002; Levy et al., 
2004). The use of ST as a harm reduction tool to reduce or eliminate cigarette smoking is still 
highly contentious among members of the public health community, but has gained some 
support. So far ST has not widely been promoted as a lower risk alternative to cigarettes, or an 
aid to reduce smoking for those trying to quit. Often, the health risk of ST compared to cigarettes 
is exaggerated by public health authorities and tobacco control advocates (Phillips, Wang & 
Guenzel, 2005). On the other hand, the tobacco industry may use ST to support current cigarette 
users and even recruit new ones (Hatsukami, Ebbert, Feuer, Stepanov, & Hect, 2007). Thus 
while there is general consensus that ST carries much less risk than smoking, STs role in tobacco 
control is still disputed (Foulds & Kozlowski, 2007; Gartner et al., 2007; Britton, 2008; Macara, 
2008), and there is much less consensus on how to proceed with regards to ST product 




2.1.2 Patterns of Use 
 
The use of ST varies depending on geographic location. In Sweden, approximately 23% of men 
use ST (i.e., snus) (Foulds et al., 2003), whereas fewer than 1% of Canadians used ST products 
including chewing tobacco or snuff in 2003 (Health Canada, 2003). In 2005, 3.2% of the United 
States (US) population aged 12 or older used ST products in the past month (SAMHSA, 2006). 
In the US, certain groups are known to have higher prevalence of ST use, including men, young 
adults, rural dwellers, those living in southern and western states, Caucasians, American 
Indians/Alaska Natives, and those with low education and blue-collar occupations (Marcus et al., 
1989; CDC, 1991; Nelson et al., 1996; Howard-Pitney & Winkleby, 2002; Tomar, 2002). 
 
2.1.3 Forms and Use 
 
ST products come in numerous forms including moist and dry snuff, chewing tobacco, tobacco 
mixtures, dissolvable compressed powdered tobacco lozenges, and the Swedish style of snuff 
known as snus. The various forms of ST may be used either orally or nasally. ST products have 
also been described as ―non-combustible oral tobacco products‖ (Hatsukami et al., 2007) to be 
more accurate and descriptive, but will continue to be referred to as ST in this paper. 
 
Moist snuff is used orally. It consists of finely ground or shredded tobacco and may be sold loose 
or in small packets known as sachets or pouches. Moist snuff is administered by placing a 
portion between the cheek and gum. Dry snuff is used orally or nasally, and is sold as a fine 
tobacco powder. Chewing tobacco is sold in three main forms: twist, plug, and loose. It is used 
orally by placing a portion in the cheek. Moist snuff and chewing tobacco are commonly called 
―spit tobacco‖ after the method for ending product use. Tobacco may be mixed as well; Alaskan 
natives add the ash from a birch tree fungus to the tobacco leaves; spices and flavourings, areca 
nut, or lime may be mixed with tobacco leaves in India, Southeast Asia, and the United Kingdom 
(Hatsukami et al., 2007).  
 
Newer forms of ―spitless‖ moist snuff contained in pouches and tobacco lozenges are being 
marketed towards current cigarette smokers. Swedish snus is a smokeless form of tobacco 
contained in pouches that is made by heat treating the tobacco rather than fermenting, which 
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tends to decrease the amount of tobacco-specific nitrosamines (TSNAs) and moisture level in 





Smokeless tobacco is known to contain 28 carcinogens, including some TSNAs (Stepanov et al., 
2006). The TSNAs arise from the tobacco curing, processing, and aging process, and are known 
to cause cancers of the oral cavity, esophagus, pancreas, and lung in laboratory animals. There 
are two TSNAs that have been linked to cancer most consistently and strongly: NNK [4-
methylnitrosamino-1-(3-pyridyl)-1-Butanone] and NNN (N-nitrosonornicotine) (Hecht, 1988; 
Hecht, 1998). 
 
There is a large range of TSNAs present in oral forms of ST in the United States (US), Sweden, 
and India. Within the US there are notable differences in TSNA levels between brands of oral ST 
and even among the same brands purchased at different locations (Hoffmann et al., 1994; CDC, 
1999). Overall though, Swedish ST products have uniformly lower TSNA levels than their 
counterparts in the US, which may result to some extent from the GothiaTek® standards set and 
followed by Swedish snus manufacturers (Hatsukami et al., 2007). 
 
Since the public health community is generally concerned with reducing the harm caused by 
smoking when considering LN-ST products, it is important to know whether the lower levels of 
TSNAs in these products result in lower uptake of these carcinogens in the human body than 
cigarettes, and whether switching from cigarettes to ST would result in decreased exposure to 
carcinogens. Only a handful of studies have explored this question. 
 
The concentrations of total NNAL [4-methylnitrosamino-1-(3-pyridyl)-butanol] and NNAL 
glucuronides (NNAL-Glucs), which are NNK metabolites, are used as a biomarker for human 
levels of carcinogens. There was enormous variability in a synthesis of studies comparing 
concentrations of urine total NNAL in users of various ST products, cigarettes (Marlboro), and 
nicotine replacement therapy (Commit). Some ST products resulted in higher urine total NNAL 
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than cigarettes, while some were lower than cigarettes and comparable to the nicotine 
replacement therapy (which is considered relatively innocuous) (Hatsukami et al., 2007). Caution 
should be taken in switching to ST products from cigarettes, as not all products reduce TSNA 
exposure. The data is limited by the fact that some participants were regular ST users, while 
some switched to ST from cigarettes; only a few of the 28 known carcinogens in ST were 
measured; and the data are more than 20 years old and need updating. 
 
Of the studies examining switching to a LN-ST, there can be significant decreases in exposure to 
carcinogens (Hatsukami et al., 2004; Hatsukami et al., 2007). Similarly, studies examining 
switching from cigarettes to lower nitrosamine ST show that there can be drastic reductions in 
exposure to carcinogens, including NNAL (Mendoza-Baumgart et al., 2007). Whether these 
reductions would translate into decreased risk for negative health outcomes is uncertain. 
 
2.1.5 Health Effects 
 
As with toxicant concentrations, the negative health effects of ST may depend on product type 
which in turn may be associated with the products country of origin (Foulds et al., 2003; 
Critchley & Unal, 2003). The potential adverse health effects associated with ST include 
cardiovascular diseases, metabolic disorders, reproductive deficits, and oral and extra-oral 
cancers. However, the evidence is mixed on the degree to which these diseases are attributable to 
ST, if at all in some cases. 
 
In the 52-country INTERHEART study, an association was found between chewing tobacco and 
acute myocardial infarction (Teo et al., 2006). Two large US prospective cohort studies in the 
Cancer Prevention Study, CPS-I and CPS-II, found that chewing tobacco and snuff use were 
associated with and increased risk of coronary heart disease and cerebrovascular disease deaths 
(Henley et al., 2005). In a study of construction workers in Sweden, snus use was associated with 
increased all-kind cardiovascular mortality (Bolinder et al., 1994). In contrast, three population 
case-control studies (Huhtasaari et al., 1992; Huhtasaari et al., 1999; Hergens et al., 2005) and 
one nested case-control study (Asplund et al., 2003) of men in Sweden have found no association 




ST use has also been implicated in the development of metabolic disorders, though not 
consistently. In a population-based cohort study of the Västerbotten Intervention Programme in 
Northern
 
Sweden, heavy Swedish snus use was found to be associated with increased risk for 
developing metabolic syndrome (Norberg et al., 2006). A study of glucose intolerance and 
tobacco use of men in Stockholm, Sweden found that heavy moist snuff use was associated with 
an increase risk of type 2 diabetes (Persson et al., 2000), whereas in a population-based sample 
of healthy men in Sweden moist snuff use was not found to be associated with diabetes or the 
metabolic syndrome (Wallenfeldt et al., 2001). Similarly, the large US Cancer Prevention 
studies, CPS-I and CPS-II, found no increased risk of type 2 diabetes associated with ST use 
(Henley et al., 2005). 
 
ST use has been linked to negative health effects for mothers and their infants, as well as for 
reproductive health in the US, Sweden, and India. In a study of Swedish women who delivered 
singleton infants snuff use was found to be associated with increased risk of low birthweight, 
preterm delivery, and pre-eclampsia (England et al., 2003). Similary, in a study of Alaska Native 
pregnant mothers the use of Iqmik (a tobacco leaf and ash mixture) was found to be associated 
with indicators of neurobehavioural effects on infants (Hurt et al., 2005). For women in Mumbai 
(Bombay), India ST use during pregnancy was found to be associated with low gestational age 
and low birthweight of infant independent of gestational age (Gupta & Sreevidya, 2004), as well 
as increased risk of still-birth (Gupta & Subramoney, 2006). And for male patients undergoing 
infertility evaluations, chewing tobacco use was found to be associated with lower fertility (Said 
et al, 2005). 
 
The data show some associations between ST use and extra-oral cancers. For example, in a study 
of men and women diagnosed with esophageal cancer in Assam, India, betel-quid chewing was 
found to be associated with increased risk for esophageal cancer (Phukan et al., 2001). The large 
US cancer prevention study (CPS-II) found that current use of snuff and chewing tobacco was 
associated with increased risk for all cancers combined, lung cancer, and liver cirrhosis (Henley 
et al., 2005). And two US case-control studies suggested an association for men but not women 
between chewing tobacco use and pancreatic cancer (Muscat et al., 1997) as well as renal cell 
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cancer (Goodman et al., 1986). Interestingly, a study of Norwegian men found an increased risk 
of pancreatic cancer for both current and former ST users (Boffetta et al., 2005). In contrast, two 
Swedish population-based case-control studies found no association between history of ST use 
and any type of gastric cancer (Ye et al., 1999), gastric cardia and esophageal cancers (Lagergren 
et al., 2000). 
 
In October, 2004 the WHO‘s International Agency for Research on Cancer (IARC) working 
group gathered to discuss the risk of ST and related TSNAs. After reviewing the available 
evidence the IARC working group concluded that ST is ―carcinogenic to humans‖ (Cogliano et 
al., 2004). 
 
A narrative systematic review of the literature examining the health risks associated with ST use 
concluded that in India betel-quid chewing was associated with a large risk of oral cancers, with 
approximately 10,000 deaths per year attributable to ST (Critchley & Unal, 2003). Similarly, in a 
US study ST users had an increased risk of cancer of the mouth and gums, pharynx, and salivary 
glands (Stockwell & Lyman, 1986). In another study of women in North Carolina, heavy snuff 
users were at much increased risk of death from oral cancers (Winn, Blot, & Shy, 1981). But in 
two Swedish case-control studies snuff users had no increased risk of oral cancers (Lewin et al., 
1998; Schildt et al., 1998).  
 
ST is found to be associated with several diseases of the teeth and gums, including gingival 
recession (Robertson et al., 1992; Robertson, Walsh & Greene, 1997) and soft tissue lesions 
(Grasser & Childers, 1997; Tomar et al., 1997; Martin et al., 1999). ST might also be associated 
with increased risk of tooth wear (Magnussen, 1991; Bowles et al., 1995), periodontal disease 
(Fisher, Taylor & Tilashalski, 2005) and dental caries (Hart, Brown & Mincer, 1995; Tomar & 
Winn, 1995; Robertson, Walsh & Greene, 1997). 
 
Addictiveness may also be considered a tobacco-related harm. The addictiveness of tobacco is 
proportional to the amount and speed of nicotine delivered. The amount and speed of nicotine 
delivery depends on the products nicotine content, pH, and method of use. The more free non-
ionized nicotine, the higher the pH, and use by smoking compared to other methods results in the 
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greatest addictive potential of a tobacco product (Hatsukami et al., 2007).  
 
ST products tend to exhibit large variation in pH and nicotine content (Hatsukami et al., 2007). 
In the US the ST products with the most nicotine are used most prevalently, and those with the 
least nicotine are used least prevalently (SAMHSA, 2006). ST products such as Ariva and Revel 
administer lower amounts of nicotine, and other products such as Stonewall administer nicotine 
in doses similar to pharmacotherapeutic 4-mg nicotine lozenges (Kotlyar et al., 2007). 
Copenhagen ST has the fastest and highest nicotine delivery properties, similar to that of 
cigarettes (Benowitz et al., 1988). 
 
There are advantages and disadvantages to both lower and higher nicotine ST products. Low 
nicotine ST products may be less addictive, but also less likely to replace cigarettes for current 
smokers. On the other hand higher nicotine products with low TSNAs may be addictive, but they 





There is general consensus that STs are much less harmful to health than cigarettes. The Royal 
College of Physicians (RCP) Tobacco Advisory Group report states that ST is ―10-1000 times 
less hazardous than smoking depending on the product‖, and supports evidence-based regulation 
of ST and harm reduction practices in tobacco control (Royal College of Physicians Tobacco 
Advisory Group [RCPTAG], 2002). And a panel of nine experts assembled to estimate the 
mortality risks of LN-ST concluded that the average relative risk compared to cigarettes for users 
of LN-ST aged 25-49 and 50+ are 9% and 5%, respectively (Levy et al., 2004). Bates et al. 
(2003) conclude based on the available evidence that STs, ―are a very substantially less 
dangerous way to use tobacco than cigarettes.‖ In support of this view they highlight the fact that 
STs are not associated with increased risk of chronic lung diseases or lung cancer; diseases for 
which over half of smoking-related deaths in Europe are attributed. They also point out that the 
evidence is unclear with regards to risk of cardiovascular disease (CVD), but that if CVD risk 
exists it appears to be much less than that associated with smoking.  Futhermore, they note that 
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ST eliminates environmental tobacco smoke, which removes a significant disease risk factor for 
non-smokers including children (Bates et al., 2003).  
 
2.2 Harm Reduction 
2.2.1 Smokeless Tobacco & Harm Reduction 
 
Given the consensus that ST poses much less risk to health than cigarettes (Stratton, Shetty, 
Wallace & Bondurant, 2001; TAGRCP, 2002), the use of ST as a harm reduction tool in tobacco 
control has been suggested (Bates et al., 2003; Kozlowski, O‘Connor & Edwards, 2003; 
Kozlowski, 2007). The Institute of Medicine (IOM) Report on the scientific basis of tobacco 
harm reduction states: ―…a product is harm reducing if it lowers total tobacco related mortality 
and morbidity even though use of that product may involve continued exposure to tobacco 
related toxicants.‖ (Stratton et al., 2001). 
 
The IOM report, Clearing the Smoke, discusses the history of tobacco harm reduction initiatives 
and concludes that none of the many efforts to produce safer cigarettes have been successful. The 
report highlights the case of the ―low yield‖ cigarette, an initiative to reduce tar, carbon 
monoxide, and nicotine delivery. In practice, the ―low yield‖ cigarette failed to reduce harm 
because users compensated for lower yields by modifying the way they smoked - inhaling deeper 
and smoking further towards the filter, for example - in order to receive higher yield (Stratton et 
al., 2001). The failure resulted also, Kozlowski (2001) argues, because many users mistakenly 
believed that ―low yield‖ cigarettes were safer than other cigarettes, and many still do 
(Kozlowski, 2001).  
 
Moreover, population harm was exacerbated for users who would have quit, would have 
remained abstinent after quitting, or would never have started smoking in the first place did not 
do so under the mistaken belief that ―low yield‖ cigarettes were safer (Stratton et al., 2001). The 






2.2.2 Potential Outcomes 
  
Tomar (2007) outlines three ways that overall population harm might be reduced with the use of 
ST, by: (1) preventing cigarette smoking uptake, (2) allowing complete abstinence from 
cigarettes with continued use of a tobacco product, or (3) providing an alternative product to 
partially replace cigarette smoking for smokers who continue to smoke. He discusses each of the 
three ways harm could be reduced, in turn, by reviewing the research. 
 
(1) Preventing cigarette smoking uptake 
  
Tomar discusses two outcomes that would emerge if the use of ST as a harm reduction tool 
actually prevented the uptake of cigarette smoking.  The first is that for the people who take up 
ST, the likelihood of cigarette smoking uptake would be less than those who did not take up ST 
in prospective cohort studies, after accounting statistically for known risk factors for smoking 
uptake. The second is that if the prevalence of ST use grew in young adults under age 25, there 
would be a corresponding decrease in the same groups smoking prevalence. 
  
Tomar concludes that there is insufficient evidence from US prospective cohort studies for ST 
use providing either a protective or preventive effect against the uptake of cigarettes. On the 
contrary, he cites evidence of increased odds of cigarette smoking uptake in those that use ST. 
Tomar argues also that the cross-sectional evidence from Sweden of such a preventive effect is 
biased in excluding certain cohorts that are most likely to use ST, or ignoring the large number of 
current smokers who do not smoke every day. Tomar also looks at secular trends in the US, 
Norway, and Sweden and concludes that there is no evidence of a preventive effect on the uptake 
of cigarette smoking, although he notes that in Sweden snus might have been used by men to 
partially replace smoking. 
  
Concerns about ST acting as a gateway to smoking uptake are valid, especially for youth given 
the tobacco industry‘s history of aggressive marketing to youth (Gartner et al., 2007; Tobacco 
Free Kids, 2008). On the other hand, the evidence from youth snus use in Sweden indicates the 
opposite of a gateway from ST to cigarettes (Foulds et al., 2003; Ramstrom & Foulds, 2006), a 
US study found that ST use did not predict later uptake of smoking when other psychosocial 
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factors were considered (O‘Connor et al., 2003), and a US national survey found only a small 
association, if any, between ST use and smoking (O‘Connor et al., 2005). Kozlowski (2007) 
argues that fears about ST as a gateway to cigarettes are not validated by the evidence (Haddock 
et al., 2001; O‘Connor et al., 2003; Kozlowski et al., 2003; Furberg et al., 2005), that the 
evidence suggests that much of the ST-smoking link is not causal, and that ST may actually offer 
a preventive effect for youth at highest risk of smoking. 
 
(2) Allowing complete abstinence from cigarettes with continued use of a tobacco product 
  
One argument made in favour of harm reduction strategies in tobacco control is the low rate of 
smoking cessation maintenance. Just over half of ever-smokers in Canada in 2003 had quit 
smoking (Health Canada, 2003) and about half (50.2%) of ever-smokers in the US in 2006 were 
currently former smokers (CDC, 2007). Though in 2000, 70% of US smokers say they want to 
quit smoking altogether, but only 4.7% of smokers who smoked most days managed to quit and 
remain abstinent for 3-12 months (CDC, 2002). 
  
Tomar‘s analysis discusses four outcomes that would emerge if the use of ST as a harm 
reduction tool were an effective tool for reducing or abstaining from cigarette smoking. The first 
is that if the prevalence of ST use grew in adults aged 35 and above, there would be 
corresponding increase in the same groups smoking cessation rates. Second, the prevalence of 
smoking and ST use in US states (or Canadian provinces) would be inversely related. Third, a 
greater smoking cessation success rate would be found for users of ST than controls in 
randomised control trials (RCTs). And finally, a higher smoking cessation rate would be found in 
observational studies where known predictors of quitting are adjusted for statistically. 
  
Upon reviewing the evidence, Tomar finds that no RCTs exist that test ST as a cessation method, 
and of the one study that specifically examined snus as a cessation method in US adults a quarter 
had quit smoking using snus at one year follow-up (Tilashalski, Rodu &  Cole, 1998) and 45% 
had quit at seven year follow-up, about half of whom reported using snus (Tilashalski, Rodu &  




Tomar looks also to the evidence from Sweden, where snus might have been used by some men 
to partially replace smoking, and concludes that snus might have a ―modest‖ role in successful 
smoking cessation. There are large gender gaps in ST use in Sweden and Norway, which Tomar 
concludes do not coincide with differences in rates of successful smoking cessation. Tomar also 
looks to US research to determine what proportion of successful smoking cessation is 
attributable to switching to ST, and finds that switching to ST accounts for a small fraction of 
successful smoking cessation. 
  
Smokeless tobacco prevalence in the US varies from less than 1% to 10% in some states, 
according to data Tomar cites from the 2003 Current Population Survey Tobacco Use 
Supplement. He finds that the prevalence of smoking and ST is not inversely related, but 
significantly positively related in the US. 
 
Although STs are proven to be less harmful than smoked forms of tobacco, in public health 
terms nicotine replacement therapies (NRT) are even less harmful (Kozlowski, 2001). NRTs 
come in various forms including nicotine-containing gum, trans-dermal patch, and nasal sprays 
and inhalers. The only toxicant the consumer is exposed to is nicotine. NRTs are generally 
regarded as safe, and as such are offered over-the-counter without prescription throughout most 
of the world (ASH, 2007). Their efficacy as an aid to smoking cessation is well-established 
(Silagy, 2002). 
 
Bates et al. (2003) point out the viability of ST as an alternative to smoking by comparing ST to 
currently available nicotine replacement therapy (NRT). They claim that ST delivers an adequate 
nicotine dose to smokers; delivering a greater arterial nicotine dose or ―spike‖ than all currently 
available NRT products, including nicotine nasal spray, but not quite the dose delivered by 
smoking. So although they say that the addictive properties of nicotine products are in general a 
bad quality, they note that the nicotine delivery characteristics of ST may be why users might 
find it to be a more useful alternative to smoking than current pharmaceutical NRTs.  
 
The possibility that the nicotine delivery characteristics of ST might make it preferable as a 
cessation aid and thereby increasing the success of smoking cessation is reflected in Sweden, 
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where in a study of 25-55 year old former smokers done by The Swedish Cancer Society and the 
Pharmacia Corporation 33% of former smokers reported using snus and 17% reported using 
NRTs during a quit attempt (TEMO, 2001). It is also reflected in more recent data which 
indicates that during a previous quit attempt 55% and 15% of males and females, respectively, 
reported using snus (Ramström, 2002). The same trend of higher use of ST than NRT seen in 
cessation attempts holds in former smokers. The cessation success rate of former smokers is 65% 
for males and 52% for females after using snus, compared to 46% and 32% for males and 37% 
and 30% for females after using nicotine gum and patch, respectively (Ramström, 2002). It 
seems that snus has been especially helpful to smokers who are more nicotine dependant; in a 
study of former smokers the mean score on the Fagerström Test for Nicotine Dependance was 
2.8 for those who had not used ST and 3.4 for those who had used ST (Fagerström & Ramström, 
1998).  
 
Kozlowski (2007) brings up perhaps the most essential point about smoking cessation products, 
which is that consumer preference often matters more than product effectiveness; some people 
prefer ST, some people prefer NRT (whether it be the patch, gum, etc.), and some people prefer 
no help whatsoever in quitting smoking (Kotlyar et al., 2007). 
 
(3) Providing an alternative product to partially replace cigarette smoking for smokers who 
continue to smoke 
 
The partial replacement of cigarettes by ST, or dual-use of the two products by smokers might 
result in a decrease in the overall number of cigarettes smoked. Tomar cites the findings from the 
data of two US national surveys (Tomar, 2002; Hatsukami, Lemmonds & Tomar, 2004) which 
show that compared to exclusive cigarette smokers, dual-users smoke fewer cigarettes. No 
difference in cigarette consumption was evident in occasional ST users compared to non-users of 
ST, but daily ST users smoked less cigarettes than non-users of ST (Tomar, 2002). Overall, 
Tomar concludes that patterns of use indicate that current smokers consume a significant fraction 
of the ST used in the US as an alternate nicotine source. 
 
To put the health risk of the various scenarios ST use into perspective, the risk/use equilibrium 
can be employed. The risk/use equilibrium of tobacco harm refers to public health harm caused 
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by the increased use of a product. Public health suffers if use rates increase faster than risk is 
lowered. But public health benefits if risk is lowered faster than use rates increase. Kozlowski 
(2007) provides an illustrative example, which is that 400% of the population would have to use 
a ST product that is 95% less harmful than cigarettes to equal the harm caused by 20% of the 
population smoking – an impossible scenario. A study comparing smokers who quit tobacco use 
altogether to smokers who switched to using snus exclusively is also illustrative. The study 
found that the health-adjusted life expectancy of the two groups was not significantly different. 
Again, to put the low risk of snus into perspective the study estimated that 14-25 never-smokers 
would have to take up snus use to cancel the health gain derived from a new tobacco user taking 




It remains unclear whether conventional cigarette smokers in Canada will use ST products as a 
substitute for cigarettes or as a cessation aid. There are also concerns that the use of ST products 
will increase in the absence of any reduction in combustible product use. Increases in the 
prevalence of ST products also have the potential to serve as ―starter‖ products from which 
young people may transition to cigarettes and other ―higher risk‖ products. 
 
2.3 What Determines Use? 
2.3.1 Factors to Consider 
 
Whether ST will prevent or promote cigarette smoking, serve as a cessation tool or complete 
replacement for smoking, or be used in conjunction with cigarettes depends on a number of 
factors, including individual stakeholder interests, consumer preferences, socio-cultural context, 
product price, promotion, age, market availability, and product regulation. 
 
The tobacco industry‘s role is to produce and market ST. They are likely to derive a broader 
range of benefits from creating harm reduced products such as LN-ST than the sales of the 
product itself. Developing harm reduced products projects the image of corporate social 
responsibility which benefits public relations, and a tobacco company with a reduced harm 
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product is more competitive. Tobacco companies are reported to be aggressively funding 
research and development of harm reduced products (ASH, 2007).  
 
The pharmaceutical industry‘s NRTs may present a counter-market to cigarettes. Kozlowski 
(2007) says that NRT and ST can be considered in competition for the counter-market to 
cigarettes because they are both ―effective, non-combustible nicotine-delivery systems‖. In 
Canada and a number of other countries, NRT is approved for ―temporary abstinence‖ from 
cigarettes, which Kozlowski points out is a direct parallel to US tobacco industry marketing of 
ST ―for when you can‘t smoke‖ (Polito, 2004) as an alternative to smoking (Hatsukami et al., 
2007). 
 
An important factor to be considered in predictions with regards to ST uptake and public health 
impact is consumer preferences. Kozlowski (2007) states that the most popular tobacco products 
provide sufficient quantities of nicotine, appeal to the user‘s sense of taste and smell, and can be 
used conveniently. When considering whether NRT would be chosen over ST or cigarettes, he 
extends this list to include health risks, image, effectiveness, addictiveness, cost and the ratio of 
cost to nicotine delivery (Kozlowski, 2007).  
 
The socio-cultural context represents an important aspect of a product‘s appeal.  Kozlowski 
(2007) reviewed the past few centuries of tobacco history, noting that ST was much more 
popular than cigarettes in the US during the 19
th
 century, but prohibitions on public spitting in 
the late 1800s (and likely other factors) decreased STs popularity and, by the 1920s, cigarette 
consumption overtook ST. Whether people will use ST depends on social norms, appeal, and 
individual openness to trying. Social norms around ST use in Canada are likely to be different 
than norms in the US, mainly because a lower prevalence rate of ST use. In Canada, ST use is 
below 1% (CTUMS, 2003), compared to 3.2% in the US (SAMHSA, 2006). To date, there are 
no published data on norms or attitudes related to ST products in Canada.  
 
Price is also an important factor in ST use, as with most consumer products. Kozlowski (2007) 
cites econometric evidence of the cross-elasticity of cigarettes, ST, and NRT, indicating that 
when cigarette prices increase so do rates of ST and NRT use (Tauras & Chaloupka, 2003; 
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Gartner et al., 2007). Similarly, data from the US Current Population Survey Tobacco Use 
Supplement (CPS-TUS) show that during the 1980s and early 1990s every 1% increase in 
cigarette price was accompanied by a 10% or more increase in the rate of ST substitution for 
cigarettes (Ohsfeldt et al., 1997; Ohsfeldt et al., 1998).  
 
In Ontario, the average retail price of a pack-a-day cigarette habit is about $52 per week (NSRA, 
2007). The cost of the relatively lower-risk ST snus product currently being test-marketed by 
Imperial Tobacco in Edmonton and Ottawa is expected to be about 80% the cost of a pack of 
premium cigarettes for a tin of 20 sachets (Srikanthan, 2008), or about $33 per week based on 
the average 16 sachet per day use (PSC, 2007). The cost of the NRT is about $53 per week for a 
21 mg (strongest) dose trans-dermal patch, and about $40 per week for 4 mg (strongest) dose 
nicotine gum based on average use of 10 pieces per day. 
 
Promotion is also crucial. ST has been promoted by US tobacco companies ―for when you can‘t 
smoke‖ (Polito, 2004). Kozlowski (2007) notes that STs have not yet been promoted as products 
to help quit smoking, and states that the tobacco companies are unlikely to make such a claim 
because ST is not regulated by the FDA. Such a claim would position ST in competition with 
NRT, which is approved under FDA regulation, which might position ST products within the 
jurisdiction of FDA regulatory authority. Although restrictions on tobacco advertising and 
marketing in Canada are far more comprehensive, ST continues to be promoted through several 
marketing channels, most notably in print advertisements in magazines and in retail displays in 
provinces where displays continue to be allowed.  
 
Age is a key factor determining tobacco use. Young adults between the ages of 18 and 30 
represent a critical group with respect to potential changes in the patterns of ST products. Young 
adulthood is a critical period during which tobacco use behaviour is established (Hammond, 
2005), the age group with the highest smoking prevalence in Canada at 15% for 15-19 year olds 
and 25% for 20-24 year olds, and the group at greatest risk for taking up smoking (CTUMS, 
2007). Industry marketing initiatives—for both cigarettes and ST products—also appear to be 
targeting the workplaces and social settings of young adults (Anon, n.d.; Teague, 1973; Katz & 
Lavack, 2002; Ling & Glantz, 2002; Hammond, Costello & Fong, 2004). The dramatic social 
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changes experienced by young adults during this time in their life may further increase their 
susceptibility to tobacco industry marketing strategies (Hammond, 2005).  
 
2.3.2 Canadian Context 
 
There are currently three tobacco companies operating in Canada: Imperial Tobacco Ltd, JTI-
Macdonald Inc, and Rothmans, Benson & Hedges, Inc. (now owned by Philip Morris 
International) (PSC, 2003). STs have been widely available on the Canadian market, including 
brands such as Skoal, Copenhagen, and Access, and no legal barriers to their market introduction 
exist.  Adult Canadian consumers may freely buy ST just as they may freely buy cigarettes 
where they are legally sold. 
 
In May, 2007 the Swedish-style ST known as snus was introduced on the Canadian market by 
BAT-Imperial Tobacco Canada using the popular ―du Maurier‖ name and brand imagery (PSC, 
2007).
 
In september 2007, Imperial began to test market snus, under its leading du Maurier brand 
at 230 retailers across Edmonton (Doyle, 2007). Then in early 2008, Imperial announced Ottawa 
as its second Canadian test market for the introduction of snus as part of the company‘s ―harm 
reduction‖ program (Srikanthan, 2008).   
 
Overall, there is very little evidence from Canada to indicate which of the outcomes discussed 
above by Tomar (2007) and Kozlowski (2007) are most likely. Their discussion is also with 
regards to the US context, where in 2005, 3.2% of the population aged 12 or older used ST 
products in the past month (SAMHSA, 2006). Currently, less than 1% of Canadians report 
current use of ST (CTUMS, 2003), and less than 1% use ST and cigarettes concurrently 
(O‘Connor et al., 2007). 
 
Other than prevalence estimates, there is a lack of even basic information about ST in Canada, 
including how current smokers perceive ST products, whether Canadian consumers are 
interested in trying ST and if so, for what purpose. In fact, the literature on ST calls for consumer 
testing to determine how features such as labelling and messages affect perceptions of ST, how 
perceptions might affect patterns of uptake and use of ST, and how methods of labelling and 
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health messages can be used to minimise the harm ST products pose to public health (Hatsukami 
et al., 2007). 
 
2.4 Perceptions of Smokeless Tobacco 
 
Perceptions of risk are an important predictor of tobacco use (Weinstein,1999; Romer & 
Jamieson, 2001). If switching to a product such as ST is believed by smokers to offer reduced 
health risk, they may be more likely to do so. Despite scientific consensus that ST poses much 
less risk to health than cigarettes (Stratton et al., 2001; TAGRCP, 2002), the Canadian public as 
well as others appear to be confused about the risks posed by ST. Moreover, it remains unclear 
what consumers think about ST, including perceptions of risk, product appeal, intentions to use 
these products and for what purpose. 
 
Approximately 68% of Canadian smokers are aware of ST products, and of those only 14% 
believe they are less harmful than conventional cigarettes (O‘Connor et al., 2007). The risk of ST 
compared to cigarettes was overestimated in data from adult smokers in Canada, Australia, the 
US, and the UK (O‘Connor et al., 2005; O‘Connor et al., 2007). In a cross-sectional survey of 
US college freshmen, nearly 90% of smoking and non-smoking respondents rated ST to be at 
least as harmful, or more harmful, than conventional cigarettes (Smith, Curbow & Stillman, 
2007). Similarly, a nationally representative sample of US high school seniors found that nearly 
60% of smoking and non-smoking students perceived ST to be of equal or greater risk than 
cigarettes (Tomar & Hatsukami, 2007). And switching from cigarettes to ST was thought to offer 
no risk reduction in about 75% in a large sample of young adults entering the US military, 
regardless of current of past smoking status (Haddock et al., 2004). The aforementioned studies 
come from regions where ST is relatively uncommon. However, data from Swedish men and 
women suggest the same overestimation of the harm of ST relative to smoking (Anon, n.d.). And 
in a recent study of Norwegian adolescents, for whom the LN-ST snus is also commonplace, 
41% still rated ST to be at least as harmful, or more harmful, than conventional cigarettes 
(Overland, Hetland & Aaro, 2008). These findings suggest that people‘s perceptions about the 




2.5 Communicating Risk: Product Health Warning Labels 
2.5.1 Effectiveness 
 
Product health warning labels are among the most direct and cost-effective means of 
communicating the risk of tobacco products. Evidence on the effectiveness of health warnings on 
cigarettes packs indicates that prominent health warnings increase perceptions of risk, promote 
smoking cessation and may lower brand appeal. (Hammond et al., 2003; Hammond et al., 2004; 
Hammond et al., 2007; Thrasher et al., 2007; White, Webster & Wakefield, 2008).  
 
Picture warnings appear to be most effective. Picture warnings may be particularly effective for 
communicating health information to those with lower levels of literacy (Millar, 1996; Createc, 
2003; Siahpush, 2006). Moreover, picture warnings are rated as more effective than text 
warnings for encouraging current smokers to quit and deterring non-smokers from starting 
(O‘Hegarty et al., 2006). Picture warnings also appear to have an impact on Canadian youth, 
with over 90% reporting that picture warnings provided them with health risk information that 
was accurate and made smoking less appealing (Health Canada, 2005). In fact, the health 
warnings on cigarettes packages are looked at and read by young smokers (80%) more than they 
are by adult smokers (66%), the health information on the back and side of cigarette packages is 
read by young smokers (31%) more than adult smokers (20%), and stop smoking tips on the 
back and side of cigarette packages are remembered more by young smokers (31%) than adult 
smokers (11%) (Environics 2004a; Environics 2004b). Overall though, both adults and youth 
report that in response to large graphic warnings they reduced their smoking, and had increased 
motivation to quit (Borland & Hill, 1997; Willemson, 2005; Cavalcante, n.d.). 
 
2.5.2 Current Standards: Packaging and Labeling Regulations 
 
In Canada at the federal level, the Tobacco Act (Health Canada, 1997) contains the regulations 
governing tobacco. Although Canada‘s tobacco regulations require that 50% of the main surface 
of the cigarette package display one of 16 colour graphic and text health warnings prescribed by 
Health Canada, ST products are required to have one of four text health warnings displayed on 
their packaging: 1) ―This product is highly addictive‖, 2) ―This product causes mouth diseases‖, 
3) ―This product is not a safe alternative to cigarettes‖, and 4) ―Use of this product can cause 
21 
 
cancer‖ (Createc, 2003). 
 
2.5.3 Health Canada Proposed Changes 
 
Smokeless tobacco products pose unique challenges for existing tobacco control policies, such as 
those regulating health warnings labels (HWLs). In contrast to the vast body of evidence on 
HWLs for cigarettes (Hammond et al., 2003; Hammond et al., 2004; Hammond et al., 2006; 
Hammond et al., 2007), there is little evidence on the impact and effectiveness of ST HWLs. 
Health Canada`s Tobacco Control Programme has recently begun to address this gap in research 
by commissioning studies to assess the impact and effectiveness of ST HWLs (Createc, 2003; 
HCTCP, 2007). 
 
In Health Canada commissioned focus groups on toxic emissions information displayed on 
packages smokers said they preferred brief, clear statements on one toxicant and its impact on 
health (Envronics, 2003b). Results in a similar Canadian focus group study that looks 
specifically at user perceptions of ST products showed that users had plenty of health risk 
information, but their recall and comprehension of the warnings could be improved. It was also 
found that messages about addiction and diseases of the mouth were viewed as most credible. 
Interestingly, users of ST thought it was addictive but that it carried less risk than combustible 
forms of tobacco for themselves and others because there is no smoke, and more harmful for 
mouth diseases such as lip, mouth and throat cancer because the product is in direct contact with 
those surfaces (Createc, 2003). In the same focus group study, ST users expressed low personal 
impact from the HWLs for various reasons. Some did not want to accept to health risks, since 
they had already switched from cigarettes to ST because of the health risks associated with 
smoking. Some were repulsed by the graphic nature of the images. Some found that the existing 
text-only HWLs on ST did not get their attention and were not convincing (Createc, 2003). 
 
Health Canada is currently in the process of developing new HWLs for all tobacco products, 
including all types of STs, which seek to ensure that tobacco product labelling remains useful 
and appropriate for its intended audiences (Health Canada, 2008). Part of the proposed changes 
for ST include expanding to 30% the portion of the principal display surface of the package 
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covered by a health warning, adding a series of statements with information on the constituent 
and health effects for three classes of toxic constituents (nicotine, lead, nitrosamines), and 
including information about carbohydrate levels to inform users of the large amount of sugar 
added to some STs (HCTCP, 2004). The proposed changes would affect the Tobacco Products 
Information Regulations section of the Tobacco Act (Health Canada, 1997). 
 
2.5.4 Public Support 
 
Along with proposing changes to the health information displayed on tobacco product labels in 
their paper, Building on Success: A Proposal for New Health-Related Information on Tobacco 
Product Labels (HCTCP, 2004), Health Canada solicited comments from stakeholders in 
governmental and non-governmental organisations, the tobacco industry, and the public. Despite 
holding different opinions with regards to the proposed options, most respondents (21 of 25) 
expressed support for the regulatory proposals and specific proposals on health and toxic 
emission/constituent information (HCTCP, 2006). 
 
In addition, the Canadian public seems to support health warning messages on tobacco products, 
find them to be informative, and find them to encourage cessation efforts. In an assessment of the 
graphic health warnings on cigarettes 1.5 years after their implementation over 70% of adult 
smokers and over 90% of youth smokers reported that the warnings effectively informed them 
about the health effects associated with tobacco; over half of adults and youth reported that the 
health warnings discouraged them from smoking around others; and over 40% of adults said the 
warnings have encouraged them to try to quit (WHO TFI, 2005). In a Health Canada 
commissioned focus group study participants expressed support for HWLs; interestingly, to 




However, the existing research on ST HWLs has been largely limited to examining the actual 
message in terms of attitudes about the message, awareness and understanding, and credibility 
(Createc, 2003; HCTCP, 2007). One relatively old study examined the impact of ST health 
warnings on ratings of intentions to use the product, and found that they had no impact 
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(Brubaker & Mitby, 1990). In a study of college aged smokers and non-smokers that examined 
the effect of including picture warning labels on three reduced-exposure products including ST, 
nicotine lozenge, and reduced-harm cigarettes, advertisements with picture warning labels 
resulted in lower ratings of product appeal and safety. Overall, smokers expressed more interest 
than non-smokers in purchasing and using the reduced-exposure products (Stark et al., 2008). 
 
There are a number of challenges and questions remaining with regards to ST HWLs, including 
the following: (1) What portion of the principal display surface to require be covered by the 
warning?, (2) How to design the shape and size of HWLs for STs, which come in a variety of 
package shapes and sizes and make a ‗one-size-fits-all‘ HWL difficult, and (3) Message content, 
including for example, whether to include health risk reduction messages about the relative risk 




Smokeless tobacco (ST) products have received increasing attention by the tobacco industry and 
public health community. Recently, Imperial Tobacco Canada began marketing the Swedish-
style ST known as snus in Canada using the popular ―du Maurier‖ name and brand imagery. 
Other types of ST have been widely available on the Canadian market, and no legal barriers to 
their market introduction exist (PSC, 2007). Currently, less than 1% of Canadians report current 
use of ST (CTUMS, 2003), and less than 1% use ST and cigarettes concurrently (O‘Connor et 
al., 2007). 
 
There are three ways that overall population harm might be reduced with the use of ST, by: (1) 
preventing cigarette smoking uptake, (2) allowing complete abstinence from cigarettes with 
continued use of a tobacco product, or (3) providing an alternative product to partially replace 
cigarette smoking for smokers who continue to smoke. Whether ST will prevent or promote 
cigarette smoking and how it might be used is a complex question that depends on a number of 





Although the health risk posed by ST appears to be much less than conventional cigarettes, the 
extent to which ST may serve as a harm reduction product is highly contentious (PSC, 2007; 
Hatsukami et al., 2007). Other than prevalence estimates, there is a lack of even basic 
information about ST in Canada. It remains unclear how large text or picture warnings on ST 
products would affect consumer perceptions not only with respect to risk, but also with respect to 
whether or not ST products are regarded by cigarette smokers as cessation aids, less hazardous 
alternatives, or products for temporary abstinence from cigarettes. There are also concerns that 
the use of ST products will increase in the absence of any reduction in combustible product use. 
Increases in the prevalence of ST products also have the potential to serve as ―starter‖ products 
from which young people may transition to cigarettes and other ―higher risk‖ products. 
 
Tobacco product warning labels seem to exert a substantial influence on product appeal, 
perceptions of health risk, health risk knowledge, and ultimately tobacco use behaviour.  ST 
products pose unique challenges for existing tobacco control policies, such as those regulating 
HWLs. In contrast to the vast body of evidence on HWLs for cigarettes (Hammond et al., 2003; 
Hammond et al., 2004; Hammond et al., 2006; Hammond et al., 2007), there is little evidence on 
the impact and effectiveness of ST HWLs. Health Canada`s Tobacco Control Programme has 
recently begun to address this gap in research by commissioning studies to assess the impact and 
effectiveness of ST HWLs (Createc, 2003; HCTCP, 2007). Health Canada is currently in the 
process of developing new HWLs for all tobacco products, including all types of STs. 
 
Overall, the study sought to expand the evidence base and address research gaps in this critical 
area, and has the potential to inform initiatives on the development of ST health warning labels 
in Canada, and elsewhere. The findings provide important information on perceptions of ST 
products with respect to their potential use as a cessation, substitution or replacement product 
among young adult cigarette smokers.
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3.0  STUDY RATIONALE & RESEARCH OBJECTIVES 
3.2 Rationale 
 
Other than prevalence estimates, there is a lack of even basic information about smokeless 
tobacco (ST) in Canada. It remains unclear how large text or picture warnings on ST products 
would affect consumer perceptions not only with respect to risk, but also with respect to whether 
or not ST products are regarded by cigarette smokers as cessation aids, less hazardous 
alternatives, or products for temporary abstinence from cigarettes. There are also concerns that 
the use of ST products will increase in the absence of any reduction in combustible product use. 
Increases in the prevalence of ST products also have the potential to serve as ―starter‖ products 
from which young people may transition to cigarettes and other ―higher risk‖ products. 
 
In contrast to the vast body of evidence on health warning labels (HWL) for cigarettes 
(Hammond et al., 2003; Hammond et al., 2004; Hammond et al., 2006; Hammond et al., 2007), 
there is little evidence on the impact and effectiveness of ST HWLs. Health Canada`s Tobacco 
Control Programme has recently begun to address this gap in research by commissioning studies 
to assess the impact and effectiveness of ST HWLs (Createc, 2003; HCTCP, 2007). Health 
Canada is currently in the process of developing new HWLs for all tobacco products, including 
all types of STs. 
 
Overall, the study sought to expand the evidence base and address research gaps in this critical 
area, and has the potential to inform initiatives on the development of ST health warning labels 
in Canada, and elsewhere. The findings also provide important information on perceptions of ST 
products with respect to their potential use as a cessation, substitution or replacement product 
among young adult cigarette smokers. 
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3.2 Research Questions 
 
The current study sought to examine perceptions of ST among young adult cigarette smokers and 
the impact of HWLs on ST products. More specifically, this study examined the following: 
 
1. How do young adult cigarette smokers in Canada perceive ST products with regards to: 
a. Product appeal 
b. Intentions to use 
c. Reasons for use (i.e., potential for use as a cessation aid, in places where they 
cannot smoke, as a less harmful alternative to smoking, etc.) 
d. Health risk and addiction 
 
2. How do young adult cigarette smokers in Canada perceive the health risk and addiction 
of ST products compared to cigarettes and nicotine replacement therapies (e.g., gum, 
patch, etc.)? 
 
3. How are young adult cigarette smokers‘ perceptions about ST products impacted by the 
form of health warning label (HWL) displayed on the products package (i.e., no HWL, 
text HWL, picture HWL)? 
a. Which form of HWL elicits the most accurate perceptions of health risk and 
addiction? 
b. What is the impact of adding a relative health risk message about the health risk 
of ST compared to smoking cigarettes? 
 
4. The extent to which young adult cigarette smokers in Canada support picture HWLs and 
relative health risk messages about the health risk of ST compared to smoking cigarettes? 
 
These questions were examined through the Smokeless Labels Study, a cohort study of 611 




4.0  METHODS 
4.1 Design Overview 
 
The Smokeless Labels Study consisted of a full-factorial, ‗between-subjects‘ experiment in 
which smokeless tobacco (ST) packages, health warning labels (HWLs) and relative health risk 
messages were systematically varied. Participants completed an online survey where they were 
asked to view a series of ST packages that had been purchased, photographed and digitally 
altered according to six experimental conditions: (1) ―Standard‖ packages, (2) ―Standard‖ 
packages with a relative health risk message added, (3) ―Standard‖ packages with a text HWL 
added, (4) ―Standard‖ packages with a text HWL and a relative health risk message added, (5) 
―Standard‖ packages with a picture HWL added, and (6) ―Standard‖ packages with a picture 
HWL and a relative health risk message added. The relative health risk message compared the 







Standard + RR message 
Condition 3: 
Text HWL 
   
Condition 4: 




Picture HWL + RR message 
   
Figure 1. Sample package conditions assigned randomly to participants 





4.2 Participants & Recruitment 
4.2.1 Participants 
 
Participants consisted of 611 young adult male and female Canadians, between 18-30 years of 
age, who were current cigarette smokers at the time of recruitment. Current smokers included 
those who smoked at least once per month, and who smoked at least 100 cigarettes in their 
lifetime. History of ST use was also assessed. Ever-users (current and former) were included 
because they were likely to be a small proportion, though being a ST ever-user may be 
associated with lower ratings of the harm of ST (Overland, Hetland & Aaro, 2008). 
 
The age group of young adults aged 18-30 is important because this age group is more likely to 
take up tobacco use during this time (Hammond, 2005), and industry marketing initiatives 
aggressively target this age group (Anon, n.d.; Katz & Lavack, 2002; Ling & Glantz, 2002; 
Hammond, Costello & Fong, 2004; Teague, 1973). Furthermore, previous studies have chosen 
the age group of 18-34 (Ramstrom, 1990; Ramstrom 2001; Kozlowski et al., 2003). 
 
4.2.2 Recruitment & Remuneration 
 
Participants were recruited from the participant panel of GMI (www.gmi-mr.com), a market 
research service. GMI maintains a panel of participants from over 200 countries, including a 
representative panel of over 400,000 Canadians. To register with GMI, participants first provided 
their contact information and agreed to GMI‘s privacy policy and user agreement. Next, they 
were prompted to check their e-mail for a confirmation notice. Participants were required to click 
on a link contained in a registration e-mail to activate their membership. Additional information 
is available online regarding on GMI‘s registration process 
(http://www.globaltestmarket.com/join.php), privacy policy 
(http://www.globaltestmarket.com/gtm_recruiting/privacypolicy.php), and user agreement 
(http://www.globaltestmarket.com/gtm_recruiting/termsofuse.php). 
 
Respondents in GMI‘s participant pool were invited to participate in the online web survey by e-
mail communication from GMI which included a link to the externally hosted online survey. The 
online survey was hosted by the Survey Research Centre at the University of Waterloo 
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(www.src.uwaterloo.ca). After opening the link to the survey, respondents completed screener 
eligibility and demographic information, and were then shown the study information and consent 
form on their computer screen. Respondents had the option to ―agree‖ and continue to the 
survey, or to ―disagree‖ and end the survey.  
 
Upon survey completion, respondents received minimum remuneration from GMI of $2.50, 
depending on the length of time taken to complete the survey. If, after beginning the survey, the 
survey was ended early or otherwise not completed, the respondents still received partial 
remuneration from GMI. 
 
4.2.3 Effect Size 
 
Samples sizes of 65 respondents in each of the six conditions would provide 80% power to 
detect a "medium" effect size equal to one half the standard deviation of each outcome measure, 
where α=.05, 2-tailed (i.e., 0.5) (Cohen, 1998). Given the lack of historical data using similar 
measures and protocols, more accurate estimates of the effect size associated with the various 
outcomes were not available. A total of 600 respondents, or 100 respondents per condition, 
should therefore provide sufficient power to detect at least a ―medium‖ effect size. 
 
4.3 Survey Protocols 
4.3.1 Screener and Demographic survey, Consent 
 
A screener and demographic survey (see APPENDIX A: Screener & Demographic Information, 
Consent) was completed first. The screener survey included key socio-demographic variables, as 
well as validated measures of tobacco dependence, and prior ST use (CTUMS, 2005). 
Respondents were then shown the study information and consent form. After agreeing to the 
consent form, respondents began the online survey. 
 
4.3.2 Background Survey 
 
The background survey assessed smoking behaviour and smoking cessation, nicotine 
replacement therapy (NRT) knowledge and use, and cigarette warning label impact and 
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awareness (see APPENDIX B: Background). The background survey drew heavily from the 
International Tobacco Control Policy Evaluation Survey (ITC Project, 2008), a telephone-
administered survey of smokers in Canada, the US, the UK, and Australia.  
 
4.3.3 Main Survey 
 
Respondents were then randomly assigned to one of the six experimental conditions (see Figure 
1) and asked to view images of four ST products followed by four NRT products (see Figure 2 
and Figure 3 for a list of products). The presentation order of ST and NRT products was 
randomised. Respondents completed the main survey in two steps. In step 1, respondents viewed 
the images sequentially and completed product-specific ratings for each product they viewed. 
They answered questions regarding their familiarity with the product, how appealing it was, 
whether they would be willing to try to product for a variety of reasons, how likely they would 
be to try it in the future, and how harmful to health they believed it was compared to both 
cigarettes and NRT or ST (see Table 1 and 
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APPENDIX C: Product-Specific Ratings). 
 
Table 1. Product-specific rating measures 
Familiarity 1. Have you ever heard of or seen this product? 
01 – Yes 
02 – No 
03 – Don‘t know 
Appeal  
 
2. Would THIS product appeal to people your age? 
01 – Not at all 
02 – Unlikely 
03 – Undecided 
04 – Somewhat 




3. Would you be willing to try this product for any of the following reasons: 
a. In places where you can‘t smoke cigarettes?  
    (01-YES, 02-NO, 03-MAYBE) 
b. For the times when you don‘t want to smoke around others?  
    (01-YES, 02-NO, 03-MAYBE) 
c. To help you cut back the amount you smoke?  
    (01-YES, 02-NO, 03-MAYBE) 
d. To help you while you are trying to quit smoking? 
    (01-YES, 02-NO, 03-MAYBE) 
e. As a long-term replacement instead of cigarettes?  




4. Overall, how likely would you be to try THIS product in the future? 
01 – Definitely not 
02 – Probably not 
03 – Undecided 
04 – Probably try 




5. In your opinion, how HARMFUL TO HEALTH is this product… 
       a.  Compared to regular cigarettes 
b. Compared to smokeless tobaccos 
c. Compared to nicotine replacement therapy 
01 – A lot less harmful 
02 – Somewhat less harmful 
03 – No difference  
04 – Somewhat more harmful 
05 – A lot more harmful 
 
In step 2 after the respondents had seen all the products they completed general ratings of ST and 
NRT products regarding how addictive they believe the products are, and answered questions 
regarding their support for picture HWLs on smokeless products and relative health risk 
information about the harm of using smokeless compared to smoking cigarettes (see Table 2 and 








(Bansai et al., 
2004) 
 
1. OVERALL, How addictive are smokeless tobacco products compared to 
cigarettes? 
2. OVERALL, How addictive are smokeless tobacco products compared to 
NRT? 
3. OVERALL, How addictive are NRTs compared to cigarettes? 
01 – A lot less addictive 
02 – A little less addictive 
03 – No difference 
04 – A little more addictive 








4. Do you think smokeless tobacco products should have picture health warnings 
similar to cigarette packages? 
01 – Disapprove Strongly 
02 – Disapprove 
03 – Undecided 
04 – Approve 
05 – Approve Strongly 
5. Are you interested in more information that compares the health risks of using 
smokeless tobacco to the health risks of smoking cigarettes? 
01 – Not at all 
02 – Probably not 
03 – Undecided 
04 – Somewhat 
05 – A lot 
 
Lastly, respondents viewed a study feedback letter that thanked them for participating, reminded 
them of the purpose of the study and the confidentiality of their responses, and provided contact 
information should they have any questions (see APPENDIX E: Feedback). 
 
4.4 STs and NRTs Presented 
 
Each respondent was shown a total of four ST package/HWL combinations according to their 
experimental condition, followed by four unmodified NRT packages. Figure 2 and Figure 3 
contain the brands (packages) of STs and NRTs selected for use in this study, respectively. The 
order in which the first four ST packages and HWLs, and the second four NRT packages were 























duMaurier snus Marlboro snus 
  


















 Fresh Mint (4mg) gum NicoDerm
®











Figure 3. NRT products displayed to respondents 
 
A variety of classes of ST were selected. The products in Figure 2 and Figure 3 include leading 
brands sold in the Canadian and United States markets. In Canada, ST is marketed most 
commonly as oral snuff and chewing tobacco (OTRU, 2006). Du Maurier, produced by Imperial 
Tobacco Ltd. is the only snus marketed in Canada.  Marlboro is a popular brand of snus in the 
United States (US), and a well-known brand globally. Copenhagen is a popular brand of snuff in 
US. Ariva is a unique form of ST, being one of the only dissolvable compressed powdered 
tobacco lozenges sold on the US market. Nicorette® and NicoDerm® are popular brands of 
nicotine gum and patch, respectively, sold in Canada. 
 
4.5 Health Warning Labels 
 
Four picture HWLs were selected from a Health Canada commissioned study to test ST HWLs 
(HCTCP, 2007), and digitally modified according to experimental condition. The original large-
font main messages on the Health Canada warnings were retained, but a smaller font narrative 
below each main message was digitally removed because it was too small to be clearly read. The 
text HWLs were identical to the picture HWLs, containing the same text main message with the 
picture digitally removed (see Figure 4). In conditions 2, 4, and 6 a relative health risk message 
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regarding the health risk of smoking cigarettes compared to using ST was added to the 
―standard‖ package, text HWL, and picture HWL respectively, which read, ―Using smokeless 
tobacco is less harmful than smoking cigarettes.‖ The display order of the four text and four 
picture HWLs on individual ST products was counter-balanced across respondents within each 
condition so that each possible combination of package and HWL was displayed and the display 
order was randomised.  The four NRT packages contained the standard health and safety 






















Figure 4. Text and picture health warning messages appearing on packages 
Note: Warnings obtained from Health Canada report (HCTCP, 2007).
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The inclusion of a relative health risk message about the health risk of using ST compared to 
smoking cigarettes addresses concerns that it has not been clearly communicated to the public 
that ST is substantially less harmful to health than cigarette smoking, in light of consistently 
inaccurate beliefs about the relative risk of ST compared to cigarettes and the reduction in risk 
that can be achieved by switching to ST (Anon, n.d.; Haddock et al., 2004; O‘Connor et al., 
2005; O‘Connor et al., 2007; Smith, Curbow & Stillman, 2007; Tomar & Hatsukami, 2007; 
Overland, Hetland & Aaro, 2008). 
 
4.6 Measures 
4.6.1 Screener and Demographic survey, Consent 
 
Eligibility 
The first questions in the background survey on age and history of cigarette and ST use assessed 
eligibility to participate in the survey. The eligibility criteria were: being a current smoker 
between ages 18-30. Survey eligibility was assessed by the questions ―Do you smoke at least 
once a month‖ and ―Have you smoked 100 cigarettes or more in your lifetime?‖ Participants who 
answered ―yes‖ to each question were eligible to complete the survey. Smokeless use was 
assessed using the question ―Have you ever used smokeless tobacco, including chewing tobacco, 
oral snuff, snus, etc.?‖ Age was determined by asking age in years at the time of the survey. 
 
Socio-Demographics 
Participants specified their gender. They were asked to identify their Ethnicity as white, 
Chinese, South Asian, black, Filipino, Latin American, Southeast Asian, Arab, West Asian, 
Japanese, Korean, Aboriginal, Another group. Ethnicity was dichotomised to ―Caucasian‖ and 
―minority‖. Education was assessed by asking respondents highest level of formal education 
completed [grade school or some high school, completed high school, technical or trade school 
or community college (some or completed), some university (no degree), completed university 
degree, post-graduate degree]. Education was re-coded to three categories: Low (grade school or 
some high school, completed high school), moderate [technical or trade school or community 
college (some or completed), some university (no degree)], and high (completed university 
degree, post-graduate degree). Income was assessed by asking respondents total annual 
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household income (Under $14,999, $15,000-$29,999, $30,000-$44,999, $45,000-$59,999, 
$60,000-$74,999, $75,000-$99,999, $100,000-$149,999, $150,000 and over). Income was re-
coded into four categories: Low (Under $14,999, $15,000-$29,999), moderate ($30,000-$44,999, 
$45,000-$59,999), high ($60,000-$74,999, $75,000-$99,999, $100,000-$149,999, $150,000 and 
over), and not given (don‘t know, refuse). 
 
4.6.2 Background Survey 
 
Smoking Behaviour & Smoking Cessation 
Several survey items assessed level of nicotine dependence, quit smoking attempts, and quit 
smoking plans. The heaviness of smoking index (HSI), an accurate measure of level of nicotine 
dependence (Chabrol et al., 2005), was calculated by summing the scores of two categorical 
variables: number of cigarettes smoked per day and the time in minutes between waking and the 
first cigarette of the day. Cigarettes per day (CPD) was assigned a value of 0 for 0-10 CPD, 1 for 
11-20 CPD, 2 for 21-30 CPD, and 3 for 31+ CPD. Time to first cigarette was assigned a value of 
0 for <60 minutes, 1 for 31-60 minutes, 2 for 6-30 minutes, and 3 for less than 5 minutes. 
 
The categorical variable quit intention was created from the responses (within the next month, 
within the next 6 months, sometime in the future, beyond 6 months, not planning to quit) to the 
question ―Are you planning to quit smoking?‖ Quit plan has five categories: Within the next 
month, within the next 6 months, sometime in the future, beyond 6 months, not planning to quit, 
not given (don‘t know, refuse). 
 
4.6.3 Main Survey 
 
Product-Specific Ratings 
In step 1 of the main survey while viewing the product on-screen, participants were asked to rate 
each of the four ST package/HWL combinations and four nicotine replacement therapy packages 
on familiarity and four health-related outcomes: 1) Familiarity, 2) Appeal, 3) Likelihood of 




Familiarity was assessed by asking the question, ―Have you ever heard of or seen this brand?‖ 
The variable familiarity was created from the responses (yes, no) to this question for ST and 
NRT separately. An index measure of overall familiarity was generated separately for ST and 
NRT for answering ‗yes‘ to at least one of the four products. 
 
Appeal was assessed by the question ―Would this product appeal to people your age?‖ The 
variable appeal was created from the responses, dichotomised to ‗Yes‘ (somewhat, a lot) and 
‗Other‘ (not at all, unlikely, undecided) for ST and NRT separately. An index measure of overall 
appeal was generated separately for ST and NRT for answering ‗yes‘ to at least one of the four 
products. 
 
Intentions to use the particular product being shown was assessed by the question ―Overall, how 
likely would you be to try this product in the future?‖ The variable likelihood of future use was 
created from the responses, dichotomised to ‗Yes‘ (probably, definitely) and ‗Other‘ (definitely 
not, probably not, undecided) for ST and NRT separately. An index measure of overall 
likelihood of future use was generated separately for ST and NRT for answering ‗yes‘ to any of 
the four products. 
 
Reasons for using the particular product being shown were assessed by the responses (yes, no, 
maybe) to the question ―Would you be willing to try this product...‖ for five different reasons: 
(1) In places where you can‘t smoke cigarettes, (2) For the times when you don‘t want to smoke 
around others, (3) To help quit smoking cigarettes, (4) As a long-term replacement for 
conventional cigarettes, and (5) To help you cut back the amount you smoke. The responses 
were dichotomised to ‗Yes‘ (yes) and ‗Other‘ (no, maybe). Three indexes were then generated 
for reasons for use: i) a product-specific index for answering ‗yes‘ to at least one of the five 
reasons, ii) a reason-specific index for answering ‗yes‘ for at least one of the four products, and 
iii) an overall index for answering ‗yes‘ to at least one of the five reasons, for at least one of the 
four products. 
 
Relative health risk beliefs were assessed by the responses to the question ―In your opinion, how 
HARMFUL TO HEALTH is this product compared to regular cigarettes?‖ The variables ST-
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cigarette relative risk and NRT-cigarette relative risk were generated separately for ST and 
NRT from the responses, dichotomised to ‗less harmful‘ (a lot less harmful, somewhat less 
harmful) and ‗the same or more harmful‘ (no difference, somewhat more harmful, a lot more 
harmful). An index measure of overall (ST/NRT)-cigarette relative risk was generated 
separately for ST and NRT for answering ‗less harmful‘ to all four products. 
 
General Ratings 
In step 2 of the main survey, following the presentation and rating of all four ST package/HWL 
combinations and four NRT packages, participants will rate: (1) ST and NRT in general on 
relative addictiveness, (2) Support for picture HWLs on ST, and (3) Support for relative health 
risk information on ST. These ratings differ from the product-specific ratings in that the 
participants were not viewing any product and were therefore rating ST, cigarettes, and NRT in 
general. 
 
Beliefs about the relative addictiveness of the three classes of products were assessed by the 
questions ―OVERALL, How addictive are smokeless tobacco products compared to cigarettes?‖, 
―OVERALL, How addictive are smokeless tobacco products compared to NRT?‖, and 
―OVERALL, How addictive are NRT compared to cigarettes?‖. There are five response 
categories (A lot less addictive than..., a little less addictive, no difference, a little more 
addictive, a lot more addictive than...), dichotomized to ―less addictive‖ (A lot less addictive 
than..., a little less addictive) and ―the same or more addictive‖ (no difference, a little more 
addictive, a lot more addictive than...). The variables ST-cigarette relative addictiveness, ST-
NRT relative addictiveness, and NRT-cigarette relative addictiveness were created from 
dichotomised responses. 
 
Questions about perceptions of the addictiveness of ST, cigarettes, and NRT offer additional 
information not obtained by asking the more general question about perceived risk of ST, 
cigarettes, and NRT. This is because in the responses to the more general question about 
perceived risk, an aggregate of many factors, the perceived harm related to addiction and/or 
nicotine may play a role. Thus a participant might reasonably justify a belief that because of 
equivalent levels of nicotine, for example, there is no difference in harm between each product, 
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or that each product places the user at risk for a particular disease such as cancer (Overland, 
Hetland & Aaro, 2008). 
 
Finally, questions regarding level of support for each of picture health warnings and package 
information on relative health risks of smoking cigarettes and using ST were asked. Support for 
each was assessed by the questions, ―Do you think smokeless tobacco products should have 
picture health warnings similar to cigarettes?)‖, and, ―Are you interested in more information 
that compares the health risks of using smokeless tobacco to the health risks of smoking 
cigarettes?‖, respectively. The variables support for picture HWL was created from the 
responses, dichotomised to ―yes‖ (approve, approve strongly) and ―no‖ (disapprove strongly, 
disapprove, undecided). The variable support for RR info was created from the responses, 
dichotomised to ―yes‖ (somewhat, a lot) and ―no‖ (not at all, probably not, undecided). 
 
The complete study protocol was first piloted with 60 respondents, to identify any design or 
survey issues prior to running the full study. No major changes were needed.
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5.0  ANALYSIS 
5.1 Statistical Analyses 
5.1.1 Descriptive Statistics 
 
All analyses were conducted using SPSS version 16.0. Univariate statistics were generated for all 
variables to assess missing values, confirm accurate coding, and examine response distributions. 
Descriptive statistics (means for continuous data and proportions for binary data, standard 
deviation and frequency where applicable) were generated for all independent and outcome 
variables.  
 
ANOVA and chi-square analyses were run to check for differences across conditions for 
continuous and categorical moderators, respectively. Tukey‘s honestly significant difference 
(HSD) test, which is a conservative post-hoc test, was used to test the significance of contrasts. 
 
5.1.2 Regression Analyses 
 
Regression models were used to test for differences between experimental conditions (warning 
label type and relative health risk message) as well as to examine the influence of the 
independent variables of gender, age, smoking status, ethnicity, education, income, HSI, and 
quit intentions. Separate logistic regression models were conducted for binary outcomes, for 
each product individually and overall, including: familiarity; appeal; likelihood of future use; 
reasons for use index; Willing to try when you can‟t smoke, when you don‟t want to smoke, 
to help cut back, to help quit, as a long-term replacement; ST-cigarette relative 
addictiveness; ST-NRT relative addictiveness; NRT-cigarette relative addictiveness; 
support for picture HWL, support for relative risk information. Models were run for the 
overall outcome across the four ST products and four NRT products, and then separately for 
each individual product. 
 
Model building proceeded in three steps. First, the main effects model was run with relative 
health risk message (RR message) and warning label type (WL Type) as the independent 
variable for each of the outcome variables listed above. The three-level WL type variable was 
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run as a ―contrast indicator‖ variable, to compare the differences between each type of warning 
label. In step 2, the two-way interaction between WL type and RR message was added to the 
main effects model, and was retained in step 3 if statistically significant at the p=.05 level. In 
step 3, the independent variables were added  
 
5.1.4 Summary Comparisons between ST and NRT 
 
McNemar symmetry chi-square test was performed to examine differences between ST and NRT 
response proportions for the following outcomes measures: appeal; likelihood of future use; 
reasons for use index; willing to try when you can‟t smoke, when you don‟t want to smoke, 




6.0   RESULTS 
 
Table 3 displays the sample characteristics of the young adult smokers by experimental 
condition. The sample was a little over half male, with a mean age of 24.8 years. About three-
quarters of respondents were daily smokers, and the mean number of cigarettes smoked per day 
was 10.05. Only 17.3% of participants had ever used smokeless tobacco (ST) and, of those, only 
8.8% had used it in the past month. Nearly a quarter of respondents were of minority ethnicity. 
The income distribution of the respondents was skewed towards higher income level, and 3.5% 
of respondents did not report any income information. Around a quarter of respondents fell into 
each of the low and high categories of education level, whereas around half fell into the 
moderate category of education level. Just over three-quarters (75.3%) of respondents reported 
being employed outside the home. About half of respondents reported that they were planning to 
quit within six months, and about half reported they were planning to quit beyond six months or 
not planning to quit. Just over two-thirds (68.8%) reported making a quit attempt in the past two 
years.  
 
Almost all respondents were aware of nicotine replacement therapy (NRT) (94.4%), and just 
under half (47.5%) had ever used NRT and 2% could not remember if they had used it. Of those 
respondents who had ever used NRT, many had used gum (45.7%) and patch (31.3%); and 
relatively few had used lozenges (6.9%), tablets (2.3%), inhaler (6.9%), nasal spray (1.1%), 
prescription Zyban (8.5%) or Wellbutrin (4.6%), and other NRT (9.0%). Respondents reported 
using NRT ―to stop smoking completely‖ (59.4%), ―to reduce the amount you smoke‖ (21.6%), 
―to cope with times when you could not smoke or were not allowed to smoke‖ (10.3%), and for 
―other reasons‖ (8.8%). 
 
ANOVA and chi-square analyses were run to check for differences across conditions for 
continuous and categorical moderators, respectively. There was a significant effect for age 






Table 3. Characteristics of the sample of young adult smokers (n=611), by experimental condition and 
overall 














Overall   
(n=611) 
Moderator % % % % % % % (n) 
Gender         
     Women 49.0% 60.0% 61.3% 49.0% 52.5% 49.0% 53.5% (327) 
     Men 51.0% 40.0% 38.7% 51.0% 47.5% 51.0% 46.5% (284) 














Smoking Status         
     Daily 74.0% 81.0% 68.9% 77.9% 72.7% 74.5% 74.8% (457) 
     Weekly 19.0% 12.0% 21.7% 14.4% 15.2% 10.8% 15.5% (95) 
     Monthly 7.0% 7.0% 9.4% 7.7% 12.1% 14.7% 9.7% (59) 
Ethnicity         
     White 79.0% 75.0% 72.6% 77.9% 78.4% 77.5% 76.7% (467) 
     Minority 21.0% 25.0% 27.4% 22.1% 21.6% 22.5% 23.3% (142) 
Income         
     Low 22.4% 26.8% 27.5% 19.8% 21.9% 29.0% 24.6% (146) 
     Mod 37.8% 33.0% 29.4% 44.6% 29.2% 33.0% 34.5% (205) 
     High 36.7% 40.2% 36.3% 30.7% 44.8% 36.0% 37.4% (222) 
     Not Given 3.1% 0% 6.9% 5.0% 4.2% 2.0% 3.5% (21) 
Education         
     Low 29.3% 27.0% 28.3% 26.9% 31.3% 28.4% 28.5% (174) 
     Mod 51.5% 55.0% 38.7% 48.1% 43.4% 46.1% 47.0% (287) 
     High 19.2% 18.0% 33.0% 25.0% 25.3% 25.5% 24.4% (149) 
HSI         
     0 33.7% 20.2% 34.0% 21.7% 29.3% 25.0% 27.4% (153) 
     1 10.5% 11.7% 11.7% 18.5% 12.0% 14.1% 13.1% (73) 
     2 22.1% 13.8% 23.4% 27.2% 21.7% 21.7% 21.6% (121) 
     3 13.7% 31.9% 19.1% 13.0% 19.6% 22.8% 20.0% (112) 
     4 16.8% 16.0% 7.4% 14.1% 12.0% 10.9% 12.9% (72) 
     5 3.2% 6.4% 4.3% 5.4% 5.4% 5.4% 5.0% (28) 
     6 0% 0% 0% 0% 0% 0% 0% (0) 
Quit Intention         
     Within 1 month 19.0% 17.0% 17.0% 18.3% 30.3% 23.5% 20.8% (127) 
     Within 6 months 29.0% 30.0% 25.5% 28.8% 20.2% 23.5% 26.2% (160) 
     Beyond 6 months 38.0% 39.0% 34.9% 32.7% 37.4% 36.3% 36.3% (222) 
     Not planning to quit 9.0% 9.0% 17.0% 16.3% 9.1% 12.7% 12.3% (75) 
     Not given 5.0% 5.0% 5.7% 3.8% 3.0% 3.9% 4.4% (27) 
 
6.1 Smokeless Tobacco 
6.1.1 Familiarity 
 
Respondents were asked if they had seen or heard of four ST products. Table 4 indicates that 
overall, 49.2% indicated that they were familiar with at least one of the ST products. 














At least one 
„yes‟ for all 
four products 
Condition % Yes % Yes % Yes % Yes % Yes 
1-No WL 11.1 10.2 44.9 8.2 54.3 
2-No WL+RR 13.0 18.0 42.9 11.3 53.7 
3-Text WL 17.1 17.9 34.0 11.3 45.7 
4-Text WL+RR 15.4 9.6 34.6 11.7 50.5 
5-Pic WL 15.2 8.2 38.1 8.2 46.9 
6-Pic WL+RR 14.7 9.9 31.7 9.8 45.0 
Overall 14.4 12.4 37.6 10.1 49.2 
Response options: 1 - No, 2 – Yes 
 
 
Table 5 displays the binary logistic regression model examining overall product familiarity. No 
differences were observed across experimental conditions. Males had higher odds of familiarity. 
Older respondents, and those who were not planning to quit compared to those planning to quit 
















Table 5. Adjusted binary logistic regression model for overall product familiarity (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.177 0.84 0.54-1.31 0.436 
     Pic vs. No WL -0.423 0.66 0.42-1.03 0.067 
     Pic vs. Text WL -0.245 0.78 0.50-1.23 0.285 
Gender (ref=female) 0.987 2.68 1.84-3.91 <.001 
Age -0.062 0.94 0.89-1.00 0.040 
Smoking Status (ref=daily) 
2
=0.397 0.820 
     Weekly 0.073 1.08 0.60-1.94 0.807 
     Monthly 0.225 1.25 0.62-2.54 0.533 




     Mod 0.211 1.23 0.80-1.91 0.345 
     High 0.086 1.09 0.63-1.88 0.758 
Income (ref=low)  
2
=3.84  0.279 
     Mod 0.297 1.35 0.83-2.20 0.234 
     High 0.443 1.56 0.95-2.56 0.080 
     Not given -0.237 0.79 0.26-2.43 0.679 
HSI 0.096 1.10 0.96-1.26 0.169 
Quit Intention (ref=Within 1 month) 
2
=12.00 0.017 
     Within 6 months -0.209 0.81 0.48-1.38 0.440 
     Beyond 6 months -0.494 0.61 0.37-1.00 0.051 
     Not planning to quit -0.698 0.50 0.25-0.98 0.045 
     Not given 1.150 3.16 0.92-10.86 0.068 
Model Adjusted R Squared 0.094 
 
Table 6 shows results from the adjusted binary logistic regression model examining the same 
familiarity outcome for each of the four ST separately. No differences were observed across 



































RR Message -0.073 0.92 
0.56-
1.54 
0.777 0.167 1.18 
0.69-
2.03 
0.543 -0.381 0.68 
0.47-
0.99 




WL Type 2=1.46 0.482 2=3.98 0.137 2=3.95 0.139 2=1.66 0.436 
     Text vs. No WL 0.350 1.42 
0.77-
2.63 
0.265 -0.160 0.85 
0.46-
1.58 
0.612 -0.298 0.74 
0.47-
1.17 




     Pic vs. No WL 0.058 1.06 
0.56-
2.00 
0.857 -0.695 0.50 
0.25-
1.00 
0.050 -0.454 0.64 
0.40-
1.01 




     Text vs. Pic WL -0.292 0.75 
0.40-
1.38 
0.351 -0.536 0.59 
0.29-
1.19 
0.137 -0.156 0.86 
0.54-
1.37 




Model Adjusted R 
Squared 






Respondents were asked if the ST products would appeal to people their age. Table 7 indicates 
that overall, 53.0% indicated that at least one of the ST products would appeal to people their 
age. Respondents indicated that duMaurier would appeal most and Copenhagen would appeal 
least to those their age. 
 










At least one 
„yes‟ for any 
four products 
Condition % Yes % Yes % Yes % Yes % 
1-No WL 30.6 29.3 18.8 39.2 67.0 
2-No WL+RR 45.4 29.5 16.1 38.7 63.3 
3-Text WL 38.8 32.0 16.5 30.1 57.3 
4-Text WL+RR 40.6 32.4 13.7 36.3 59.0 
5-Pic WL 18.1 12.8 16.7 9.4 31.9 
6-Pic WL+RR 22.2 21.0 16.2 20.6 38.9 
Overall 32.7 26.3 16.3 29.1 53.0 
Response options: 1 –Not at all, 2 –Unlikely, 3 –Undecided, 4 –Somewhat, 5 – Very 
*Dichotomised to ‗Yes‘ (4-5) and ‗Other‘ (1-3) 
 
Table 8 displays the binary logistic regression model examining overall product appeal. The 
main effect of viewing a health warning was significant. Specifically, those who viewed products 
with a picture warning label had lower odds of appeal compared to those who viewed products 
with either a text warning or no warning. Those who smoked weekly compared to daily, ethnic 








Table 8. Adjusted binary logistic regression model for overall product appeal (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.255 0.77 0.49-1.24 0.284 
     Pic vs. No WL -1.370 0.26 0.16-0.41 <.001 
     Pic vs. Text WL -1.109 0.33 0.21-0.53 <.001 
Gender (ref=female) 0.322 1.38 0.93-2.04 0.105 
Age -0.044 0.96 0.90-1.02 0.160 
Smoking Status (ref=daily) 
2
=6.38 0.041 
     Weekly 0.829 2.29 1.20-4.36 0.012 
     Monthly 0.215 1.24 0.60-2.56 0.562 




     Mod -0.099 0.91 0.57-1.43 0.674 
     High 0.079 1.08 0.61-1.91 0.786 
Income (ref=low)  
2
=13.74  0.003 
     Mod 0.260 1.30 0.78-2.16 0.317 
     High 0.822 2.28 1.35-3.83 0.002 
     Not given -0.643 0.53 0.16-1.71 0.284 
HSI 0.039 1.04 0.90-1.20 0.598 
Quit Intention (ref=Within 1 month) 
2
=3.906 0.419 
     Within 6 months -0.284 0.75 0.43-1.31 0.317 
     Beyond 6 months -0.203 0.82 0.48-1.38 0.451 
     Not planning to quit -0.709 0.49 0.24-1.03 0.059 
     Not given 0.081 1.08 0.32-3.67 0.897 
Model Adjusted R Squared 0.137 
 
Table 9 shows results from the adjusted binary logistic regression model examining the same 
appeal outcome for each of the four ST products separately. For duMaurier, the main effect of 
viewing a relative risk message was significant, and was associated with increased odds of 
appeal. For duMaurier, Marlboro, and Ariva, the main effect of viewing a health warning was 
significant. More specifically, viewing a picture warning label increased odds of appeal 
compared to viewing either text or no warning. 
 
Viewing a relative risk message was not significantly associated with appeal in the main effects 
model for duMaurier (2=3.26, p=.071), but became significant when the predictors were added 


































RR Message 0.493 1.64 
1.10-
2.43 
0.014 0.300 1.35 
0.89-
2.04 
0.156 -0.119 0.89 
0.55-
1.43 




WL Type 2=20.53 <.001 2=12.77 0.002 2=0.390 0.82 2=26.09 <.001 
     Text vs. No WL 0.138 1.15 
0.73-
1.81 
0.551 0.178 1.20 
0.74-
1.92 
0.463 -0.094 0.91 
0.51-
1.64 




     Pic vs. No WL -0.971 0.38 
0.23-
0.63 
<.001 -0.760 0.47 
0.28-
0.80 
0.005 -0.186 0.83 
0.46-
1.49 




     Text vs. Pic WL -1.109 0.33 
0.20-
0.55 
<.001 -0.938 0.39 
0.23-
0.67 
0.088 -0.092 0.91 
0.50-
1.66 




Model Adjusted R 
Squared 




6.1.3 Likelihood of Future Use 
 
Respondents were asked how likely they would be to try each product in the future. Table 10 
shows that overall, 43.6% indicated that they were likely to try at least one of the ST products. 
Respondents indicated that they would be most likely to try Ariva and least likely to try 
Copenhagen. 
 











At least one 
























1-No WL 53.5 26.5 24.5 25.5 13.3 8.2 32.0 32.0 49.0 
2-No WL+RR 19.2 45.5 26.3 27.3 19.6 12.4 34.0 39.2 63.5 
3-Text WL 23.1 20.2 20.4 23.3 14.6 10.7 23.5 23.5 35.6 
4-Text WL+RR 17.5 35.0 18.6 26.5 16.5 7.8 24.5 34.3 55.6 
5-Pic WL 27.1 14.6 21.9 11.5 6.2 8.2 27.1 13.5 26.6 
6-Pic WL+RR 15.7 19.6 12.7 18.6 9.8 8.8 24.2 19.2 31.3 
Overall 20.9 26.9 20.7 22.2 13.3 9.3 27.5 27.0 43.6 
Response options: 1 - Definitely not, 2 - Probably not, 3 - Undecided, 4 - Probably try, 5 - Definitely try 
*Dichotomised to ‗Yes‘ (4-5) and ‗Other‘ (1-3) 
 
 
Table 11 displays the logistic regression model examining overall likelihood of future use. The 
main effects of viewing a relative risk message and a health warning were both significant. 
Participants who viewed a relative health risk message on products had higher odds of reporting 
future use, while those who viewed a picture warning label had lower odds of reporting future 
use compared to those who viewed either a text warning or no warning. Minorities also had 




Table 11. Adjusted binary logistic regression model for overall likelihood of future product use (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.365 0.69 0.45-1.08 0.109 
     Pic vs. No WL -1.320 0.27 0.17-0.43 <.001 
     Pic vs. Text WL -0.955 0.39 0.24-0.62 <.001 
Gender (ref=female) 0.201 1.22 0.83-1.79 0.303 
Age -0.050 0.95 0.90-1.01 0.104 
Smoking Status (ref=daily) 
2
=0.54 0.763 
     Weekly 0.117 1.12 0.62-2.04 0.699 
     Monthly -0.189 0.83 0.40-1.72 0.613 




     Mod -0.131 0.88 0.56-1.38 0.571 
     High 0.260 1.30 0.74-2.27 0.361 
Income (ref=low)    0.191 
     Mod 0.276 1.32 0.80-2.17 0.277 
     High 0.433 1.54 0.93-2.55 0.091 
     Not given -0.603 0.55 0.16-1.88 0.338 
HSI -0.084 0.92 0.80-1.06 0.243 
Quit Intention (ref=Within 1 month) 
2
=7.77 0.101 
     Within 6 months 0.265 1.30 0.76-2.25 0.340 
     Beyond 6 months 0.507 1.66 0.99-2.79 0.054 
     Not planning to quit -0.226 0.80 0.39-1.64 0.538 
     Not given -0.353 0.70 0.22-2.24 0.551 
Model Adjusted R Squared 0.127 
 
 
Table 12 shows results from the adjusted logistic regression model examining the same 
likelihood of future use outcome for each of the four ST products separately. For duMaurier and 
Ariva, the main effect of viewing a relative health risk message and a health warning were both 
significant.  For Marlboro, the main effect of viewing a health warning was significant. For 
duMaurier, Marlboro, and Ariva, participants viewing a health warning label had lower odds of 
reporting future use, and participants viewing a relative risk message had higher odds of 
reporting future use. Specifically, participants who viewed a picture warning label had lower 


































RR Message 0.843 2.32 
1.53-
3.53 
<.001 0.401 1.49 
0.96-
2.31 
0.072 -0.012 0.99 
0.54-
1.83 




WL Type 2=16.82 <.001 2=9.97 0.007 2=0.45 0.798 2=25.04 <.001 
     Text vs. No WL -0.323 0.72 
0.45-
1.16 
0.177 -0.078 0.92 
0.56-
1.52 
0.757 -0.073 0.93 
0.44-
1.94 




     Pic vs. No WL -1.102 0.33 
0.20-
0.56 
<.001 -0.84 0.43 
0.25-
0.75 
0.003 -0.254 0.78 
0.37-
1.65 




     Text vs. Pic WL -0.779 0.46 
0.27-
0.79 
0.004 -0.764 0.47 
0.27-
0.82 
0.008 -0.180 0.84 
0.39-
1.80 




Model Adjusted R 
Squared 
0.104 0.098 0.065 0.103 
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6.1.4 Reasons for Product Use 
 
Respondents were asked whether they would be willing to try each of the four ST products for 
five reasons. Three indexes were generated: i) a product-specific index for answering ‗yes‘ to at 
least one of the five reasons, ii) a reason-specific index for answering ‗yes‘ for at least one of the 
four products, and iii) an overall index for answering ‗yes‘ to at least one of the five reasons, for 
at least one of the four products. Though the overall index takes into account only ‗yes‘ 
responses, it is worth noting that at least 95% of respondents answered ‗yes‘ or ‗maybe‘ to at 
least one of the five questions about willingness to try at least one of the four ST products. 
 
Reason #1: Willing to try ST in places where you cannot smoke. 
 
Table 13 shows that overall, nearly half (48.9%) of the respondents answered that they were 
willing to use at least one of the four ST products in places where they cannot smoke. 
Respondents were most willing to try duMaurier and least willing to try Copenhagen. 
 
Table 13. Responses* to the question, ―Would you be willing to try this product in places where you 










At least one 





















1-No WL 47.5 32.3 52.0 29.6 82.7 10.2 40.8 34.7 55.7 
2-No WL+RR 37.1 30.9 47.9 28.1 74.7 13.7 29.6 34.7 54.3 
3-Text WL 52.0 27.5 58.3 18.4 76.0 14.4 53.4 22.3 48.5 
4-Text WL+RR 44.2 34.6 51.5 30.7 82.5 11.7 40.8 28.2 57.0 
5-Pic WL 68.0 21.6 67.7 24.7 81.6 12.2 64.9 28.9 47.8 
6-Pic WL+RR 67.6 16.7 72.5 14.7 85.1 5.0 67.0 13.0 30.3 
Overall 52.7 27.3 58.3 24.3 80.5 11.2 49.4 26.9 48.9 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
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Table 14 displays the logistic regression model examining ‗willingness to try where you can‘t 
smoke‘ index. No differences were observed across experimental conditions. Participants 
reporting a moderate income level had higher odds of reporting willingness to try at least one 
product. The interaction between warning label and relative risk message was significant in the 
main effects model, and was therefore included in the full model. In the full model, the 




Table 14. Adjusted binary logistic regression model for overall ‗willingness to try where you can‘t 
smoke‘ index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.651 0.52 0.13-2.06 0.352 
     Pic vs. No WL 0.575 1.78 0.44-7.13 0.417 
     Pic vs. Text WL 1.226 3.41 0.84-13.83 0.086 
RR Message (by WL Type) 
2
=7.05 0.030 
     For Text WL 0.320 1.38 0.58-3.29 0.472 
     For Pic WL -0.855 0.43 0.17-1.04 0.060 
Gender (ref=female) 0.193 1.21 0.83-1.77 0.314 
Age -0.008 0.99 0.94-1.05 0.787 
Smoking Status (ref=daily) 
2
=0.82 0.665 
     Weekly -0.243 0.78 0.44-1.40 0.411 
     Monthly 0.054 1.06 0.52-2.14 0.882 




     Mod -0.171 0.84 0.54-1.30 0.443 




     Mod 0.551 1.73 1.06-2.84 0.028 
     High 0.470 1.60 0.97-2.63 0.064 
     Not given 1.118 3.06 0.94-9.99 0.064 
HSI 0.032 1.03 0.90-1.19 0.648 
Quit Intention (ref=Within 1 month) 
2
=11.15 0.025 
     Within 6 months 0.007 1.01 0.60-1.70 0.979 
     Beyond 6 months 0.494 1.64 0.99-2.70 0.053 
     Not planning to quit -0.314 0.73 0.36-1.47 0.377 
     Not given -0.689 0.50 0.16-1.59 0.242 




Reason #2: Willing to try ST when you do not want to smoke around others. 
 
Table 15 shows that overall, nearly half (47.6%) of the respondents answered that they were 
willing to use at least one of the four ST products when they don’t want to smoke around others. 
Respondents were most willing to try duMaurier and least willing to try Copenhagen. 
 
Table 15. Responses* to the question, ―Would you be willing to try this product for the times when you 










At least one 





















1-No WL 50.5 33.0 56.1 24.5 83.7 8.2 46.9 30.6 50.5 
2-No WL+RR 37.8 28.6 45.7 24.5 77.3 10.3 28.9 33.0 54.3 
3-Text WL 56.9 25.5 57.3 21.4 80.8 12.5 48.1 23.1 48.5 
4-Text WL+RR 47.6 31.1 53.4 27.2 84.3 11.8 41.7 33.0 51.5 
5-Pic WL 63.5 25.0 64.6 25.0 83.5 10.3 62.9 27.8 46.7 
6-Pic WL+RR 72.0 17.0 75.2 14.9 86.3 8.8 71.0 11.0 34.0 
Overall 54.7 26.7 58.8 22.9 82.7 10.3 49.9 26.4 47.6 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 16 displays the logistic regression model examining ‗willingness to try when you don‘t 
want to smoke around others‘ index. No differences were observed across experimental 
conditions. Participants who viewed a picture warning label had lower odds of reporting 
willingness to try at least one product compared to those who did not view any warning label. 
 
Warning labels were significantly associated with willingness to try in the main effects model 





Table 16. Adjusted binary logistic regression model for overall ‗willingness to try when you don‘t want 
to smoke around others‘ index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.173 0.84 0.54-1.30 0.437 
     Pic vs. No WL -0.530 0.59 0.38-0.92 0.019 
     Pic vs. Text WL -0.356 0.70 0.45-1.09 0.116 
Gender (ref=female) 0.232 1.26 0.87-1.82 0.216 
Age -0.001 1.00 0.94-1.06 0.971 
Smoking Status (ref=daily) 
2
=0.26 0.877 
     Weekly -0.097 0.91 0.51-1.62 0.742 
     Monthly -0.164 0.85 0.43-1.69 0.642 




     Mod -0.045 0.96 0.62-1.47 0.837 




     Mod 0.298 1.35 0.84-2.17 0.221 
     High 0.196 1.22 0.75-1.98 0.429 
     Not given 0.713 2.04 0.67-6.17 0.207 
HSI 0.026 1.03 0.90-1.17 0.710 
Quit Intention (ref=Within 1 month) 
2
=6.02 0.197 
     Within 6 months -0.156 0.86 0.51-1.44 0.559 
     Beyond 6 months 0.294 1.34 0.82-2.19 0.239 
     Not planning to quit -0.313 0.73 0.37-1.44 0.368 
     Not given -0.232 0.79 0.27-2.30 0.669 

















Reason #3: Willing to try ST to help cut back the amount you smoke. 
 
Table 17 shows that overall, nearly half (48.8%) of the respondents answered that they were 
willing to use at least one of the four ST products to help cut back the amount they smoke. 
Respondents were most willing to try Ariva and least willing to try Copenhagen. 
 
Table 17. Responses* to the question, ―Would you be willing to try this product to help you cut back the 










At least one 





















1-No WL 54.1 26.5 54.6 20.6 80.6 8.2 36.1 34.0 55.3 
2-No WL+RR 35.7 30.6 48.9 29.8 74.0 14.6 29.9 29.9 56.0 
3-Text WL 54.3 27.6 60.6 18.3 84.5 7.8 51.9 25.0 48.5 
4-Text WL+RR 43.1 32.4 53.5 27.7 79.4 16.7 43.7 30.1 54.1 
5-Pic WL 65.6 23.7 67.3 23.5 81.8 11.1 64.3 24.5 43.5 
6-Pic WL+RR 70.0 15.0 71.6 13.7 83.3 7.8 62.0 20.0 35.7 
Overall 53.7 26.0 59.6 22.1 80.7 11.0 48.1 27.2 48.8 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 18 displays the logistic regression model examining ‗willingness to try to help cut back‘ 
index. The main effect of viewing a warning label was significant. Participants who viewed a 
picture warning label had lower odds of reporting willingness to try ST compared to those who 








Table 18. Adjusted binary logistic regression model for overall ‗willingness to try to help cut back‘ 
index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.273 0.76 0.49-1.18 0.219 
     Pic vs. No WL -0.658 0.52 0.33-0.80 0.003 
     Pic vs. Text WL -0.386 0.68 0.44-1.06 0.086 
Gender (ref=female) -0.055 0.95 0.66-1.36 0.768 
Age -0.056 0.95 0.89-1.00 0.058 
Smoking Status (ref=daily) 
2
=1.63 0.444 
     Weekly -0.316 0.73 0.41-1.29 0.279 
     Monthly -0.332 0.72 0.35-1.46 0.358 




     Mod 0.193 1.21 0.79-1.86 0.378 




     Mod 0.239 1.27 0.79-2.05 0.324 
     High 0.146 1.16 0.71-1.87 0.553 
     Not given -0.393 0.68 0.23-2.00 0.479 
HSI 0.025 1.03 0.90-1.17 0.711 
Quit Intention (ref=Within 1 month) 
2
=3.30 0.508 
     Within 6 months 0.270 1.31 0.78-2.20 0.308 
     Beyond 6 months 0.378 1.46 0.90-2.38 0.129 
     Not planning to quit 0.039 1.04 0.53-2.04 0.910 
     Not given -0.123 0.88 0.31-2.55 0.820 

















Reason #4: Willing to try ST to help while you are trying to quit smoking. 
 
Table 19 shows that overall, nearly half (48.1%) of the respondents answered that they were 
willing to use at least one of the four ST products to help while they are trying to quit smoking. 
Respondents were most willing to try Ariva and least willing to try Copenhagen. 
 
Table 19. Responses* to the question, ―Would you be willing to try this product to help you while you 










At least one 





















1-No WL 51.5 27.3 51.0 20.8 82.7 9.2 34.7 25.5 48.4 
2-No WL+RR 32.3 31.3 42.3 33.0 74.5 11.2 24.0 31.2 60.9 
3-Text WL 58.3 21.4 58.3 19.4 77.7 11.7 48.5 23.3 44.0 
4-Text WL+RR 43.7 31.1 57.6 23.2 76.7 19.4 38.2 33.3 58.2 
5-Pic WL 66.7 22.9 69.1 21.3 83.5 12.4 66.3 22.4 40.0 
6-Pic WL+RR 69.7 13.1 69.3 12.9 85.3 7.8 57.0 25.0 37.1 
Overall 53.6 24.5 58.0 21.7 80.0 12.0 44.9 26.8 48.1 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 20 displays the logistic regression model examining ‗willingness to try to help quit‘ index. 
The main effects of viewing a relative risk message and a health warning were both significant. 
Participants who viewed a relative health risk message had higher odds of reporting willingness 
to try ST, and those who viewed a picture health warning label had lower odds of reporting 
willingness to try ST compared to those who did not view a warning label. Participants who were 
planning to quit smoking beyond six months compared to those planning to quit within one 




Viewing a relative risk message was not significantly associated with willingness to try ST to 
help quit in the main effects model (2=3.76, p=.053), but became significant when the predictors 
were added to the model. 
 
Table 20. Adjusted binary logistic regression model for overall ‗willingness to try to help quit‘ index 
(n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.215 0.81 0.52-1.25 0.336 
     Pic vs. No WL -0.623 0.54 0.34-0.84 0.006 
     Pic vs. Text WL -0.408 0.665 0.43-1.04 0.073 
Gender (ref=female) -0.066 0.94 0.65-1.36 0.726 
Age 0.001 1.00 0.94-1.06 0.984 
Smoking Status (ref=daily) 
2
=1.71 0.425 
     Weekly -0.372 0.69 0.38-1.24 0.212 
     Monthly 0.024 1.02 0.50-2.08 0.946 




     Mod -0.031 0.97 0.63-1.50 0.890 




     Mod 0.048 1.05 0.65-1.70 0.844 
     High 0.030 1.03 0.63-1.68 0.902 
     Not given 0.155 1.17 0.38-3.64 0.789 
HSI 0.042 1.04 0.91-1.19 0.539 
Quit Intention (ref=Within 1 month) 
2
=8.22 0.084 
     Within 6 months 0.252 1.29 0.76-2.18 0.350 
     Beyond 6 months 0.637 1.89 1.15-3.11 0.012 
     Not planning to quit 0.362 1.44 0.73-2.84 0.298 
     Not given -0.242 0.78 0.26-2.37 0.668 









Reason #5: Willing to try ST as a long-term replacement instead of cigarettes. 
 
Table 21 shows that overall, nearly a third (31.7%) of the respondents answered that they were 
willing to use at least one of the four ST products as a long-term replacement instead of 
cigarettes. Respondents were most willing to try duMaurier and Ariva and least willing to try 
Copenhagen. 
 
Table 21. Responses* to the question, ―Would you be willing to try this product as a long-term 










At least one 





















1-No WL 71.9 14.6 71.9 15.6 85.7 8.2 66.7 19.8 35.5 
2-No WL+RR 59.8 27.8 70.4 17.3 83.8 10.1 58.6 24.2 42.6 
3-Text WL 70.2 16.3 71.2 15.4 89.3 4.9 66.7 20.6 31.0 
4-Text WL+RR 60.6 25.0 68.0 20.0 80.8 16.3 65.0 21.4 40.0 
5-Pic WL 80.4 14.4 82.1 12.6 90.5 7.4 84.5 12.4 25.8 
6-Pic WL+RR 83.0 8.0 79.2 9.9 89.2 4.9 82.0 8.0 15.5 
Overall 70.9 17.7 73.7 15.2 86.5 8.7 70.5 17.8 31.7 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 22 displays the logistic regression model examining ‗willingness to try as a long-term 
replacement‘ index. The main effect of viewing a warning label was significant. Participants who 
viewed a picture health warning lower had higher odds of reporting willingness to try ST 
compared to those who viewed either a text warning or no warning label. Ethnic minorities had 






Table 22. Adjusted binary logistic regression model for overall ‗willingness to try as a long-term 
replacement‘ index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.099 0.91 0.58-1.43 0.668 
     Pic vs. No WL -1.034 0.36 0.21-0.59 <.001 
     Pic vs. Text WL -0.935 0.39 0.24-0.66 <.001 
Gender (ref=female) 0.164 1.18 0.79-1.76 0.425 
Age -0.021 0.98 0.92-1.04 0.516 
Smoking Status (ref=daily) 
2
=0.61 0.738 
     Weekly -0.222 0.80 0.43-1.48 0.480 
     Monthly 0.056 1.06 0.49-2.26 0.886 




     Mod -0.072 0.93 0.58-1.50 0.769 




     Mod 0.209 1.23 0.73-2.08 0.433 
     High 0.098 1.10 0.65-1.88 0.719 
     Not given -0.963 0.38 0.08-1.84 0.230 
HSI -0.139 0.87 0.75-1.01 0.068 
Quit Intention (ref=Within 1 month) 
2
=5.40 0.248 
     Within 6 months 0.364 1.44 0.80-2.59 0.226 
     Beyond 6 months 0.508 1.66 0.95-2.90 0.073 
     Not planning to quit -0.136 0.87 0.40-1.93 0.737 
     Not given 0.020 1.02 0.32-3.30 0.973 













Reasons for Use Index 
 
Table 23 shows that overall, two-thirds (66.3%) of the respondents answered that they were 
willing to use at least one of the four ST products for at least one of the five reasons. 
Respondents were most willing to try Ariva and least willing to try Copenhagen. 
 
Table 23. ‗Yes‘ responses to at least one of five specific questions regarding willingness to try the ST 













Condition % Yes 
b
 % Yes 
b
 % Yes 
b
 % Yes 
b
 % Yes 
c
 
1-No WL 46.8 44.8 17.3 53.7 73.3 
2-No WL+RR 53.1 44.1 27.4 55.2 73.0 
3-Text WL 42.4 39.2 19.4 47.0 67.4 
4-Text WL+RR 48.0 45.8 22.0 54.5 74.2 
5-Pic WL 39.6 34.1 20.4 40.4 55.4 
6-Pic WL+RR 30.2 30.0 15.8 35.0 53.8 
Overall 43.4 39.6 20.3 47.6 66.3 
b 
Overall index for answering ‗yes‘ to at least one of the five reasons, for at least one of the four products 
c 
Product-specific index for answering ‗yes‘ to at least one of the five reasons 
 
Table 24 displays the logistic regression model examining overall reasons for use index. The 
main effect of viewing a warning label was significant. Participants who viewed a picture 
warning label had lower odds of reporting willingness to use ST (for at least one of the five 
reasons for at least one of the four products) compared to those who viewed either a text warning 








Table 24. Adjusted binary logistic regression model for overall reasons for product use index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.168 0.85 0.51-1.39 0.509 
     Pic vs. No WL -0.915 0.40 0.25-0.65 <.001 
     Pic vs. Text WL -0.747 0.47 0.29-0.77 0.003 
Gender (ref=female) -0.011 0.99 0.66-1.49 0.956 
Age -0.046 0.95 0.90-1.05 0.147 
Smoking Status (ref=daily) 
2
=0.19 0.911 
     Weekly 0.118 1.13 0.59-2.15 0.720 
     Monthly -0.052 0.95 0.45-2.02 0.893 




     Mod 0.108 1.11 0.70-1.77 0.648 




     Mod 0.376 1.46 0.87-2.44 0.154 
     High 0.373 1.45 0.86-2.46 0.164 
     Not given 0.372 1.45 0.41-5.15 0.565 
HSI 0.053 1.05 0.91-1.22 0.487 
Quit Intention (ref=Within 1 month) 
2
=9.36 0.053 
     Within 6 months -0.001 1.00 0.57-1.76 0.997 
     Beyond 6 months 0.392 1.48 0.86-2.55 0.159 
     Not planning to quit -0.456 0.63 0.31-1.31 0.216 
     Not given -0.775 0.46 0.15-1.44 0.183 
Model Adjusted R Squared 0.075 
 
Table 25 shows the results from the adjusted logistic regression model examining the same 
reasons for use index outcome for each of the four ST products separately. For duMaurier and 
Ariva, the main effect of viewing a warning label was significant.  When viewing duMaurier, 
Marlboro, and Ariva, participants who viewed a picture warning label had lower odds of future 


































RR Message 0.036 1.04 
0.72-
1.49 
0.846 0.049 1.05 
0.72-
1.52 
0.798 0.220 1.25 
0.81-
1.93 




WL Type 2=9.16 0.010 2=7.43 0.024 2=1.30 0.521 2=10.41 0.005 
     Text vs. No WL -0.221 0.80 
0.52-
1.24 
0.321 -0.089 0.91 
0.59-
1.43 
0.694 -0.154 0.86 
0.51-
1.45 




     Pic vs. No WL -0.667 0.50 
0.32-
0.79 
.003 -0.603 0.55 
0.35-
0.87 
0.010 -0.315 0.73 
0.43-
1.25 




     Text vs. Pic WL -0.466 0.63 
0.40-
0.99 
0.045 -0.513 0.60 
0.38-
0.95 
0.031 -0.161 0.85 
0.50-
1.46 




Model Adjusted R 
Squared 





6.1.5 Relative Risk Beliefs 
 
Respondents were asked to rate the health risk of the four ST products compared to cigarettes 
and NRTs. 
 
a) Smokeless Tobacco vs. Cigarette Relative Risk Beliefs 
 
Table 26 shows that overall, 27.9% of the respondents answered incorrectly that all four ST 
products are the same or more harmful than cigarettes. Depending on the product, between 30% 
and 47% of respondents incorrectly believed that ST and cigarettes are equally harmful, and a 
small proportion believed that ST is more harmful than cigarettes. Respondents perceived Ariva 
to be least harmful and Copenhagen to be most harmful compared to cigarettes. 
 
Table 26. Responses* to the question, ―In your opinion, how harmful to health is this product compared 




































1-No WL 44.9 41.6 39.1 47.1 48.8 26.7 25.0 67.9 26.7 
2-No WL+RR 30.1 65.1 30.2 66.3 43.5 46.5 17.6 77.6 14.7 
3-Text WL 48.3 36.0 42.4 40.2 41.3 26.1 34.4 53.8 38.4 
4-Text WL+RR 37.5 53.1 35.1 52.6 45.3 32.6 25.0 64.6 25.6 
5-Pic WL 50.5 34.1 48.3 37.1 47.7 23.9 42.2 45.6 32.5 
6-Pic WL+RR 45.8 44.8 33.7 48.0 52.6 30.9 31.6 58.9 28.1 
Overall 43.0 45.6 38.1 49.2 46.6 30.6 29.5 61.1 27.9 
Response options: 1 – A lot less harmful, 2 – Somewhat less harmful, 3 – No difference, 4 – Somewhat 
more harmful, 5 – A lot more harmful 
*Dichotomised to ‗less harmful‘ (1-2) and ‗the same or more harmful‘ (3-5) 
 
Table 27 displays the logistic regression model examining overall ST-cigarette relative risk 
beliefs. The main effect of viewing a relative risk message was significant. Participants who 
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viewed a relative risk message had higher odds of reporting correct beliefs about the health risk 
of ST compared to cigarettes. Those who viewed a picture health warning label had lower odds 
of reporting correct beliefs compared to those who did not view a warning label. Males, those 
with moderate education, and those with high income had higher odds of reporting correct 
beliefs. 
 
Viewing a warning label was significantly associated with ST-cigarette relative risk beliefs in the 
main effects model (2=6.39, p=.041), but became non-significant when the predictors were 
added to the model. 
 
Table 27. Adjusted binary logistic regression model for overall ST-cigarette relative risk beliefs (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.364 0.70 0.39-1.23 0.210 
     Pic vs. No WL -0.669 0.51 0.29-0.92 0.025 
     Pic vs. Text WL -0.306 0.74 0.41-1.34 0.315 
Gender (ref=female) 0.665 1.95 1.19-3.17 0.008 
Age -0.071 0.93 0.86-1.01 0.070 
Smoking Status (ref=daily) 
2
=0.17 0.920 
     Weekly 0.072 1.07 0.51-2.27 0.851 
     Monthly -0.141 0.87 0.35-2.15 0.761 




     Mod 0.687 1.99 1.07-3.68 0.029 




     Mod 0.534 1.71 0.87-3.33 0.118 
     High 0.754 2.13 1.09-4.15 0.027 
     Not given -0.328 0.72 0.08-6.43 0.769 
HSI 0.161 1.17 0.98-1.40 0.077 
Quit Intention (ref=Within 1 month) 
2
=4.36 0.359 
     Within 6 months -0.448 0.64 0.32-1.26 0.197 
     Beyond 6 months 0.033 1.03 0.56-1.93 0.917 
     Not planning to quit -0.141 0.87 0.35-2.17 0.763 
     Not given 0.758 2.14 0.52-8.73 0.291 




Table 28 shows results from the adjusted logistic regression model examining the same ST-
cigarette relative risk beliefs outcome for each of the four ST products separately. For all four 
products, the main effect of viewing a relative risk message was significant. For duMaurier and 
Ariva, the main effect of viewing a warning label was significant. For all four products, 
participants who viewed a relative health risk message had higher odds of reporting correct 
beliefs.  For duMaurier and Ariva, participants who viewed a warning label had lower odds of 
reporting correct beliefs. Specifically, those who viewed a picture warning label had lower odds 
of reporting correct beliefs compared to those who did not view a warning label for duMaurier 
and Marlboro, and had lower odds of reporting correct beliefs compared to those who viewed 
either a text warning or no warning for Ariva. 
 
For Marlboro, viewing a warning label was significantly associated with ST-cigarette relative 
risk beliefs in the main effects model (2=6.21, p=.045), but became non-significant when the 


































RR Message 0.871 2.39 
1.62-
3.52 
<.001 0.677 1.97 
1.35-
2.87 
<.001 0.582 1.79 
1.18-
2.71 




WL Type 2=6.76 0.034 2=5.12 0.077 2=2.31 0.315 2=13.99 0.001 
     Text vs. No WL -0.377 0.69 
0.43-
1.10 
0.117 -0.394 0.67 
0.43-
1.06 
0.091 -0.265 0.77 
0.47-
1.26 




     Pic vs. No WL -0.619 0.54 
0.34-
0.86 
0.010 -0.503 0.60 
0.38-
0.96 
0.032 -0.375 0.69 
0.42-
1.13 




     Text vs. Pic WL -0.242 0.79 
0.49-
1.25 
0.311 -0.109 0.90 
0.67-
1.41 
0.639 -0.109 0.90 
0.54-
1.50 




Model Adjusted R 
Squared 




b) Smokeless Tobacco vs. Nicotine Replacement Therapy Relative Risk Beliefs 
 
Table 29 shows that overall, nearly half (48.0%) of the respondents answered correctly that all 
four smokeless tobacco products are more harmful than NRT. Respondents perceived Ariva to be 
least harmful and Copenhagen to be most harmful compared to NRT. 
 
Table 29. Responses* to the question, ―In your opinion, how harmful to health is this product compared 
























1-No WL 74.7 79.1 91.9 34.6 31.6 
2-No WL+RR 81.9 68.4 87.1 50.0 39.2 
3-Text WL 80.9 77.3 87.8 67.8 52.4 
4-Text WL+RR 77.6 75.8 88.4 57.5 52.6 
5-Pic WL 86.9 87.5 93.0 73.3 55.3 
6-Pic WL+RR 81.8 81.3 92.5 66.3 55.4 
Overall 80.6 78.4 90.1 58.6 48.0 
Response options: 1 – A lot less harmful, 2 – Somewhat less harmful, 3 – No difference, 4 – Somewhat 
more harmful, 5 – A lot more harmful 
*Dichotomised to ―less harmful‖ (1-2) and ―the same or more harmful‖ (3-5) 
 
Table 30 displays the logistic regression model examining overall ST-NRT relative risk beliefs, 
generated from the average across the four products. The main effect of viewing a warning label 
was significant. Participants who viewed either a picture or a text health warning label had 
higher odds of reporting accurate beliefs compared to those who did not view a warning label. 
Older participants had higher odds of reporting accurate beliefs. Males, ethnic minorities, those 
who smoke weekly compared to those who smoke daily, and those reporting moderate or high 





Table 30. Adjusted binary logistic regression model for overall ST-NRT relative risk beliefs (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.764 2.15 1.28-3.61 0.004 
     Pic vs. No WL 1.112 3.04 1.81-5.11 <.001 
     Pic vs. Text WL 0.348 1.42 0.86-2.35 0.18 
Gender (ref=female) -0.498 0.61 0.40-0.93 0.021 
Age 0.087 1.09 1.02-1.17 0.001 
Smoking Status (ref=daily) 
2
=6.39 0.041 
     Weekly -0.874 0.42 0.21-0.83 0.012 
     Monthly -0.383 0.68 0.32-1.46 0.325 




     Mod 0.387 1.47 0.88-2.45 0.137 




     Mod -0.603 0.55 0.31-0.96 0.037 
     High -0.890 0.41 0.23-0.73 0.002 
     Not given -0.239 0.79 0.20-3.15 0.735 
HSI -0.118 0.89 0.76-1.04 0.136 
Quit Intention (ref=Within 1 month) 
2
=1.99 0.738 
     Within 6 months 0.228 1.26 0.70-2.27 0.449 
     Beyond 6 months -0.063 0.94 0.53-1.65 0.827 
     Not planning to quit 0.338 1.40 0.63-3.10 0.406 
     Not given -0.054 0.95 0.22-4.03 0.942 
Model Adjusted R Squared 0.117 
 
Table 31 shows results from the adjusted logistic regression model examining the same ST-NRT 
relative risk beliefs outcome for each of the four ST products separately. The main effect of 
viewing a relative risk message was significant for Marlboro. For Marlboro, participants who 
viewed a relative health risk message had lower odds of reporting accurate beliefs, and those 
who viewed a picture warning label had higher odds of reporting accurate beliefs compared to 
those who did not view a warning. 
 
For Marlboro, viewing a warning label was associated with ST-NRT relative risk beliefs in the 
main effects model (2=6.14, p=.046), but became non-significant when the predictors were 
added to the model. On the contrary, viewing a relative risk message was not significantly 
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associated with ST-NRT relative risk beliefs in the main effects model (2=2.79, p=.095), but 
became significant when the predictors were added to the model. 
 
The interaction between warning label and relative risk message was significant in the main 
effects model for Ariva, and was therefore included in the full model. In the full model, the 
interaction between relative risk message and warning label type remained significant (
2
=6.12, 
p=.047), such that the odds of reporting willingness to try decreased with the presence of a 


































RR Message -0.190 0.83 
0.51-
1.34 
0.444 -0.483 0.62 
0.39-
0.99 
0.043 -0.289 0.75 
0.39-
1.43 




WL Type 2=2.83 0.243 2=5.66 0.059 2=3.10 0.212 2=14.60 0.001 
     Text vs. No WL -0.076 0.93 
0.52-
1.65 
0.795 0.122 1.13 
0.65-
1.95 
0.663 -0.311 0.73 
0.35-
1.55 




     Pic vs. No WL 0.421 1.52 
0.83-
2.81 
0.178 0.683 1.98 
1.10-
3.56 
0.023 0.437 1.55 
0.66-
3.60 




     Pic vs. Text WL 0.497 1.64 
0.89-
3.04 
0.112 0.561 1.75 
0.97-
3.17 
0.064 0.748 2.11 
0.92-
4.86 




RR Message (by 
WL Type) 
-- -- -- -- -- -- 2=6.12 0.047 








Model Adjusted R 
Squared 




6.2 Nicotine Replacement Therapy 
6.2.1 Familiarity 
 
Respondents were asked if they had seen or heard of four NRT products.  Table 32 shows that 
overall, 96.8% indicated that they were familiar with at least one of the products. Respondents 
were most familiar with nicotine patch and least familiar with nicotine lozenge. 
 











At least one 
„yes‟ for all 
four products 
Condition % Yes % Yes % Yes % Yes % Yes 
1-No WL 89.9 85.0 66.0 46.9 97.9 
2-No WL+RR 90.8 89.0 66.0 46.9 96.9 
3-Text WL 86.7 88.6 61.5 42.9 95.0 
4-Text WL+RR 85.3 90.4 66.0 53.4 97.0 
5-Pic WL 86.9 86.9 63.6 43.8 94.8 
6-Pic WL+RR 92.2 89.1 63.4 43.4 99.0 
Overall 88.6 88.2 64.4 46.2 96.8 
Response options: 1 - No, 2 – Yes 
 
Table 33 displays the binary logistic regression model examining overall product familiarity. No 
differences were observed across experimental conditions. Males, those with high education, 
those with higher HSI score, and those who did not provide quit intentions compared to those 











Table 33. Adjusted binary logistic regression model for overall product familiarity (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.451 0.64 0.13-3.07 0.574 
     Pic vs. No WL -0.856 0.42 0.07-2.45 0.338 
     Pic vs. Text WL -0.406 0.67 0.13-3.45 0.630 
Gender (ref=female) -2.484 0.08 0.01-0.53 0.008 
Age -0.134 0.87 0.69-1.11 0.267 
Smoking Status (ref=daily) 
2
=2.40 0.302 
     Weekly -1.688 0.18 0.02-1.59 0.124 
     Monthly -0.827 0.44 0.04-5.04 0.507 




     Mod -1.083 0.34 0.05-2.53 0.291 
     High -2.830 0.06 0.01-0.51 0.010 
Income (ref=low)  
2
=1.66  0.646 
     Mod 0.097 1.10 0.22-5.55  
     High 1.104 3.02 0.44-20.56 0.260 
     Not given 18.804 1.47x10
8
 0.00 0.998 
HSI -0.959 0.38 0.22-0.68 0.001 
Quit Intention (ref=Within 1 month) 
2
=6.26 0.181 
     Within 6 months -0.672 0.51 0.04-6.16 0.597 
     Beyond 6 months -1.236 0.29 0.03-3.18 0.311 
     Not planning to quit -1.482 0.23 0.02-2.99 0.260 
     Not given -4.186 0.02 0.00-0.50 0.019 
Model Adjusted R Squared 0.072 
 
 
Table 34 shows results from the adjusted binary logistic regression model examining the same 
familiarity outcome for each of the four NRT products separately. No differences were observed 



































RR Message 0.018 1.02 
0.55-
1.87 
0.954 0.199 1.22 
0.70-
2.12 
0.480 0.028 1.03 
0.71-
1.50 




WL Type 2=0.21 0.900 2=1.83 0.401 2=0.21 0.900 2=0.82 0.665 
     Text vs. No WL -0.151 0.86 
0.41-
1.79 
0.687 0.423 1.53 
0.77-
3.01 
0.223 -0.034 0.97 
0.61-
1.52 




     Pic vs. No WL -0.155 0.86 
0.40-
1.85 
0.692 0.007 1.01 
0.52-
1.94 
0.984 0.072 1.08 
0.68-
1.71 




     Text vs. Pic WL -0.004 1.00 
0.48-
2.08 
0.992 -0.416 0.66 
0.33-
1.33 
0.246 0.106 1.11 
0.70-
1.77 




Model Adjusted R 
Squared 






Respondents were asked if the products would appeal to people their age. Table 35 indicates that 
overall, 85.8% indicated that at least one of the products would appeal to people their age. 
Respondents indicated that Nicotine gum would appeal most and Nicotine inhaler would appeal 
least to those their age. 
 











At least one 
„yes‟ for all 
four products 
Condition %Yes %Yes %Yes %Yes % 
1-No WL 60.0 64.6 43.3 58.6 87.4 
2-No WL+RR 64.9 67.7 50.0 63.0 89.0 
3-Text WL 56.9 61.9 38.2 56.4 79.4 
4-Text WL+RR 65.3 80.4 52.0 66.0 91.8 
5-Pic WL 56.8 65.6 39.6 58.1 82.6 
6-Pic WL+RR 60.4 71.4 46.9 60.4 84.8 
Overall 60.7 68.6 45.0 60.4 85.8 
Response options: 1 –Not at all, 2 –Unlikely, 3 –Undecided, 4 –Somewhat, 5 – Very 
*Dichotomised to ‗Yes‘ (4-5) and ‗Other‘ (1-3) 
 
Table 36 displays the logistic regression model examining overall product appeal. No differences 
were observes across experimental conditions. Males had lower odds of appeal, and those with 












Table 36. Adjusted binary logistic regression model for overall product appeal (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.337 0.71 0.36-1.41 0.333 
     Pic vs. No WL -0.486 0.62 0.31-1.20 0.157 
     Pic vs. Text WL -0.149 0.86 0.46-1.62 0.645 
Gender (ref=female) -0.863 0.42 0.24-0.74 0.002 
Age -0.019 1.02 0.94-1.11 0.653 
Smoking Status (ref=daily) 
2
=0.209 0.901 
     Weekly -0.171 0.84 0.37-1.90 0.681 
     Monthly -0.152 0.86 0.33-2.24 0.755 




     Mod -0.084 0.92 0.48-1.75 0.800 
     High -0.141 0.87 0.39-1.92 0.727 
Income (ref=low)  
2
=6.93  0.074 
     Mod 0.437 1.55 0.78-3.07 0.211 
     High 0.768 2.16 1.05-4.42 0.036 
     Not given -0.674 0.51 0.14-1.88 0.312 
HSI -0.084 0.92 0.75-1.13 0.418 
Quit Intention (ref=Within 1 month) 
2
=4.62 0.329 
     Within 6 months 0.545 1.72 0.74-3.99 0.203 
     Beyond 6 months -0.157 0.85 0.42-1.73 0.662 
     Not planning to quit -0.248 0.78 0.32-1.91 0.588 
     Not given -0.523 0.59 0.11-3.19 0.542 
Model Adjusted R Squared 0.053 
 
 
Table 37 shows results from the adjusted binary logistic regression model examining the same 
appeal outcome for each of the four NRT products separately. For Nicotine gum and inhaler, 



































RR Message 0.279 1.32 
0.91-
1.93 
0.148 0.462 1.59 
1.08-
2.34 
0.020 0.380 1.46 
1.02-
2.10 




WL Type 2=1.10 0.578 2=1.43 0.490 2=0.29 0.867 2=0.50 0.779 
     Text vs. No WL 0.076 1.08 
0.68-
1.72 
0.748 0.283 1.33 
0.83-
2.13 
0.243 -0.044 0.96 
0.62-
1.49 




     Pic vs. No WL -0.166 0.85 
0.53-
1.34 
0.480 0.081 1.09 
0.68-
1.74 
0.735 -0.120 0.89 
0.57-
1.39 




     Text vs. Pic WL -0.243 0.79 
0.49-
1.25 
0.307 -0.202 0.82 
0.50-
1.33 
0.413 -0.120 0.89 
0.57-
1.39 




Model Adjusted R 
Squared 




6.2.3 Likelihood of Future Use 
 
Respondents were asked how likely they would be to try each product in the future. Table 38 
shows that overall, over three-quarters (77.4%) indicated that they were likely to try at least one 
of the four NRT products in the future. Respondents indicated that they would be most likely to 
try nicotine gum and least likely to try nicotine inhaler. 
 












At least one 
























1-No WL 24.0 51.0 19.0 53.0 16.2 46.5 22.4 58.2 81.4 
2-No WL+RR 51.9 50.0 13.5 60.4 25.3 49.5 25.3 51.6 76.1 
3-Text WL 27.2 47.6 30.8 45.2 26.9 38.5 28.2 41.7 68.0 
4-Text WL+RR 25.7 50.5 22.8 57.4 14.9 55.4 22.5 64.7 80.6 
5-Pic WL 21.1 53.7 14.3 56.1 21.1 42.1 25.3 54.7 80.6 
6-Pic WL+RR 25.5 51.0 16.2 61.6 23.0 44.0 21.4 51.0 77.9 
Overall 24.3 50.6 19.6 55.5 21.2 46.0 24.2 53.6 77.4 
Response options: 1 - Definitely not, 2 - Probably not, 3 - Undecided, 4 - Probably try, 5 - Definitely try 
*Dichotomised to Yes (4-5) and Other (1-3) 
 
Table 39 displays the logistic regression model examining overall likelihood of future use rating. 
No differences were observed across experimental conditions. Ethnic minorities, those reporting 
high income, and those planning to quit within six months compared to those planning to quit 
within one month had higher odds of reporting future use. Older respondents, those who smoke 
weekly compared to those who smoke daily, those reporting a high education level, and those not 
planning to quit compared to those planning to quit within one month had lower odds of 






Table 39. Adjusted binary logistic regression model for overall likelihood of future product use (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.031 1.03 0.58-1.82 0.916 
     Pic vs. No WL 0.011 1.01 0.56-1.81 0.972 
     Pic vs. Text WL -0.020 0.98 0.55-1.75 0.980 
Gender (ref=female) 0.127 1.14 0.71-1.83 0.602 
Age -0.083 0.92 0.85-0.99 0.034 
Smoking Status (ref=daily) 
2
=4.00 0.135 
     Weekly -0.710 0.49 0.25-0.99 0.046 
     Monthly -0.301 0.74 0.32-1.74 0.489 




     Mod -0.222 0.80 0.45-1.43 0.454 




     Mod 0.407 1.50 0.81-2.77 0.193 
     High 0.653 1.92 1.02-3.61 0.042 
     Not given -0.635 0.53 0.16-1.81 0.312 
HSI 0.073 1.08 0.90-1.28 0.420 
Quit Intention (ref=Within 1 month) 
2
=37.95 <.001 
     Within 6 months 0.826 2.28 1.09-4.79 0.029 
     Beyond 6 months 0.076 1.08 0.58-2.00 0.809 
     Not planning to quit -1.498 0.22 0.10-0.48 <.001 
     Not given -1.196 0.30 0.09-1.07 0.064 
Model Adjusted R Squared 0.185 
 
Table 40 shows results from the adjusted logistic regression model examining the same 
likelihood of future use outcome for each of the four NRT products separately. For nicotine gum, 
patch, and inhaler, no differences were observed across experimental conditions. 
 
For nicotine gum, viewing a relative risk message was significantly associated with likelihood of 
future use in the main effects model (2=4.31, p=.038), but became non-significant when the 
predictors were added to the model.  
 
The interaction between warning label and relative risk message was significant in the main 
effects model for nicotine lozenge, and was therefore included in the full model. In the full 
86 
 
model, the interaction remained significant (
2
=9.02, p=.011), such that the odds of reporting 
likelihood of future use increased with the presence of a relative risk message when a text 



































RR Message -1.02 0.90 
0.63-
1.29 
0.580 0.315 1.37 
0.95-
1.98 
0.093 0.205 1.23 
0.85-
1.76 




WL Type 2=0.41 0.816 2=0.03 0.985 2=1.24 0.539 2=6.93 0.031 
     Text vs. No WL 0.131 1.14 
0.74-
1.77 
0.558 0.040 1.04 
0.66-
1.63 
0.862 0.083 1.09 
0.70-
1.70 




     Pic vs. No WL 0.015 1.01 
0.65-
1.57 
0.948 0.019 1.02 
0.65-
1.60 
0.933 -0.168 0.85 
0.54-
1.32 




     Text vs. Pic WL -0.116 0.89 
0.57-
1.39 
0.610 -0.021 0.98 
0.62-
1.55 
0.929 -0.251 0.78 
0.50-
1.22 




RR Message (by 
WL Type) 
-- -- -- -- -- -- 2=9.02 0.011 








Model Adjusted R 
Squared 




6.2.4 Reasons for Product Use 
 
Respondents were asked whether they would be willing to try each of the four NRT products for 
five reasons. Three indexes were generated: i) and index for each product for answering ‗yes‘ to 
at least one of the five reasons, ii) an index for each reason for answering ‗yes‘ for at least one of 
the four products, and iii) an overall index for answering ‗yes‘ to at least one of the five reasons, 
for at least one of the four products. Although the overall index explained above accounts for 
only ‗yes‘ responses, at least 78% of respondents answered ‗yes‘ or ‗maybe‘ to at least one of the 
five questions about willingness to try at least one of the four NRT products. 
 
Reason #1: Willing to try ST in places where you cannot smoke. 
 
Table 41 shows that overall, over half (51.0%) of the respondents answered that they were 
willing to use at least one of the four NRT products in places where they cannot smoke. 
Respondents were most willing to try the nicotine lozenge and about equally willing to try the 
patch, gum, and inhaler. 
 
Table 41. Responses* to the question, ―Would you be willing to try this product in places where you 











At least one 





















1-No WL 41.0 25.0 29.3 20.2 42.4 20.2 30.0 26.0 52.0 
2-No WL+RR 34.7 14.3 22.4 19.4 42.1 12.6 24.5 27.6 41.9 
3-Text WL 40.0 22.9 33.3 20.0 35.0 34.0 34.6 26.0 57.0 
4-Text WL+RR 39.6 19.8 28.4 22.5 41.6 17.8 22.5 25.5 50.5 
5-Pic WL 35.8 26.3 26.8 28.9 50.0 24.0 31.6 35.8 57.6 
6-Pic WL+RR 47.5 18.8 33.7 20.8 45.0 21.0 33.0 24.0 46.5 
Overall 39.8 21.2 29.1 21.9 42.6 21.7 29.4 27.4 51.0 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 




Table 42 displays the logistic regression model examining ‗willingness to try where you can‘t 
smoke‘ index. The main effect of viewing a relative risk message was significant. Participants 
who viewed a relative health risk message had lower odds of reporting willingness to try NRT. 
Those planning to quit within six months or beyond six months compared to those planning to 
quit within one month had higher odds of reporting willingness to try NRT. 
 
Table 42. Adjusted binary logistic regression model for overall ‗willingness to try where you can‘t 
smoke‘ index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.242 1.27 0.82-1.98 0.281 
     Pic vs. No WL 0.280 1.32 0.85-2.05 0.210 
     Pic vs. Text WL 0.038 1.04 0.67-1.62 0.868 
Gender (ref=female) -0.017 0.98 0.68-1.42 0.929 
Age 0.005 1.01 0.95-1.07 0.859 
Smoking Status (ref=daily) 
2
=0.86 0.651 
     Weekly -0.273 0.76 0.43-1.36 0.354 
     Monthly -0.095 0.91 0.46-1.80 0.784 




     Mod 0.183 1.20 0.75-1.85 0.407 




     Mod -0.075 0.93 0.57-1.50 0.761 
     High -0.437 0.65 0.40-1.05 0.080 
     Not given 0.328 1.39 0.46-4.20 0.561 
HSI -0.017 0.98 0.86-1.12 0.807 
Quit Intention (ref=Within 1 month) 
2
=13.28 0.010 
     Within 6 months 0.767 2.15 1.28-3.64 0.004 
     Beyond 6 months 0.548 1.73 1.06-2.82 0.028 
     Not planning to quit -0.143 0.87 0.44-1.72 0.682 
     Not given 0.095 1.10 0.37-3.29 0.865 







Reason #2: Willing to try ST when you do not want to smoke around others. 
 
Table 43 shows that overall, nearly half (48.6%) of the respondents answered that they were 
willing to use at least one of the four NRT products when they don’t want to smoke around 
others. Respondents were most willing to try the nicotine lozenge and about equally willing to 
try patch, gum, and inhaler. 
 
Table 43. Responses* to the question, ―Would you be willing to try this product for the times when you 











At least one 





















1-No WL 40.0 30.0 30.3 19.2 48.5 23.2 31.3 26.3 52.6 
2-No WL+RR 40.8 14.3 23.5 18.4 46.9 14.3 30.6 23.5 37.5 
3-Text WL 47.2 17.9 34.3 18.1 45.6 31.1 33.0 27.2 50.5 
4-Text WL+RR 38.2 23.5 35.9 18.4 50.5 16.2 32.0 25.2 49.5 
5-Pic WL 40.0 26.3 25.0 33.3 53.6 21.6 30.5 38.9 58.1 
6-Pic WL+RR 47.5 13.9 37.3 18.6 53.5 20.8 37.0 21.0 44.0 
Overall 42.4 20.9 31.2 20.9 49.7 21.3 32.4 26.9 48.6 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 44 displays the logistic regression model examining ‗willingness to try when you don‘t 
want to smoke around others‘ index. The main effect of viewing a relative risk message was 
significant. Participants who viewed a relative health risk message on the smokeless products 
had lower odds of reporting willingness to try NRT. Those planning to quit within six months 








Table 44. Adjusted binary logistic regression model for overall ‗willingness to try when you don‘t want 
to smoke around others‘ index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.320 1.38 0.89-2.14 0.152 
     Pic vs. No WL 0.363 1.44 0.93-2.23 0.104 
     Pic vs. Text WL 0.043 1.04 0.67-1.63 0.849 
Gender (ref=female) 0.164 1.18 0.82-1.70 0.381 
Age 0.031 1.03 0.97-1.09 0.294 
Smoking Status (ref=daily) 
2
=0.45 0.798 
     Weekly -0.195 0.82 0.46-1.46 0.503 
     Monthly -0.051 0.95 0.48-1.87 0.882 




     Mod 0.187 1.21 0.79-1.85 0.391 




     Mod 0.037 1.04 0.64-1.67 0.879 
     High -0.163 0.85 0.52-1.38 0.508 
     Not given 0.341 1.41 0.48-4.13 0.535 
HSI -0.047 0.95 0.83-1.09 0.495 
Quit Intention (ref=Within 1 month) 
2
=11.86 0.018 
     Within 6 months 0.753 2.12 1.26-3.58 0.005 
     Beyond 6 months 0.375 1.45 0.89-2.37 0.132 
     Not planning to quit -0.132 0.88 0.45-1.72 0.702 
     Not given 0.724 2.06 0.69-6.17 0.195 













Reason #3: Willing to try ST to help cut back the amount you smoke. 
 
Table 45 shows that overall, nearly half (49.2%) of the respondents answered that they were 
willing to use at least one of the four NRT products to help cut back the amount they smoke. 
Respondents were most willing to try nicotine lozenge and least willing to try nicotine gum. 
 
Table 45. Responses* to the question, ―Would you be willing to try this product to help you cut back the 











At least one 





















1-No WL 28.0 26.0 23.2 23.2 38.4 30.3 26.0 26.0 56.1 
2-No WL+RR 31.6 17.3 26.8 17.5 27.6 21.4 25.5 22.4 41.1 
3-Text WL 33.0 24.5 27.4 17.9 34.6 33.7 30.1 27.2 51.0 
4-Text WL+RR 33.0 19.4 23.3 23.3 34.0 19.0 16.7 31.4 53.6 
5-Pic WL 27.7 28.7 28.9 23.7 42.9 21.4 33.0 31.9 52.7 
6-Pic WL+RR 36.6 12.9 27.7 14.9 37.6 18.8 33.0 17.0 41.0 
Overall 31.7 21.4 26.2 20.1 35.8 24.2 27.3 26.0 49.2 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 46 displays the logistic regression model examining ‗willingness to try to help cut back‘ 
index. No differences were observed across experimental conditions. Participants who were 
planning to quit smoking within or beyond six months compared to those who were planning to 










Table 46. Adjusted binary logistic regression model for overall ‗willingness to try to help cut back‘ 
index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.122 1.13 0.73-1.75 0.584 
     Pic vs. No WL -0.102 0.90 0.58-1.40 0.646 
     Pic vs. Text WL -0.224 0.80 0.51-1.25 0.322 
Gender (ref=female) -0.119 0.89 0.62-1.28 0.524 
Age 0.000 1.00 0.94-1.06 0.979 
Smoking Status (ref=daily) 
2
=1.40 0.497 
     Weekly -0.269 0.76 0.43-1.35 0.357 
     Monthly 0.167 1.18 0.60-2.34 0.631 




     Mod 0.045 1.05 0.68-1.60 0.837 




     Mod -0.078 0.93 0.57-1.49 0.748 
     High -0.486 0.62 0.38-1.00 0.049 
     Not given -0.229 0.80 0.27-2.31 0.673 
HSI 0.025 1.03 0.90-1.17 0.709 
Quit Intention (ref=Within 1 month) 
2
=7.17 0.127 
     Within 6 months 0.617 1.85 1.10-3.12 0.020 
     Beyond 6 months 0.495 1.64 1.01-2.67 0.047 
     Not planning to quit 0.172 1.19 0.61-2.32 0.614 
     Not given -0.023 0.98 0.31-3.04 0.968 

















Reason #4: Willing to try ST to help while you are trying to quit smoking. 
 
Table 47 shows that overall, nearly half (46.7%) of the respondents answered that they were 
willing to use at least one of the four NRT products to help while they are trying to quit smoking. 
Respondents were most willing to try nicotine lozenge and least willing to try nicotine gum. 
 
Table 47. Responses* to the question, ―Would you be willing to try this product to help you while you 











At least one 





















1-No WL 25.0 22.0 21.2 19.2 34.3 26.3 24.0 26.0 46.9 
2-No WL+RR 27.1 15.6 24.5 13.3 24.7 16.5 22.7 23.7 34.4 
3-Text WL 24.8 24.8 22.6 23.6 31.7 30.8 29.1 31.1 54.5 
4-Text WL+RR 21.4 26.2 18.4 23.3 26.7 19.8 15.7 28.4 50.0 
5-Pic WL 23.2 24.2 28.9 25.8 42.3 24.7 31.6 31.6 54.9 
6-Pic WL+RR 28.4 16.7 27.0 15.0 33.0 17.0 29.0 18.0 39.4 
Overall 25.0 21.6 23.7 20.1 32.1 22.6 25.3 26.5 46.7 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 48 displays the logistic regression model examining ‗willingness to try to help quit‘ index. 
The main effects of viewing a relative risk message and a health warning were significant. 
Participants who viewed a relative health risk message had lower odds of reporting willingness 
to try NRT, and those who viewed a text health warning label on the smokeless products had 
higher odds of reporting willingness to try NRT compared to those who did not view a warning 
label. Those who were planning to quit smoking within or beyond six months compared to those 
planning to quit within one month had higher odds of reporting willingness to try NRT. 
 
Warning labels were not significantly associated with willingness to try NRT in the main effects 




Table 48. Adjusted binary logistic regression model for overall ‗willingness to try to help quit‘ index 
(n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.569 1.77 1.13-2.75 0.012 
     Pic vs. No WL 0.322 1.38 0.88-2.15 0.156 
     Pic vs. Text WL -0.247 0.78 0.50-1.22 0.275 
Gender (ref=female) 0.005 1.01 0.70-1.45 0.978 
Age 0.024 1.02 0.97-1.09 0.414 
Smoking Status (ref=daily) 
2
=1.59 0.451 
     Weekly -0.361 0.70 0.39-1.25 0.223 
     Monthly -0.224 0.80 0.40-1.61 0.530 




     Mod 0.139 1.15 0.74-1.77 0.530 




     Mod -0.384 0.68 0.42-1.10 0.119 
     High -0.459 0.63 0.39-1.03 0.066 
     Not given -0.515 0.60 0.20-1.77 0.352 
HSI -0.012 0.99 0.86-1.13 0.863 
Quit Intention (ref=Within 1 month) 
2
=7.85 0.097 
     Within 6 months 0.693 2.00 1.17-3.41 0.011 
     Beyond 6 months 0.596 1.82 1.10-3.00 0.020 
     Not planning to quit 0.321 1.38 0.70-2.72 0.353 
     Not given 0.701 2.02 0.67-6.11 0.215 













Reason #5: Willing to try ST as a long-term replacement instead of cigarettes. 
 
Table 49 shows that overall, over a third (35.9%) of the respondents answered that they were 
willing to use at least one of the four NRT products as a long-term replacement instead of 
cigarettes. Respondents were most willing to try the nicotine lozenge and about equally willing 
to try nicotine patch, gum, and inhaler. 
 
Table 49. Responses* to the question, ―Would you be willing to try this product as a long-term 











At least one 





















1-No WL 63.0 20.0 57.1 15.3 72.7 11.1 58.0 21.0 36.1 
2-No WL+RR 56.1 14.3 54.1 17.3 59.8 18.6 53.1 21.4 35.8 
3-Text WL 59.4 19.8 51.9 23.1 55.2 25.7 59.2 17.5 42.2 
4-Text WL+RR 60.2 18.4 57.8 17.6 61.0 14.0 56.9 17.6 35.4 
5-Pic WL 60.4 19.8 59.8 17.5 63.5 18.8 59.1 23.7 39.3 
6-Pic WL+RR 70.3 9.9 60.4 12.9 68.0 14.0 63.6 9.1 26.8 
Overall 61.6 17.1 56.8 17.3 63.3 17.1 58.3 18.3 35.9 
Response options: 1 - No, 2 – Maybe, 3 – Yes 
*Dichotomised to ‗Yes‘ (3) and ‗Other‘ (1-2) 
a 
Reason-specific index for answering ‗yes‘ for at least one of the four products 
 
Table 50 displays the logistic regression model examining ‗willingness to try as a long-term 
replacement‘ index. The main effect of viewing a relative risk message was significant. 
Participants who viewed a relative risk message on the products had lower odds of reporting 
willingness to try NRT. Those who were planning to quit smoking within or beyond six months 
compared to those planning to quit within one month had higher odds of reporting willingness to 
try NRT. 
 
Viewing a relative risk message was not significantly associated with willingness to try NRT in 
the main effects model (2=2.61, p=.107), but became significant when the predictors were added 




Table 50. Adjusted binary logistic regression model for overall ‗willingness to try as a long-term 
replacement‘ index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.228 1.26 0.80-1.98 0.325 
     Pic vs. No WL -0.157 0.86 0.54-1.37 0.512 
     Pic vs. Text WL -0.384 0.68 0.42-1.09 0.111 
Gender (ref=female) 0.074 1.08 0.73-1.59 0.708 
Age 0.000 1.00 0.94-1.06 0.974 
Smoking Status (ref=daily) 
2
=1.96 0.376 
     Weekly 0.350 1.42 0.78-2.59 0.253 
     Monthly 0.403 1.50 0.72-3.09 0.276 




     Mod 0.295 1.34 0.85-2.13 0.209 




     Mod -0.160 0.85 0.52-1.40 0.527 
     High -0.421 0.66 0.39-1.09 0.105 
     Not given -1.027 0.36 0.09-1.37 0.134 
HSI 0.109 1.12 0.97-1.29 0.136 
Quit Intention (ref=Within 1 month) 
2
=13.35 0.010 
     Within 6 months 0.767 2.15 1.23-3.78 0.008 
     Beyond 6 months 0.685 1.98 1.17-3.38 0.011 
     Not planning to quit -0.203 0.82 0.38-1.76 0.604 
     Not given 0.361 1.43 0.44-4.65 0.548 












Reasons for Use Index 
 
Table 51 shows that overall, nearly two-thirds (68.2%) of the respondents answered that they 
were willing to use at least one of the four NRT products for at least one of the five reasons. 
Respondents were most willing to try the nicotine lozenge and least likely to try the nicotine 
patch. 
 
Table 51. ‗Yes‘ responses to at least one of five specific questions regarding willingness to try the NRT 

























1-No WL 42.0 35.7 41.4 44.4 68.8 
2-No WL+RR 30.2 36.1 38.9 43.3 65.2 
3-Text WL 40.4 40.4 49.5 46.6 69.4 
4-Text WL+RR 44.0 40.6 36.7 50.0 70.7 
5-Pic WL 46.2 50.5 37.2 53.3 75.6 
6-Pic WL+RR 28.0 30.0 35.7 33.3 60.4 
Overall 38.4 38.8 40.0 45.1 68.2 
b 
Overall index for answering ‗yes‘ to at least one of the five reasons, for at least one of the four products 
c 
Product-specific index for answering ‗yes‘ to at least one of the five reasons 
 
Table 52 displays the logistic regression model examining overall reasons for use index. No 
differences were observed across experimental conditions. Participants who were planning to 
quit within six months or beyond six months compared to those who were planning to quit within 
one month had higher odds of reporting willingness to try NRT (for at least one the four products 









Table 52. Adjusted binary logistic regression model for overall reasons for product use index (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.152 1.16 0.72-1.89 0.537 
     Pic vs. No WL 0.026 1.03 0.64-1.65 0.915 
     Pic vs. Text WL -0.127 0.88 0.54-1.44 0.614 
Gender (ref=female) -0.008 0.99 0.66-1.49 0.971 
Age -0.030 0.97 0.91-1.03 0.353 
Smoking Status (ref=daily) 
2
=0.69 0.708 
     Weekly -0.128 0.88 0.47-1.63 0.684 
     Monthly -0.301 0.74 0.36-1.53 0.418 




     Mod 0.215 1.24 0.77-1.99 0.372 




     Mod 0.018 1.02 0.60-1.73 0.946 
     High -0.404 0.67 0.39-1.13 0.134 
     Not given 0.505 1.66 0.42-6.47 0.467 
HSI 0.034 1.03 0.89-1.20 0.657 
Quit Intention (ref=Within 1 month) 
2
=19.09 0.001 
     Within 6 months 0.984 2.68 1.53-4.67 0.001 
     Beyond 6 months 0.955 2.60 1.55-4.34 <.001 
     Not planning to quit 0.174 1.19 0.60-2.36 0.617 
     Not given 0.512 1.67 0.50-5.54 0.402 
Model Adjusted R Squared 0.058 
 
Table 53 shows results from the adjusted logistic regression model examining the same reasons 
for use index outcome for each of the four NRT products separately. For nicotine patch, gum, 
and inhaler, no differences were observed across experimental conditions. 
 
For nicotine patch, viewing a relative risk message was significantly associated with willingness 
to try NRT in the main effects model (2=4.61, p=.032), but became non-significant when the 
predictors were added to the model.  
 
The interaction between warning label and relative risk message was in the main effects model 
for nicotine lozenge, and was therefore included in the full model. In the full model, the 
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interaction between relative risk message and warning label type remained significant (
2
=9.04, 
p=.011), such that the odds of reporting willingness to try NRT decreased in the presence of a 



































RR Message -0.325 0.72 
0.50-
1.04 
0.084 -0.222 0.80 
0.56-
1.15 
0.226 -0.273 0.76 
0.53-
1.10 




WL Type 2=2.09 0.352 2=1.59 0.452 2=1.80 0.406 2=7.29 0.026 
     Text vs. No WL 0.325 1.38 
0.89-
2.16 
0.153 0.215 1.24 
0.80-
1.92 
0.338 0.092 1.10 
0.70-
1.71 




     Pic vs. No WL 0.121 1.13 
0.72-
1.78 
0.601 0.268 1.31 
0.84-
2.03 
0.235 -0.216 0.81 
0.51-
1.27 




     Text vs. Pic WL -0.204 0.82 
0.52-
1.28 
0.376 0.053 1.05 
0.68-
1.64 
0.815 -0.308 0.74 
0.46-
1.16 




RR Message (by 
WL Type) 
-- -- -- -- -- -- 2=9.04 0.011 








Model Adjusted R 
Squared 
0.055 0.023 0.068 0.061 
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6.2.5 Relative Risk Beliefs 
 
Respondents were asked to rate the health risk of the four NRT products compared to cigarettes 
and ST products. 
 
a) Nicotine Replacement Therapy vs. Cigarette Relative Risk Beliefs 
 
Table 54 shows that overall, nearly two-thirds (65.3%) of the respondents answered correctly 
that all four NRT products are less harmful than cigarettes. Respondents perceived gum to be 
least harmful and inhaler to be most harmful compared to cigarettes. 
 
Table 54. Responses* to the question, ―In your opinion, how harmful to health is this product compared 





































1-No WL 14.9 83.0 14.7 84.2 18.9 81.1 14.4 81.1 69.0 
2-No WL+RR 12.2 82.2 18.0 76.4 20.5 73.9 14.6 80.9 67.4 
3-Text WL 19.6 72.8 15.6 76.0 19.8 74.7 17.9 78.9 59.6 
4-Text WL+RR 18.6 77.3 13.4 84.5 16.7 76.0 16.3 80.6 63.8 
5-Pic WL 23.1 73.6 18.7 79.1 26.4 69.2 18.0 79.8 59.5 
6-Pic WL+RR 14.1 82.8 12.8 86.2 13.4 85.6 16.3 82.7 72.5 
“Less harmful” 17.1 78.7 15.5 81.1 19.2 76.9 16.3 80.7 65.3 
Response options: 1 – A lot less harmful, 2 – Somewhat less harmful, 3 – No difference, 4 – Somewhat 
more harmful, 5 – A lot more harmful 
*Dichotomised to ‗less harmful‘ (1-2) and ‗the same or more harmful‘ (3-5) 
 
Table 55 displays the logistic regression model examining overall NRT-cigarette relative risk 
beliefs. No differences were observed across experimental conditions. Ethnic minorities had 






Table 55. Adjusted binary logistic regression model for overall NRT-cigarette relative risk beliefs 
(n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.252 0.78 0.48-1.26 0.305 
     Pic vs. No WL -0.087 0.92 0.56-1.50 0.728 
     Pic vs. Text WL 0.165 1.18 0.73-1.91 0.503 
Gender (ref=female) -0.211 0.81 0.54-1.21 0.306 
Age -0.024 0.98 0.92-1.04 0.454 
Smoking Status (ref=daily) 
2
=3.84 0.146 
     Weekly -0.605 0.55 0.30-1.01 0.053 
     Monthly -0.087 0.92 0.43-1.95 0.820 




     Mod 0.092 1.10 0.67-1.78 0.712 




     Mod 0.134 1.14 0.67-1.94 0.619 
     High -0.031 0.97 0.57-1.65 0.910 
     Not given 1.296 3.66 0.71-18.80 0.121 
HSI -0.119 0.89 0.77 0.118 
Quit Intention (ref=Within 1 month) 
2
=1.83 0.768 
     Within 6 months -0.333 0.72 0.40-1.27 0.254 
     Beyond 6 months -0.149 0.86 0.50-1.49 0.593 
     Not planning to -0.220 0.80 0.38-1.69 0.562 
     Not given -0.600 0.55 0.16-1.92 0.348 
Model Adjusted R Squared 0.065 
 
Table 56 shows results from the adjusted logistic regression model examining the same NRT-
cigarette relative risk beliefs outcome for each of the four NRT products separately. For nicotine 
patch, gum, and lozenge, no differences were observed across experimental conditions. 
 
For inhaler, the interaction between warning label and relative risk message was significantly 
associated with NRT-cigarette relative risk beliefs in the main effects model (2=7.43, p=.024), 



































RR Message 0.253 1.29 
0.82-
2.02 
0.273 0.305 1.36 
0.85-
2.17 
0.202 -0.357 0.70 
0.33-
1.47 




WL Type 2=1.97 0.374 2=0.46 0.796 2=3.92 0.141 2=0.216 0.897 
     Text vs. No WL -0.344 0.71 
0.41-
1.236 
0.224 -0.071 0.93 
0.54-
1.62 
0.800 -0.910 0.40 
0.08-
2.14 




     Pic vs. No WL -0.361 0.70 
0.39-
1.23 
0.213 0.127 1.14 
0.64-
2.03 
0.667 -1.68 0.19 
0.04-
0.98 




     Text vs. Pic WL -0.017 0.98 
0.57-
1.69 
0.951 -0.199 1.22 
0.68-
2.18 
0.502 0.768 0.46 
0.09-
2.37 




RR Message (by 
WL Type) 
-- -- -- -- 2=5.23 0.073 -- -- 
     For Text WL -- -- -- -- -- -- -- -- 0.591 1.81 
0.63-
5.16 
0.270 -- -- -- -- 
     For Pic WL -- -- -- -- -- -- -- -- 1.26 3.52 
1.20-
10.36 
0.022 -- -- -- -- 
Model Adjusted R 
Squared 




b) Nicotine Replacement Therapy vs. Smokeless Tobacco Relative Risk Beliefs 
 
Table 57 shows that overall, 14.8% of the respondents answered accurately that all four NRT 
products are less harmful than ST. Respondents perceived lozenge to be least harmful and gum 
to be most harmful compared to ST. 
 
Table 57. Responses* to the question, ―In your opinion, how harmful to health is this product compared 





































1-No WL 59.8 35.9 67.0 29.7 53.4 37.5 64.4 33.3 11.6 
2-No WL+RR 58.0 29.5 68.5 25.8 57.5 33.3 67.1 29.4 14.3 
3-Text WL 61.1 28.9 61.7 27.7 55.1 32.6 53.8 40.9 8.0 
4-Text WL+RR 53.2 40.4 52.6 42.3 46.8 39.4 54.3 41.5 19.1 
5-Pic WL 58.4 34.8 57.3 38.2 53.8 34.1 57.3 41.6 16.5 
6-Pic WL+RR 62.2 33.7 65.2 32.6 57.6 31.5 66.7 32.3 19.1 
“Less harmful” 58.8 33.9 62.0 32.8 54.0 34.8 60.4 36.6 14.8 
Response options: 1 – A lot less harmful, 2 – Somewhat less harmful, 3 – No difference, 4 – Somewhat 
more harmful, 5 – A lot more harmful 
*Dichotomised to ‗less harmful‘ (1-2) and ‗the same or more harmful‘ (3-5) 
 
Table 58 displays the logistic regression model examining overall NRT-ST relative risk beliefs. 
No differences were observed across experimental conditions. Ethnic minorities had higher odds 










Table 58. Adjusted binary logistic regression model for overall NRT-ST relative risk (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL 0.202 1.22 0.61-2.45 0.567 
     Pic vs. No WL 0.429 1.54 0.78-3.01 0.211 
     Pic vs. Text WL 0.227 1.26 0.66-2.39 0.489 
Gender (ref=female) 0.344 1.41 0.81-2.46 0.224 
Age -0.017 0.98 0.90-1.07 0.706 
Smoking Status (ref=daily) 
2
=1.30 0.522 
     Weekly -0.483 0.62 0.26-1.49 0.282 
     Monthly 0.051 1.05 0.42-2.62 0.914 




     Mod -0.375 0.69 0.35-1.35 0.276 




     Mod -0.165 0.85 0.41-1.77 0.660 
     High -0.023 0.98 0.47-2.03 0.951 
     Not given 0.085 1.09 0.21-5.68 0.920 
HSI -0.103 0.90 0.74-1.11 0.323 
Quit Intention (ref=Within 1 month) 
2
=3.11 0.540 
     Within 6 months 0.454 1.57 0.72-3.44 0.255 
     Beyond 6 months 0.250 1.28 0.60-2.74 0.517 
     Not planning to quit -0.378 0.69 0.22-2.16 0.519 
     Not given -0.271 0.76 0.08-6.98 0.810 
Model Adjusted R Squared 0.043 
 
Table 59 shows results from the adjusted logistic regression model examining the same NRT-ST 
relative risk beliefs outcome for each of the four NRT products separately. For nicotine patch, 
gum, and inhaler, no differences were observed across experimental conditions. For lozenge, 
participants who viewed a text warning label had higher odds of reporting accurate beliefs 



































RR Message 0.037 1.04 
0.70-
1.53 
0.853 0.027 1.03 
0.69-
1.54 
0.897 -0.007 0.99 
0.67-
1.47 




WL Type 2=0.297 0.862 2=4.27 0.118 2=0.371 0.831 2=4.58 0.101 
     Text vs. No WL 0.123 1.13 
0.70-
1.83 
0.617 0.496 1.64 
1.00-
2.71 
0.052 0.100 1.11 
0.68-
1.79 




     Pic vs. No WL 0.108 1.11 
0.69-
1.80 
0.661 0.424 1.53 
0.92-
2.54 
0.101 -0.045 0.96 
0.59-
1.55 




     Text vs. Pic WL 0.015 0.99 
0.61-
1.59 
0.951 0.072 0.93 
0.57-
1.51 
0.772 0.145 0.87 
0.54-
1.40 




Model Adjusted R 
Squared 




6.3 Relative Addictiveness Beliefs 
 
Respondents were asked to rate the addictiveness of the four ST products compared to cigarettes 
and NRT, and to rate the four NRTs compared to cigarettes. Table 60 indicates that overall, 
nearly half (48.1%) of respondents believed that ST is less addictive than cigarettes, over a 
quarter (27.3%) believed that ST is less addictive than NRT, and almost three-quarters (71.3%) 
believed that NRT is less addictive than cigarettes. 
 























ST compared to Cigarettes (% ST “Less Addictive”) 
 51.2 60.3 47.2 48.8 37.9 44.8 48.1 
ST compared to NRT (% ST “Less Addictive”) 
 29.1 32.0 25.3 30.2 22.2 25.8 27.3 
NRT compared to Cigarettes (% NRT “Less Addictive”) 
 78.4 78.3 63.4 69.6 69.3 70.1 71.3 
Response options: 1 – A lot less addictive, 2 – Somewhat less addictive, 3 – No difference, 4 – 
Somewhat more addictive, 5 – A lot more addictive 
*Dichotomised to ‗less addictive‘ (1-2) and ‗the same or more addictive‘ (3-5) 
 
Table 61 displays the logistic regression model examining ST-cigarette relative addictiveness 
beliefs. The main effect of viewing a relative risk message was significant. Participants who 
viewed a relative risk message had higher odds of believing ST is less addictive than cigarettes. 
Thos who viewed a picture warning label had lower odds of believing ST is less addictive than 
cigarettes. Those reporting no plans to quit smoking and not providing quit plans had lower odds 





Viewing a warning label was significantly associated with NRT-cigarette relative addictiveness 
beliefs in the main effects model (2=6.84, p=.033), but became non-significant when the 
predictors were added to the model. The opposite was seen for relative risk message, where in 
the main effects model it was non-significantly associated with NRT-cigarette relative 
addictiveness (2=1.75, p=.186), and became significant when the predictors were added to the 
model. 
 
Table 61. Adjusted binary logistic regression model for ST-Cigarette relative addictiveness (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.228 0.80 0.49-1.28 0.351 
     Pic vs. No WL -0.576 0.56 0.35-0.91 0.020 
     Pic vs. Text WL -0.348 0.71 0.44-1.14 0.157 
Gender (ref=female) 0.157 1.17 0.79-1.73 0.435 
Age -0.040 0.96 0.90-1.02 0.211 
Smoking Status (ref=daily) 
2
=1.61 0.446 
     Weekly 0.359 1.43 0.78-2.63 0.246 
     Monthly -0.077 0.93 0.44-1.93 0.837 




     Mod -0.415 0.66 0.41-1.06 0.086 




     Mod 0.079 1.08 0.64-1.84 0.770 
     High 0.388 1.47 0.87-2.50 0.152 
     Not given 0.115 1.12 0.29-4.33 0.867 
HSI -0.064 0.94 0.81-1.08 0.387 
Quit Intention (ref=Within 1 month) 
2
=10.29 0.036 
     Within 6 months -0.090 0.91 0.53-1.59 0.750 
     Beyond 6 months -0.380 0.68 0.41-1.15 0.152 
     Not planning to quit -0.950 0.39 0.18-0.83 0.014 
     Not given -1.418 0.24 0.06-0.99 0.048 
Model Adjusted R Squared 0.075 
 
Table 62 displays the logistic regression model examining ST-NRT relative addictiveness 
beliefs. No differences were observed across experimental conditions. Participants reporting no 
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plans to quit smoking had lower odds of believing ST is less addictive than cigarettes compared 
to those who reported plans to quit within one month. 
 
Table 62. Adjusted binary logistic regression model for ST-NRT relative addictiveness (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.141 0.87 0.52-1.45 0.590 
     Pic vs. No WL -0.354 0.70 0.41-1.19 0.189 
     Pic vs. Text WL -0.212 0.81 0.48-1.37 0.427 
Gender (ref=female) 0.405 1.50 0.97-2.31 0.066 
Age -0.011 0.99 0.92-1.06 0.750 
Smoking Status (ref=daily) 
2
=1.57 0.455 
     Weekly 0.202 1.22 0.65-2.30 0.530 
     Monthly -0.376 0.69 0.30-1.56 0.369 




     Mod -0.130 0.88 0.52-1.49 0.632 




     Mod -0.199 0.82 0.46-1.46 0.501 
     High 0.172 1.19 0.67-2.10 0.553 
     Not given -0.034 0.97 0.23-4.09 0.964 
HSI -0.071 0.93 0.79-1.09 0.380 
Quit Intention (ref=Within 1 month) 
2
=5.51 0.239 
     Within 6 months -0.336 0.71 0.40-1.29 0.265 
     Beyond 6 months -0.472 0.62 0.36-1.09 0.100 
     Not planning to quit -0.914 0.40 0.17-0.92 0.032 
     Not given -0.105 0.90 0.24-3.35 0.875 
Model Adjusted R Squared 0.053 
 
Table 63 displays the logistic regression model examining NRT-cigarette relative addictiveness 
beliefs. The main effect of viewing a warning label was significant. Participants who viewed a 
text warning label had lower odds of believing NRT is less addictive than cigarettes compared to 






Table 63. Adjusted binary logistic regression model for NRT-Cigarette relative addictiveness (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.645 0.52 0.31-0.88 0.014 
     Pic vs. No WL -0.445 0.64 0.38-1.09 0.099 
     Pic vs. Text WL -0.200 1.22 0.75-1.99 0.422 
Gender (ref=female) -0.294 0.75 0.49-1.14 0.174 
Age -0.063 0.94 0.88-1.00 0.061 
Smoking Status (ref=daily) 
2
=0.45 0.800 
     Weekly -0.218 0.80 0.42-1.53 0.505 
     Monthly -0.053 0.95 0.44-2.07 0.895 




     Mod 0.191 1.21 0.74-1.98 0.446 




     Mod 0.663 1.94 1.13-3.35 0.017 
     High 0.462 1.59 0.92-2.73 0.094 
     Not given 1.260 3.52 0.74-16.86 0.115 
HSI 0.034 1.04 0.89-1.21 0.660 
Quit Intention (ref=Within 1 month) 
2
=3.78 0.437 
     Within 6 months -0.115 0.89 0.48-1.65 0.714 
     Beyond 6 months -0.435 0.65 0.37-1.15 0.136 
     Not planning to quit -0.139 0.87 0.40-1.90 0.727 
     Not given -0.819 0.44 0.12-1.58 0.208 
Model Adjusted R Squared 0.065 
 
6.4 Summary Comparisons between ST and NRT 
 
Table 64 displays a summary of differences between parallel outcomes measures obtained for ST 
and NRT. Respondents were significantly more familiar with NRT products, rated NRT products 
significantly more appealing, and indicated that they would use NRT products in the future 
significantly more. No differences were observed for willingness to use ST and NRT for any of 
the five reasons examined. NRT was perceived to be significantly less harmful to health and 





Table 64. Summary comparisons between core outcome measures for ST and NRT (n=611) 




Familiarity 49.2% 96.8% 
2
=266.29 <.001 
Appeal 53.0% 85.8% 
2
=133.61 <.001 
Likelihood of Future Use 43.6% 68.2% 
2
=154.94 <.001 
Use product for any of five reasons 66.3% 68.2% 
2
=0 1.00 
     #1: When can‘t smoke 48.9% 51.0% 
2
=0.38 0.540 
     #2: When don‘t want to smoke 47.6% 48.6% 
2
=0.25 0.617 
     #3: To help cut back 48.8% 49.2% 
2
=0 1.00 
     #4: To help quit 48.1% 46.7% 
2
=0.36 0.551 
     #5: As a long-term replacement 31.7% 35.9% 
2
=2.48 0.115 
ST/NRT-Cigarette Relative Risk 22.8% 65.3% 
2
=167.79 <.001 





6.5 Support for Picture Health Warning Labels on ST Packages 
 
Respondents were asked to what extent they support picture health warning labels on ST 
packages. Table 65 indicates that 71.4% of respondents support picture warning labels. 
 
Table 65. Responses* to the question, ―Do you think smokeless tobacco products should have picture 






















% Yes 76.8 70.7 66.7 74.5 64.6 75.0 71.4 
Response options: 1 - Disapprove strongly, 2 - Disapprove, 3 - Undecided, 4 - Approve, 5 - Approve 
strongly 
*Dichotomised to ‗Yes‘ (4-5) and ‗Other‘ (1-2) 
 
Table 66 displays the logistic regression model examining support for picture warning labels. No 
differences were observed across experimental conditions. Participants who reported having no 
plans to quit smoking had lower odds of support for picture warning labels on ST compared to 




Table 66. Adjusted binary logistic regression model for overall support for ST picture health warnings 
(n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.204 0.82 0.50-1.32 0.408 
     Pic vs. No WL -0.331 0.72 0.44-1.16 0.179 
     Pic vs. Text WL -0.127 0.88 0.55-1.40 0.593 
Gender (ref=female) 0.138 1.15 0.77-1.71 0.497 
Age 0.023 1.02 0.96-1.09 0.463 
Smoking Status (ref=daily) 
2
=0.326 0.850 
     Weekly -0.135 0.87 0.48-1.60 0.664 
     Monthly 0.095 1.10 0.52-2.35 0.806 




     Mod 0.339 1.40 0.88-2.23 0.152 




     Mod 0.068 1.07 0.64-1.80 0.797 
     High -0.028 0.97 0.58-1.64 0.915 
     Not given -0.096 0.91 0.30-2.75 0.865 
HSI -0.047 0.95 0.83-1.10 0.528 
Quit Intention (ref=Within 1 month) 
2
=7.70 0.103 
     Within 6 months -0.205 0.81 0.46-1.45 0.487 
     Beyond 6 months -0.147 0.86 0.50-1.49 0.598 
     Not planning to quit -0.928 0.40 0.20-0.79 0.009 
     Not given -0.233 0.79 0.25-2.51 0.693 
Model Adjusted R Squared 0.030 
 
 
6.6 Support for Relative Health Risk Information on ST Packages 
 
Respondents were asked to what extent are interested in seeing information that compares the 
health risk of using ST to cigarettes on ST packages. Table 67 indicates that 67.8% of 






Table 67. Responses* to the question, ―Are you interested in seeing information on smokeless packages 






















% Yes 72.0 72.2 67.6 72.3 60.6 61.6 67.8 
Response options: 1 – Not at all, 2 – Unlikely, 3 – Undecided, 4 – Somewhat, 5 – A lot 
*Dichotomised to ‗Yes‘ (4-5) and ‗Other‘ (1-2) 
 
Table 68 displays the logistic regression model examining support for relative risk information. 
The main effect of viewing a warning label was significant. Participants who viewed a picture 
warning label had lower odds of support for relative risk information. Respondents who did not 




















Table 68. Adjusted binary logistic regression model for support for ST health risk rating (n=611) 
 Beta OR 95% CI p value 




     Text vs. No WL -0.212 0.81 0.50-1.30 0.380 
     Pic vs. No WL -0.647 0.52 0.33-0.83 0.006 
     Pic vs. Text WL -0.435 0.65 0.41-1.02 0.063 
Gender (ref=female) -0.141 0.87 0.59-1.28 0.472 
Age -0.013 0.99 0.93-1.05 0.677 
Smoking Status (ref=daily) 
2
=0.71 0.701 
     Weekly -0.256 0.77 0.42-1.41 0.402 
     Monthly -0.117 0.89 0.43-1.83 0.750 




     Mod -0.069 0.93 0.60-1.46 0.761 




     Mod 0.164 1.18 0.72-1.94 0.519 
     High 0.194 1.21 0.73-2.01 0.451 
     Not given -1.152 0.32 0.11-0.95 0.040 
HSI -0.033 0.97 0.84-1.11 0.644 
Quit Intention (ref=Within 1 month) 
2
=2.36 0.670 
     Within 6 months 0.040 1.04 0.60-1.81 0.887 
     Beyond 6 months -0.081 0.92 0.55-1.54 0.758 
     Not planning to quit -0.453 0.64 0.32-1.26 0.196 
     Not given -0.125 0.88 0.30-2.63 0.823 




7.0   DISCUSSION 
 
To our knowledge, this research is the first to examine the impact of health warning labels on 
Canadian smokers‘ perceptions of smokeless tobacco (ST) appeal, health risk beliefs, and 
intentions to use ST products. It is also the first study to examine the impact of adding a relative 
health risk message to tobacco packaging regarding the health risk of ST compared to smoking 
cigarettes. This research addresses gaps identified in previous research on ST that called for 
testing to determine how features such as labeling and relative risk messages affect perceptions 
of ST, how perceptions might affect patterns of uptake and use of ST, and how methods of 
labeling and health messages can be used to minimise the harm ST products pose to public 
health. 
 
The findings indicate an effect of health warning labels and relative health risk messages on ST 
product appeal, health risk beliefs and intentions to use the products. The findings also suggest 
that young adult Canadian smokers are open to trying ST products concurrently with smoking, as 
a replacement for smoking, as well as for cessation assistance, but that many are confused about 
the much lower health risk of using ST relative to smoking. 
 
7.1 Smokers‟ awareness of ST products 
 
Half (49%) of the respondents were familiar with at least one of the four ST products. Relatively 
low familiarity with ST was expected given that less than 1% of Canadians use ST (CTUMS, 
2003) and even fewer smoke and use ST concurrently (O‘Connor et al., 2007). In fact, only 
17.3% of the respondents in this study had ever used ST and, of those, 8.8% had used it in the 
past month.  In fact, only 17% of the respondents in this study had ever used ST. These findings 
concur with previous research which indicates that 68% of adult Canadian smokers are aware of 
ST products (O‘Connor et al., 2007). Smokers are likely more aware of ST than non-smokers 
because they are more sensitive to ST advertising, which is often targeted to adult smokers ―for 
when you can‘t smoke‖ (Polito, 2004), and as an alternative to smoking (Hatsukami et al., 2007). 
On the other hand, nearly all (97%) respondents were familiar with at least one of the four 




Respondents were most familiar with the Copenhagen snuff (38%), followed by duMaurier snus 
(14%) and Marlboro snus (12%). Respondents were least familiar with the Ariva compressed 
tobacco lozenge (10%). It is not surprising that respondents were most familiar with Copenhagen 
snuff, since it has been on the Canadian market for many years and is a leading ST brand. The 
duMaurier snus was only introduced to select Canadian markets in 2008, though it was widely 
advertised in newspapers (http://goodhealth.freeservers.com/du_Maurier_snus_ad_12_2009.jpg). 
Marlboro snus and Ariva lozenge are both relatively new products and are not sold in Canada, 
therefore it is not surprising that young adult Canadian smokers were least aware of these 
products. Consumers might also know of the sister product to Ariva lozenge, Stonewall lozenge, 
which is manufactured by the same company, Star Scientific, Inc. (Chester, VA). However, 
familiarity with Stonewall was not assessed. 
 
Males were found to be more familiar with ST, whereas older respondents, and those who were 
not planning to quit were less familiar with ST. The finding that males were more familiar with 
ST products may be related to the fact that ST users tend to be male (Tomar, 2003). ST users 
also tend to be in male-dominated blue-collar occupations (Marcus et al., 1989; Lee et al., 2007). 
Therefore, males may be more exposed to ST products because of their social circles, 
occupations, involvement in sports and recreation, as well as other reasons. The finding that 
those who were not planning to quit were less familiar with ST could be because they are 
satisfied with their current smoking habit and are not interested in alternatives such as ST, and 
therefore either have not sought them out or noticed them in advertising. The finding that 
younger respondents were more familiar with ST is likely due to the fact that ST use is highest 
among younger adults (Marcus et al., 1989; CDC, 1991; Nelson et al., 1996; Howard-Pitney & 
Winkleby, 2002; Tomar, 2002). 
 
7.2 Appeal of ST products 
 
Just over half (53%) of respondents found at least one of the four ST products appealing. 
Respondents found duMaurier snus (33%) to be most appealing, followed by Ariva lozenge 
(29%), Marlboro snus (26%), and Copenhagen snuff (16%). The finding that Marlboro snus was 
less appealing than the similar looking duMaurier snus product suggests that awareness of the 
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product, and particularly brand familiarity, may play a role in product appeal. A significantly 
larger proportion (86%) of the respondents found at least one of the four NRT products 
appealing. Previous research also indicates that smokers find NRT more appealing than ST 
(Shiffman, Gitchell, Rohay, Hellebusch & Kemper, 2007). 
 
The appeal of a particular product seems to be based more on the perceptions of that brand than 
the sensory qualities of the product itsself, as exemplified in a British American Tobacco report: 
―One of every two smokers is not able to distinguish in blind (masked) tests between similar 
cigarettes…for most smokers and the decisive group of new, younger smokers, the consumer‘s 
choice is dictated more by psychological, image factors than by relatively minor differences in 
smoking characteristics.‖ (British American Tobacco, 1978). Therefore, although Marlboro is 
one of the most globally recognised brands, the duMaurier snus – having branding and imagery 
that is well-known to Canadian smokers – was most appealing. However, the finding that 
Copenhagen was least appealing, despite the finding that respondents were by far most aware of 
this product, suggests that other factors, such as the product characteristics and perceived risk, 
play a significant role in product appeal. In fact, the current study found that Copenhagen snuff 
was perceived to be the most harmful to health compared to cigarettes. 
 
Product characteristics, packaging, flavour descriptors, and even social factors appear to 
influence the appeal of tobacco products and ST. The product appearance and characteristics 
may influence appeal of these ST products to young adult smokers such that the Ariva lozenge, 
which is similar in appearance to a breath mint and contained in a package similar to chewing 
gum, is rated higher in appeal than the Copenhagen snuff, which is similar in appearance to black 
coffee grounds and contained in a package much like a tuna can. Features such as the package 
colour may also influence appeal due to perceptions of health risk or other factors. For example, 
Copenhagen packaging is predominantly black and was found least appealing, whereas Ariva 
lozenge packaging is light green and was found relatively more appealing by respondents. For 
cigarette packaging, research indicates that colour does influence perceptions; the closer to white 
the package is the cleaner, healthier, and lower delivery and strength a product is perceived to be 
(Wakefield, Morley, Horan & Cummings, 2002). Flavour descriptors may also affect appeal. For 
example, Copenhagen does not advertise flavouring on the package, whereas Ariva advertises 
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wintergreen flavor. Previous research has found that cigarette packages with flavour descriptors 
compared favourably to those with more traditional descriptors (Manning, Kelly & Comello, 
2009). Package material may be an important factor too. Plain packaging has also been found to 
reduce the appeal of cigarettes for both young people (Northrup & Pollard, 1995; Rootman & 
Flay, 1995; Freeman, Chapman & Rimmer, 2008) and adults (Wakefield, Germain & Durkin, 
2008). For example, in the current study the duMaurier and Copenhagen products presented 
came in metal packaging, the Ariva lozenge was packaged in paper, and the Marlboro was 
packaged in plastic. package preference research done by Philip Morris found that ―a plastic 
pack has particular appeal among the young, fitting their lifestyle of sports, outdoor activities and 
being ‗on the go‘‖ (Wakefield, Morley, Horan & Cummings, 2002). Finally, social acceptability 
may also affect ST appeal. Previous research has found that ST users perceived use of their 
product as socially risky, and they regarded ST use as having a lower image in urban centres than 
rural areas (Créatec, 2003). 
 
Viewing a picture health warning significantly decreased appeal. The general finding that health 
warning labels decreased appeal concurs with the literature on cigarettes, where prominent health 
warnings covering a significant proportion of the package lowered appeal (Borland & Hill, 1997; 
Willemsen, 2005; Borland et al, 2009). The specific finding that picture warnings were 
associated with the lowest appeal is supported by previous research examining the effect of 
picture warning labels on reduced exposure products including ST and cigarettes (Thrasher et al., 
2007; Stark et al., 2008). Picture warnings have particular impact on young Canadians, with over 
90% reporting that pictorial warnings provided them with health risk information that made 
smoking less appealing (Health Canada, 2005). 
 
It is surprising that viewing the relative risk message describing ST as lower risk than cigarettes 
was not associated with higher appeal, given that perceptions of risk are an important predictor 
of tobacco use (Weinstein, 1999; Romer & Jamieson, 2001), and in light of the finding 





Those who smoked weekly compared to daily, ethnic minorities, and those with high income 
rated the ST products most appealing. The finding that those who smoked less frequently rated 
the ST as more appealing may be related to a desire by these smokers to stop smoking 
completely. Weekly smokers may have already cut down their smoking substantially, for 
example, but cannot or do not want to eliminate smoking completely. They may be influenced by 
the social unacceptability of smoking and are looking to eliminate smoking by using a more 
discrete product to obtain nicotine. It is also possible that cigarette smoking is not so deeply 
ingrained into less frequent smokers‘ behaviour or self-concept, allowing them to consider 
alternative products more readily than more committed smokers. It is interesting that less 
frequent or less nicotine dependant smokers found ST more appealing in light of the evidence 
from Sweden where ST was particularly helpful as a cessation aid for more nicotine dependant 
smokers (Fagerström & Ramström, 1998). Perhaps more nicotine dependant smokers are more 
reluctant users of ST. 
 
The finding that higher income was associated with higher appeal might be related to perceived 
risk or willingness to use ST. This study found that those with higher income had more accurate 
health risk beliefs about ST compared to smoking, and were also more willing to try ST for the 
times when they cannot smoke. That is, those who correctly believed that ST is less harmful than 
smoking also found ST more appealing. Research indicates that smokers find products that are 
perceived to be less harmful as more appealing (Geertsema, Phillips & Heavner, under review; 
Heavner, Rosenberg & Phillips, 2009). Respondents may also have found ST more appealing 
because they saw utility in using ST for the times when they cannot smoke, or they may have 
seen utility in the use of ST because they find it to be appealing. 
 
It is interesting that ethnic minorities found ST to be more appealing in light of evidence from 
the US which shows that in recent years ST prevalence has decreased markedly among 
nonwhites (Mumford, Levy, Gitchell & Blackman, 2005), and that ST users are almost 
exclusively white (Rodu & Cole, 2009). However, research also indicates that ST prevalence is 
disproportionately high in the US among American/Indians and Alaskan Natives (Spangler et al., 
2009). Therefore, Canadian smokers belonging to certain ethnic groups may find ST particularly 
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appealing. However, this is difficult to determine from this study given the low frequency of 
respondents in each of the eleven minority groups assessed. 
 
7.3 Likelihood of smokers taking up ST 
 
Almost half (44%) of respondents indicated that they were likely to try at least one of the four ST 
products, even though only 17% had ever used ST. This finding has implications for the impact 
and efficacy of advertising of ST on young adult Canadian smokers, and provides information 
about how young adult Canadian smokers might use ST products. On the other hand, 
significantly more (77%) respondents indicated that they were likely to try at least one of the 
four NRT products. 
 
The responses for likelihood of future use followed the same general trend as the ratings of 
product appeal. It is intuitive that products which are rated as more appealing (duMaurier snus, 
Ariva lozenge, Marlboro snus) would receive higher intentions for future use. The same factors 
that influence appeal might also influence likelihood of future use, either directly, through 
increased product appeal, or another mechanism. 
 
It should be noted that the wording of the question, ―Overall, how likely would you be to try this 
product in the future?‖ is limited by its generality. The question does not access the various 
reasons a respondent might use a ST product, such as to substitute for smoking when they do not 
want to smoke or cannot smoke, or to help cut back or quit smoking altogether. There are 
reasons a respondent might choose to use ST that are personal and could not be anticipated. This 
question has value, therefore, in determining how likely young adult smokers would be to try ST 
for any reason or in general, not limited to the reasons mentioned above and detailed in section 
7.4.  
 
Respondents were slightly more (66%) willing to use at least one of the four ST products when 
prompted to consider one of five potential reasons for using ST. Thus, when smokers were 
offered specific reasons for using ST, they rated themselves as more open to trying ST than when 




Viewing a picture health warning significantly lowered likelihood of future ST use, and viewing 
a relative risk message significantly raised likelihood of future ST use. There was a trend 
towards decreased odds of future ST use as the health warning was increased from none, to text, 
to picture. But only when comparing picture warnings to text warnings or no warning was the 
decrease statistically significant. These findings are consistent with the literature on cigarette 
warnings. In a study that assessed the impact of the introduction of picture warning labels in 
Canada on adolescents, it was found that the adolescents noticed, thought, and talked about the 
warnings more, and in turn both experimental and regular smokers had more thoughts about 
quitting and forgoing cigarettes (White, Webster & Wakefield, 2008). However, the current 
finding is not consistent with a relatively old study examining the impact of text warning labels 
on ST for high school students which found that text warning labels had no effect on students‘ 
ratings of whether they would use ST in the future (Brubaker & Mitby, 1990). 
 
The finding that viewing a picture health warning decreased likelihood of future ST use indicates 
that the picture health warning labels achieved their ultimate purpose – to discourage use of the 
product. This finding is consistent with the literature for cigarettes which indicates that picture 
warnings are effective at reducing cigarette consumption (Borland & Hill, 1997; Hammond, 
Fong, McDonald, Cameron & Brown, 2003; White, Webster & Wakefield, 2008; Borland et al., 
2009). 
 
The finding that viewing a relative health risk message comparing the harm of using ST to 
smoking cigarettes raised likelihood of future use suggests that the relative health risk message 
was successful in achieving its purpose – to encourage accurate health risk perceptions about ST, 
and an informed choice of tobacco product. This is a significant finding since tobacco users have 
been shown to be more open to trying a reduced risk product (Stark et al., 2008; Geertsema, 
Phillips & Heavner, under review; Heavner, Rosenberg & Phillips, 2009). 
 
Minorities were found to have higher likelihood of future ST use. This is an interesting finding 
given that in recent years in the US, use of ST by minorities has significantly decreased 
(Mumford, Levy, Gitchell & Blackman, 2005), and ST users are almost exclusively white (Rodu 
& Cole, 2009). However, in this study minorities also found ST to be more appealing. There may 
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be differences between young adult minority Canadian smokers and US ST users that make them 
more likely to embrace ST use; a notion that is supported by the finding in this study that 
minorities were more willing to try ST as a long-term replacement for smoking. 
 
7.4 Potential for ST use for smoking substitution, replacement, and cessation 
 
Whether ST will prevent or promote cigarette smoking, serve as a cessation tool or complete 
replacement for smoking, or be used in conjunction with cigarettes is unknown and depends on a 
number of factors. The proportion of respondents willing to try each product for each of the five 
reasons follows the same general trends as how aware respondents were of each product, and 
how appealing they found each product. This finding suggests that product awareness, product 
appeal, the factors that influence product awareness and appeal, and certainly other factors, 
influenced willingness to try ST for each of the five reasons detailed in the following sub-
sections. 
 
About half of the respondents were willing to try at least one of the four STs for the times when 
they cannot smoke, when they do not want to smoke around others, to help cut back, and to help 
quit. About one-third of the respondents were willing to try at least one of the four STs as a long-
term replacement for smoking. There was no significant difference in the proportion of 
respondents who expressed willingness to try NRT for each of the same five reasons. 
 
There is a trend towards decreased willingness to try ST for all five reasons as the health warning 
is increased from none, to text, to picture. Specifically, the difference between picture warning 
and no warning was significant for four of the five reasons examined (with the exception being 
when they cannot smoke around others). The finding that picture warnings decrease willingness 
to try ST for each of the five reasons is reflected in the literature for cigarette warning labels, 
which indicates that picture warnings increase perceptions of harm and decrease product 
consumption (Stark et al., 2008; Geertsema, Phillips & Heavner, under review; Heavner, 
Rosenberg & Phillips, 2009). 
 
For example, previous research examining the effect of picture warning labels on reduced 
exposure products including ST found that smokers and non-smokers rated products with picture 
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warnings as more harmful (Stark et al., 2008). The notion smokers are less willing to try a 
product in place of cigarettes that they perceive to be equally or more harmful is reflected in 
studies examining smokers‘ reasons for not considering switching to ST (Geertsema, Phillips & 
Heavner, under review; Heavner, Rosenberg & Phillips, 2009).  
 
Viewing a text warning on ST packages reduces willingness to try ST, but viewing a relative risk 
message appears to compensate for this reduction in willingness to try ST for each of the five 
reasons. On the other hand, there was a decrease in willingness to try ST for each of the five 
reasons when the relative risk message was added to packages with a picture warning label, 
which was unexpected (see section 7.4.4). However, for all five reasons the compensatory 
increase in willingness to try ST was not statistically significant. In short, the relative risk 
message compensated for the decrease in willingness to try ST for packages with a text warning, 
but decreased willingness to try ST even further for packages with a picture warning. 
 
7.4.1 Potential for use as a substitution when smokers cannot smoke 
 
Nearly half (49%) of the respondents indicated that they were willing to use at least one of the 
four ST products in places where they cannot smoke. The large proportion of smokers in this 
study who said they would use ST in places where they cannot smoke may have been influenced 
by (or may have influenced) ST advertising. ST is commonly marketed to adult tobacco users 
―for when you can‘t smoke‖ (Polito, 2004) and as an alternative to smoking (Hatsukami et al., 
2007). Full-page newspaper advertisements for the recently test-marketed duMuarier snus read, 
―the handy tobacco option…smoke free, chew free and spit free, SNUS is an alternative for adult 
tobacco users‖ (http://goodhealth.freeservers.com/du_Maurier_snus_ad_12_2009.jpg). The 
marketing strategy ‗for when you can‘t smoke‘ is likely a strategic response on the part of 
tobacco companies to the many smoke-free policies that have been enacted in Canada in recent 
years (OTRU, 2009). A study of industry documents on the development of ST products 
supports the notion that the tobacco industry deliberately developed ST to target smokers in 
response to smoking restrictions, health concerns, the growing social unacceptability of smoking, 
and the changing demographics of ST users (Carpenter, Connolly, Ayo-Yusuf & Wayne, 2009). 
That is, in North America ST appears to have been developed and marketed to be used alongside 
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cigarettes. Furthermore, the evidence indicates that dual-use of cigarettes and ST is not 
uncommon (Mumford, Levy, Gitchell, & Blackman, 2005; Rodu & Cole, 2009). 
 
The finding that a significant proportion of smokers in this study were willing to try ST in places 
where they cannot smoke concurs with the findings from research on secular trends in Sweden 
which indicate that Swedish snus might have been used by men to partially replace smoking 
(Tomar, 2007), and the findings from two US national surveys (Tomar, 2002; Hatsukami, 
Lemmonds & Tomar, 2004) which showed that dual-users of cigarettes and ST smoked fewer 
cigarettes; and daily ST users smoked less than occasional and non-users of ST, who did not 
smoke fewer cigarettes. That dual-users of cigarettes and ST smoke fewer cigarettes is further 
supported by a cancer prevention trial studying dual-use and smoking cessation (Wetter et al., 
2002). Dual-use was also evident in a Health Canada commissioned focus group study of the 
effect of warnings on ST users which found that users had mainly chosen to use ST to get 
nicotine when they could not smoke, such as during sporting events or recreational activities, at 
work, and at home (Créatec, 2003). In short, this finding indicates that a significant proportion of 
smokers may want to use ST as a nicotine substitution while continuing to smoke. The literature 
suggests that use of ST in this fashion could decrease total cigarette consumption. 
 
Participants with a moderate income level were more willing to try at least one ST product when 
they cannot smoke. This finding is contrasted by research showing that ST users had lower 
income than never users of tobacco (Rodu & Cole, 2009), although exclusive smokers and 
primarily ST users may not be comparable groups. One potential explanation is that those with a 
moderate income may work in occupations and/or frequent public spaces where smoking is 
restricted or socially unacceptable more often than those with low or high incomes, and therefore 
out of necessity are more open to using ST when they cannot smoke. 
 
7.4.2 Potential for use as a substitution when smokers do not want to smoke around others 
 
Nearly half (48%) of the respondents were willing to use at least one of the four ST products 
when they do not want to smoke around others. The appearance of the product may have had a 
significant effect on smokers‘ willingness to try ST when they do not want to smoke around 
others. The three products that respondents indicated they were most willing to use are 
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comprised of two teabag-like snus products and one lozenge – ST forms that appear easy and 
discrete to use (i.e., spit-free). In contrast, the ST product respondents indicated they were least 
willing to use was the coffee ground-like snuff – a product which does not appear easy or 
discrete to use. The idea that smokers may be more likely to consider using a product that looks 
discrete to use is supported in a study of adult Canadian smokers, which found that 44% of 
women and 36% of men would not consider switching to ST because it was socially 
unacceptable or gross. Interestingly though, when asked about a hypothetical product that could 
be used discretely, 79% of those indicated that they would consider switching (Heavner, 
Rosenberg & Phillips, 2009). As the authors of the study note, these erroneous beliefs 
demonstrate the lack of awareness among smokers with regards to modern ST products which 
are spit free and can be used discretely, and indicate that with minimal education efforts smokers 
may consider switching to ST. 
 
Some factors that may influence smokers‘ product choices include the various social and legal 
pressures smokers face to not smoke around others, and children in particular. Indeed, a lack of 
secondhand smoke has been cited by ST users as an important reason for using ST (Créatec, 
2003). Furthermore, as of Jan 1, 2010, smoking in cars with children will be restricted in six of 
the thirteen Canadian provinces and territories, and in Ontario many municipalities have banned 
smoking near playgrounds, parks, public pools, zoos, and popular family-oriented recreational 
sites (OTRU, 2009). Interestingly, a 2008 survey of Ontario adults found that more provisions 
are supported: smoking bans were supported in multi-unit dwellings, for adults smoking at home 
with children present, in parks and beaches, and on sidewalks (OTRU, 2009).  
 
Health authorities are concerned with protecting adults and children from secondhand smoke as 
well. In their 2004 position paper, the Ontario Medical Association recommends protection from 
secondhand smoke for children at home, in vehicles, and in care facilities (OMA, 2004). 
Internationally, Article 8 of the WHO‘s Framework Convention on Tobacco Control requires 
member states to implement smoke-free legislation to protect people from secondhand smoke 





7.4.3 Potential for use as a partial replacement to reduce cigarette smoking 
 
Nearly half (49%) of the respondents were willing to use at least one of the four ST products to 
help cut back the amount they smoke. Rodu and Godshall (2006) have stated that, ―Many 
smokers are unable – or at least unwilling – to achieve cessation through complete nicotine and 
tobacco abstinence; they continue smoking despite the very real and obvious adverse health 
consequences. Conventional smoking cessation policies and programs generally present smokers 
with two unpleasant alternatives: quit, or die.‖ As reduced harm tobacco products, the use of ST 
to cut back on smoking presents a viable alternative for these ―inveterate‖ smokers. This study 
demonstrates that a substantial proportion of young adult Canadian smokers are willing to use ST 
to help cut back the amount they smoke. The results of this study are contrasted by a Health 
Canada commissioned focus group study of the effect of warnings on ST users which found that 
many smokers used ST for nicotine relief, and not necessarily to cut back on smoking (Créatec, 
2003). 
 
7.4.4 Potential for use as a cessation aid to help smokers quit 
 
Nearly half (48%) of the respondents were willing to use at least one of the four ST products to 
help while they are trying to quit smoking. These are interesting findings given that smoking 
cessation rates are generally quite low. In 2003, just over half of ever-smokers in Canada had 
quit smoking (Health Canada, 2003) and in 2006 about half (50%) of ever-smokers in the US 
were currently former smokers (CDC, 2007). Though in 2000, 70% of US smokers said they 
want to quit smoking altogether, only 5% of smokers who smoked most days managed to quit 
and remain abstinent for 3-12 months (CDC, 2002). ST may therefore be used viably as a 
cessation aid by young adult smokers in addition to, or as an alternative to, more traditional 
cessation assistance. 
 
A frequent argument made against the use of ST as a cessation aid in harm reduction is the 
widespread non-prescription availability of NRT, which has proven effective in smoking 
cessation (Silagy, 2002; ASH, 2007). However, a 2003 meta-analysis indicated that the long-
term quit rate for those who use non-prescription NRT is only 7% (Hughes, Shiffman, Callas & 
Zhang, 2003). Therefore, ST might be a viable alternative to NRT for some smokers, including 
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―inveterate‖ smokers. The 1998 US National Health Interview Survey (NHIS) indicated that 6% 
former smokers quit with the help of ST (Tomar, 2007), which is comparable to the success rate 
for those using NRT. 
 
There is a significant body of evidence which indicates that smokers have successfully used ST 
to help them quit. The 1991 US NHIS indicated that 33.3% of current ST users were former 
smokers (Centers for Disease Control and Prevention, 1993). Data from the 2000 US National 
Health Interview Survey show that male smokers who tried ST to help quit had the highest 
success rate (73%), compared to those who tried nicotine patch (35%), gum (34%), and inhaler 
(28%) (Rodu & Phillips, 2008). And another study has demonstrated short-term efficacy of ST as 
a smoking cessation aid (Tønnesen, Mikkelsen & Bremann, 2008). On the other hand, NRT has 
been preferred over ST in a number of studies. (Mendoza-Baumgart et al., 2007; Shiffman et al., 
2007). In this study, 48% of the young adult smokers had ever used any NRT, and of those, 
respondents had used gum (46%), patch (31%), lozenges (7%), tablets (2%), inhaler (7%), and 
nasal spray (1%). However, all respondents remained current smokers upon entry into ths study; 
they had not successfully quit using traditional NRT. Although they were not asked, it is possible 
that NRT had helped them cut back on cigarette consumption.  
 
Regardless of the efficacy of ST and NRT as cessation aids, the nicotine delivery characteristics 
of ST may make it preferable for smoking cessation compared to NRT. There is a notable 
difference in the level of nicotine in ST compared to NRT. ST products contain much higher 
levels of nicotine than NRT; high enough that they are generally recognized as being addictive 
(Tilashalski, Rodu & Mayfield, 1994; Richter & Spierto, 2003). For example, NRT patch 
delivers nicotine in low levels such that concurrent smoking is common (Benowitz, 1988). On 
the other hand, the nicotine in ST is absorbed more slowly, but results in peak blood nicotine 
levels similar to cigarettes that persist for longer than the levels from cigarettes (Henningfield, 
1995). However, high-strength nicotine patches have been tested and may provide more adequate 
nicotine replacement (Dale et al., 1995; Ebbert et al., 2007). Regardless, the quantity of nicotine 
consumed by ST users and smokers is similar (Ramstrom, 2003). In short, lower nicotine ST 
products may be less addictive, but also less likely to replace cigarettes for current smokers. On 
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the other hand higher nicotine products may be addictive, but they are more likely to replace the 
more harmful cigarette (Hatsukami et al., 2007). 
 
The notion that the nicotine delivery characteristics might make ST a preferable smoking 
cessation aid compared to NRT is supported in data from Sweden, where ST used as a cessation 
aid also shows a higher success rate compared to NRT (TEMO, 2001; Ramström, 2002), 
particularly for smokers who are more nicotine dependant (Fagerström & Ramström, 1998). 
However, in the US ST accounts for a small fraction of successful smoking cessation, according 
to Tomar (2007). A US longitudinal study of smokers that examined the use of ST as a cessation 
aid found that a quarter had quit using ST at one year follow-up, and about a quarter had quit and 
remained abstinent using ST at seven year follow-up (Tilashaki, Rodu & Cole, 2005). However, 
consumer preference may matter more than product effectiveness; some people prefer ST, some 
people prefer NRT, and some people prefer no help whatsoever in quitting smoking (Kotlyar et 
al., 2007). For example, a study that examined preferences, usage, and health risk of NRT 
lozenge and ST lozenges found that Ariva lozenge was preferred over NRT lozenge, even though 
feelings of withdrawal and craving, and carcinogen uptake were similar between the Ariva and 
NRT lozenge (Mendoza-Baumgart et al., 2007). 
 
Participants who were planning to quit smoking beyond six months compared to those planning 
to quit within one month were found to have significantly higher willingness to try ST to help 
quit smoking. These smokers who plan to quit, but not in the immediate future, may be more 
willing to try ST because their desire to quit smoking or quit using tobacco is less urgent than 
those who plan to quit within a month or six months, for example. These smokers may be more 
willing to delay complete tobacco abstinence by using ST as an alternative tobacco product. 
Previous research indicated that smokers who were trying to cut down were more willing to 
substitute ST for cigarettes (Timberlake, 2009). Previous research also indicated that smokers 
who had plans to quit in the more distant future were more open to switching to ST than smokers 
with no plans to quit (Heavner, Rosenberg & Phillips, 2009). The current research and previous 
research taken together suggest that smokers with distant quit plans, but not proximal or non-




7.4.5 Potential for use as a long-term complete replacement for cigarettes 
 
Nearly a third (32%) of the respondents were willing to use at least one of the four ST products 
as a long-term replacement instead of cigarettes. Research has shown that the long-term use of a 
nicotine replacement product in place of cigarettes is not uncommon. Despite the fact that the 
FDA limits use of NRTs to 10-12 weeks (based on concern about nicotine addiction, not health 
per se), many users continue to use NRT for up to six months and beyond (Henningfield, 1995; 
Garvey et al., 2000; Shiffman, Hughes, Pillitteri, & Burton, 2003). This study concurs with 
previous research on smokers‘ willingness to switch to ST as a long-term replacement. A small 
study of adult Canadian (Edmonton) smokers indicated that 10% had considered switching to 
ST, and 40% had considered switching to NRT. Those who had not considered switching to ST 
or NRT offered reasons related to their perceived health risks of these products, which were 
erroneous (Heavner, Rosenberg & Phillips, 2009). Similarly, research has shown that over half 
of US smokers believe incorrectly that nicotine causes cancer (Cummings et al., 2004). These 
findings support the notion that smokers‘ reluctance to switch to ST (and NRT) is partly a result 
of misperceptions about the relative health risks of these products compared to smoking. Many 
also indicated that they did not consider switching to ST because it was socially unacceptable or 
gross (Heavner, Rosenberg & Phillips, 2009). As the authors of the study note, these false beliefs 
demonstrate the lack of awareness among smokers with regards to modern ST products which 
are spit free and can be used discretely. Interestingly though, when asked about a hypothetical 
product that could be used discretely, most of those who did not consider switching because they 
found ST socially unacceptable indicated that they would consider switching (Heavner, 
Rosenberg & Phillips, 2009). 
 
The notion that smokers would be especially interested in using ST products as long-term 
replacements for cigarettes when given accurate information about relative health risk is 
supported by research which indicates that the majority of smokers were interested in switching 
to an oral nicotine product when it was described similarly to modern pouch or sachet style ST 
(snus); that is, a tobacco product that carries 1% of the health risk of smoking cigarettes and is 
nearly as satisfying (Geertsema, Phillips & Heavner, under review; Heavner, Rosenberg & 
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Phillips, 2009). These smokers may fall under the category of ―inveterate‖ smokers described by 
Rodu and Godshall, who are unwilling or unable to completely eliminate tobacco use. 
 
7.5 Smokers‟ health risk beliefs about ST, cigarettes and NRT 
 
7.5.1 Smokeless Tobacco vs. Cigarettes 
 
Over a quarter (28%) of respondents had misperceptions about the relative health risks of ST and 
cigarettes and incorrectly believed that all four ST products were at least as harmful, or more 
harmful than cigarettes. Depending on the product, between 30% and 47% of respondents 
incorrectly indicated that ST and cigarettes are equally harmful, and a small proportion believed 
that ST is more harmful than cigarettes. In fact, ST carries much lower health risk than smoking 
(Stratton, Shetty, Wallace & Bondurant, 2001; TAGRCP, 2002; Levy et al., 2004). 
 
Misperceptions about the relative risk of ST and cigarettes are not uncommon. Previous research 
has shown that 68% of adult Canadian smokers are aware of ST products, and of those only 14% 
believe they are less harmful than conventional cigarettes (O‘Connor et al., 2007). The risk of ST 
compared to cigarettes was also overestimated in data from adult smokers in Australia, the US, 
and the UK (O'Connor et al., 2005; O'Connor et al., 2007; Smith, Curbow & Stillman, 2007), and 
high school seniors in the US (Tomar & Hatsukami, 2007). A 2000 study of 36,012 young adult 
US Air Force entrants found that the vast majority underestimated the harm reduction potential 
of switching from smoking to using ST (Haddock et al, 2004). On the contrary, both Americans 
(Phillips, Wang & Guenzel, 2005) and Canadians (Heavner, Rosenberg & Phillips, 2009) 
overwhelmingly hold the incorrect belief that switching to ST from smoking will result in a large 
increase in the risk of oral cancer. Similarly, a study of Canadian university students found that 
half believed that ST ‗definitely causes oral cancer‘ (Geertsema, Phillips & Heavner, under 
review). Even in Norway and Sweden, where ST is more commonly used, adolescents 
(Øverland, Hetland & Aarø, 2008) and adults (Anon, n.d.) overestimate the harm of ST relative 
to smoking. 
 
On the other hand, a focus group study commissioned by Health Canada found that adult 
smoking and non-smoking ST users perceived ST to be generally less harmful than smoking 
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cigarettes. In fact, the study found that ST users had a strong tendency to view ST as less harmful 
than smoking; partly because many ST users who still smoked had taken up ST in order to 
reduce cigarette consumption (Créatec, 2003). A large study of adult smokers in Canada, the US, 
the UK, and Australia also found that users of ST were more likely to believe ST is less harmful 
than cigarettes (O‘Connor et al., 2007). This is likely because they use the product, and engage in 
some form of self-exempting belief or optimistic bias. 
 
That so many people are misinformed about the relative health risk of ST compared to smoking 
is not surprising given the finding from a systematic review of internet content in 2003 that 
found that the risks of ST and smoking cigarettes were almost always made confusing, most 
often by websites which implied that the risks are comparable, as well as by about a third of 
websites which claimed that ST is equally or more harmful than smoking. Public health 
authorities and tobacco control advocates also tend to exaggerate the health risk of ST compared 
to cigarettes (Phillips, Wang & Guenzel, 2005). Phillips and Heavner (2009) argue that the 
problem is exacerbated by the Canadian prohibition on the dissemination of accurate information 
about the relative harms of tobacco products. 
 
The notorious failure of the ―low yield‖ cigarette is also used often as a counter-argument to the 
promotion of reduced harm ST (Stratton et al., 2001). In fact, the failure of the ―low yield‖ 
cigarette, which was incorrectly perceived to be lower risk, was at least informative – the 
widespread commercial success of the product demonstrated that smokers will readily change 
their current tobacco product and take up a new product that is (perceived to be) less harmful to 
their health. Though, as Kozlowski (2007) notes, ―The longstanding, current, and legal 
availability of smokeless tobacco products gives some reason to believe that those who like 
smoking will not readily come to prefer smokeless tobacco.‖ 
 
Viewing a picture health warning label significantly decreased correct beliefs about the health 
risk of ST compared to cigarettes, and viewing a relative risk message significantly increased 
correct beliefs about the health risk of ST compared to cigarettes. This finding is supported by 
previous research examining the effect of picture warning labels on reduced exposure products 
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including ST, which found that smokers and non-smokers rated products with picture warnings 
as more harmful (Stark et al., 2008). 
 
The finding that picture warning labels resulted in erroneous beliefs about the health risk of 
using ST compared to smoking concurs with the results found in the literature for picture 
warnings on cigarette packages. Picture warnings increase knowledge (Thrasher, Hammond, 
Fong & Arillo-Santillán, 2007) and concerns (O‘Hegarty et al., 2006) about the health effects of 
smoking, as well thoughts of harm (Borland et al., 2009). A similar result is seen in the current 
study‘s findings, in that picture warnings seem to have increased perceptions of ST risk, but to 
inaccurate levels. In contrast, text warnings did not have the effect of increasing misperceptions 
about ST health risk. This is a striking finding given that Hammond‘s (2009) evidence review on 
tobacco warning labels reports that, ―Several large studies have shown that large text-based 
warnings are associated with increased perceptions of risk.‖ Compared to picture warnings, text 
warnings on ST seem to cultivate far more accurate beliefs about the true health risk of ST 
compared to cigarettes. 
 
Interestingly, a Health Canada commissioned focus group study found that adult smoking and 
non-smoking ST users expressed low personal impact from picture warnings for a variety of 
reasons; some did not want to accept the health risks since they had already switched from 
cigarettes to reduce personal harm, and some found the images repulsive. However, some noted 
that the text warnings did not get their attention and were not convincing (Créatec, 2003). So 
while text warnings encourage more accurate health risk beliefs than picture warnings, they may 
not necessarily have their desired impact. 
 
Regardless of the type of warning label, the addition of a relative health risk message on the 
package was effective in promoting accurate perceptions about the health risk of ST compared to 
cigarettes. However, the effect of the relative health risk message was not sufficient to counter 
the increase misperceptions caused by the picture warning label. In fact, for packages with a 
picture warning, the relative risk message reduced misperceptions only to around the levels seen 




Males, those with moderate education, and those with high income had significantly higher 
correct beliefs about the health risk of ST compared to cigarettes. Males may hold more accurate 
beliefs about the relative health risk of ST compared to cigarettes because they are more familiar 
with ST, and are more likely to be exposed to modern ST products in their social groups 
consisting of other males. The finding that higher socioeconomic status smokers hold more 
correct beliefs about the health risk of ST is concurs with previous research which found that 
higher socioeconomic status smokers were more knowledgeable about the health risks of 
smoking, and had less misperceptions about nicotine (Siahpush, McNeill, Hammond & Fong, 
2006). 
 
The responses to the survey questions assessing relative health risk beliefs were dichotomised to 
‗less harmful‘ and ‗the same or more harmful‘. The choice to dichotomise to ―less harmful‖ and 
―the same or more harmful‖ was made based on the strong epidemiological evidence indicating 
that using ST is much less harmful to health than smoking (Stratton, Shetty, Wallace & 
Bondurant, 2001; TAGRCP, 2002; Levy et al., 2004), and based on the choice of dichotomised 
responses used in previous studies (O‘Connor et al., 2007, Øverland, Hetland & Aarø, 2008). 
The same method was used to dichotomise responses to the questions assessing relative risk and 
relative addictiveness beliefs about ST compared to NRT, and NRT compared to cigarettes. 
 
7.5.2 Smokeless Tobacco vs. Nicotine Replacement Therapy 
 
Less than half (48%) of the respondents answered accurately that all four smokeless tobacco 
products are the same or more harmful than nicotine replacement therapy. Interestingly, when 
viewing NRT and responding to the analogous question less than a fifth (15%) of respondents 
answered accurately that all four NRTs are less harmful than ST. This finding indicates that a 
large proportion of smokers are confused about the relative health risks of ST and NRT. There is 
little other research on perceptions about the relative risk of ST compared to NRT, however 
misperceptions about the health risks of nicotine are common. In a study consisting of a large 
sample of smokers in Canada, the US, the UK, and Australia, more than 40% believed 
incorrectly that the nicotine in cigarettes is the primary cause of cancer (Siahpush, McNeil, 




Viewing either a picture or a text health warning label significantly increased accurate beliefs 
about the risk of ST compared to NRT, likely by increasing perceptions of the risk of ST relative 
to NRT. 
 
Older participants were found to have significantly more accurate beliefs, and males, ethnic 
minorities, those who smoke weekly compared to those who smoke daily, and those reporting 
moderate or high income were found to have significantly less accurate beliefs. These findings 
are contradicted by previous research on perceptions about the health risks of cigarettes which 
found that younger participants and those with higher income and education levels had more 
accurate perceptions about both the health risk of cigarettes and the health risk of nicotine. 
Although, the same study found also that females tended to have more accurate beliefs, but the 
association was not significant (Siahpush, McNeill, Hammond & Fong, 2006). 
 
7.6 Smokers‟ beliefs about the addictiveness of ST, cigarettes and NRT 
 
7.6.1 Smokeless Tobacco vs. Cigarettes 
 
Nearly half (48%) of respondents believed that ST is less addictive than cigarettes. Similarly, 
previous research has found that adult smoking and non-smoking ST users perceived ST to be 
less addictive than smoking cigarettes. However, ST users also reported feeling the most strongly 
addicted to nicotine, and their product (Créatec, 2003). 
 
Viewing a picture warning label significantly decreased the accurate belief that ST is less 
addictive than cigarettes, and viewing a relative risk message significantly increased the accurate 
belief that ST is less addictive than cigarettes. These findings indicate that the effects of viewing 
text warning labels and viewing relative health risk messages early on in the survey remained 
and had an effect on later perceptions of the addictiveness of ST compared to cigarettes. Picture 
warnings seem to have increased perceptions of the addictiveness of ST to inaccurate levels, 
whereas the relative health risk message seems to have been effective at encouraging accurate 




Those reporting no plans to quit smoking and those who did not provide quit plans were found to 
be significantly less likely to accurately believe that ST is less addictive than cigarettes compared 
to those planning to quit within one month. Smokers who do not plan to quit may be more 
content with smoking cigarettes, more reluctant to consider alternative products, and/or may 
ascribe all tobacco products as equally ‗bad‘ and addictive. This hypothesis is consistent with the 
earlier hypothesis that smokers with distant quit plans, but not proximal or non-existent quit 
plans are more likely to consider using ST. 
 
7.6.2 Smokeless Tobacco vs. Nicotine Replacement Therapy 
 
Over a quarter (27%) of respondents incorrectly believed that ST is less addictive than NRT. STs 
generally deliver higher levels of nicotine than NRTs (Benowitz, 1988; Tilashalski, Rodu & 
Mayfield, 1994; Richter & Spierto, 2003; Kotlyar et al., 2007), and are therefore likely to be 
more addictive than NRT. However, there is a lack of other research on smokers‘ perceptions of 
the addictiveness of ST compared to NRT. Misperceptions may be partially due to the 
knowledge that nicotine is the addictive agent in tobacco, and nicotine in the active ingredient in 
NRT. 
 
Participants reporting no plans to quit smoking were found to be significantly more likely to 
have accurate beliefs about the addictiveness of ST compared to NRT. Of possible concern, this 
finding indicates that smokers who are planning to quit have inaccurate perceptions about the 
addictive properties of one of the lowest risk smoking alternatives, NRT, which might prevent 
the use of NRT (and favor the use of ST) for smoking cessation. 
 
7.6.3 Nicotine Replacement Therapy vs. Cigarettes 
 
Almost three-quarters (71%) believed correctly that NRT is less addictive than cigarettes. This 
finding complements previous findings that many smokers are still confused about the health 





Viewing a text warning label on the ST products decreased the accurate belief that NRT is less 
addictive than cigarettes. This finding indicates that there may have been a carry-over effect of 
viewing text warning labels on ST that affected later perceptions of the addictiveness of NRT 
compared to cigarettes. It is possible that respondents came to associate the ST products 
presented to them as a kind of NRT, or alternative product to smoking, possibly because 
respondents were asked about how they might use both the ST and NRT products as alternatives 
to smoking. However, this is unlikely given that a similar effect was seen for beliefs about the 
addictiveness of ST compared to cigarettes. 
 
7.7 Smokers support picture health warning labels on ST packages 
 
Nearly three-quarters (71%) of respondents supported picture warning labels. The results of this 
study confirm previous research which found strong support for tobacco health warnings and the 
valuable health risk information they provide. For example, a Health Canada commissioned 
study just prior to the introduction of picture warning labels in Canada found that when asked 
unprompted, both adult (20%) and youth (25%) smokers and non-smokers suggested introducing 
picture warning labels on cigarettes (Environics Research Group, 1999). Furthermore, in a 2002 
Brazilian survey of 2,216 adults upon introduction of picture health warnings on cigarettes, 73% 
of smokers approved of the new warnings (Cavalcante, n.d.). And in an assessment of the 
Canadian picture health warnings on cigarettes 1.5 years after their implementation over 70% of 
adult smokers and over 90% of youth smokers reported that the warnings effectively informed 
them about the health effects associated with smoking; over half of adults and youth reported 
that the health warnings discouraged them from smoking around others; and over 40% of adults 
said the warnings have encouraged them to try to quit (WHO TFI, 2005). 
 
Participants who reported having no plans to quit smoking supported picture warning labels on 
ST significantly less than those planning to quit within one month, which seems to be consistent 
with previous research. A telephone survey of adult smokers and ex-smokers performed to gather 
data for the introduction of newer, stronger cigarette health warnings in Australia in 1995, found 
strong support for the proposed stronger warning labels, and those wanting to quit were more 
likely to want more health information (Borland & Hill, 1997). It seems that those who are 
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planning to quit support more health information on the package, and those who do not plan to 
quit are not interested in more information. 
 
7.8 Smokers support relative health risk information on ST packages 
 
Two-thirds (68%) of respondents supported relative health risk information on smokeless 
tobacco packages. The data from this study concurs with the findings of widespread support of 
health risk information on cigarettes packages. For example, two years following the 
implementation of picture warnings in Uruguay 62% of adult smokers reported that they would 
like more health information on the package, whereas 8% reported that they would like to see 
less health information (reported from unpublished data in Hammond, 2009). Similar findings 
were observed following the implementation of picture warnings in Thailand (reported from 
unpublished data in Hammond, 2009). Furthermore, a telephone survey of adult smokers and ex-
smokers performed to gather data for the introduction of newer, stronger cigarette health 
warnings in Australia in 1995, found that 38% thought there should be more health information, 
whereas just 2% thought there should be less. Interestingly, younger smokers and those who 
wanted to quit were more likely to want more health information (Borland & Hill, 1997). In 
addition, a Health Canada commissioned study just prior to the introduction of picture warning 
labels in Canada found that when asked unprompted, both adult (10%) and youth (21%) smokers 
and non-smokers suggested adding more detailed information to the warning labels on cigarettes 
(Environics, 1999). And another series of Health Canada commissioned studies that evaluated 
the picture warning labels found that 59% of adult smokers and 73% of youth smokers report 
that the warning labels provide them with valuable information about the health effects 
associated with smoking (Environics, 2004a, 2004b). After the introduction of cigarette warnings 
in Canada, it was also found that half of adult smokers in southwestern Ontario, Canada wanted 
to see more health risk information on cigarette packages, whereas only 27% thought the 
warnings contained ―too much‖ health risk information (Hammond, Fong, McDonald, Brown & 
Cameron, 2004). Finally, ITC project research indicates that the proportion of smokers who want 
to see more information on cigarette packages is greater than the proportion who want to see less 
information in all ITC countries, including those where picture warnings are already 




Viewing a picture warning label significantly decreased support for relative risk information. 
The finding that those who viewed a picture warning were less likely to support relative risk 
information probably results from a number of factors. First, picture warning labels tend to 
increase perceptions about the risk of ST products (Stark et al., 2008). Furthermore, picture 
warnings on cigarette packages have been found to increase concerns about the health effects of 
products (O‘Hegarty et al., 2006) and thoughts of harm from the product (Borland et al., 2009). 
If perceptions of the health risk of the ST products were raised sufficiently by the picture 
warning labels, respondents may have begun to question the credibility of the relative risk 
messages telling them that ST is much less harmful to health than smoking. In fact, a Health 
Canada commissioned focus group study on the effect of warnings on ST users perceptions 
found that users tended to question and/or disagree with extreme images and claims on picture 
warnings (Créatec, 2003). It is probable then that the relative risk information might also be 
questioned when simultaneously viewing the strong images and claims on the picture warnings 
that the respondents viewed. However, it is surprising that the  text warnings did not also have a 
significant effect given that Hammond‘s (2009) evidence review on tobacco warning labels 
reports that, ―Several large studies have shown that large text-based warnings are associated with 
increased perceptions of risk.‖ 
 
7.9 Study Limitations and Future Research 
 
The current study has a number of limitations. First, the sample of young adult smokers may not 
be representative of all young adult Canadian smokers. The sample was obtained from the 
registered participant panel of the market research firm, GMI. Registrants with GMI must have 
computer and internet access, therefore lower socioeconomic status (SES) Canadians may be 
underrepresented in this study. Respondents could have been recruited to complete the 
computerised survey in person, which might have increased the access of lower SES smokers. 
However, the proportion of respondents in the ―low‖ income category in this study (25%) was 
similar to that in a much larger study (29%) that used the same methods to categorise income, 
and was conducted using random-digit dialing methods that likely resulted in a more 
representative sample (Hammond et al., 2007). Furthermore, a study sample recruited in person 
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would be regionally representative, whereas the participants recruited for this study came from 
across Canada. 
 
A second limitation of this study was the limited number of brands and forms of ST presented to 
respondents. The number of ST products was limited to four brands consisting of three forms: 
two snus or sachet-style STs, one loose moist snuff, and one compressed tobacco lozenge. Other 
types of ST such as chew, and other popular brands such as Skoal and Access were not included. 
This choice was made in order to keep the survey length manageable. Including more products 
would be more representative of the STs available to Canadian consumers, but may have resulted 
in longer survey length and subsequently poorer data quality. 
 
A third limitation with regards to ST products is that two of the four STs are US products, and 
are not available in Canada. Marlboro snus was included because we wanted to specifically test 
perceptions of modern ‗snus‘ STs and duMaurier was the only snus on the Canadian market. 
Other snus products might have been chosen, but Marlboro is one of the most globally 
recognised tobacco brands. Similarly, Ariva was chosen because it is a unique modern ST 
product manufactured by compressing powdered tobacco into a dissolvable lozenge. We 
hypothesised that this product might be a particularly appealing product to current smokers, and 
that it therefore warranted testing. 
 
A fourth limitation is that only current smokers were included in the sample. Non-smokers and 
former smokers were excluded. It is particularly important to understand non-smokers 
perceptions and intentions around using ST in order to establish a sound scientific basis for 
promoting ST for harm reduction while minimising public health risk. Understanding how 
former smokers might use ST could be of importance as well, since promoting ST as a harm 
reduced product might allow former smokers or those who might otherwise have quit to continue 
using tobacco and not realise the full health benefits of complete abstinence, albeit using a much 
less harmful form of tobacco than cigarettes. On the other hand, former smokers might see the 
utility of smokeless tobacco for coping with cravings and preventing relapse. However, we were 
particularly interested in examining young adult smokers perceptions of ST in this study because 




In light of the fourth limitation of this study, future studies should investigate former smokers‘, 
and particularly non-smokers‘ perceptions of ST as well as how they might use these products, if 
at all. Previous research has called for such investigations (Hatsukami et al, 2007), including 
research to examine the effect of communicating the relative risk of tobacco products (Zeller & 
Hatsukami, 2009), and the potential ill effects of promoting ST in tobacco harm reduction 
(Kozlowski, 2007; Tomar, 2007). 
 
Future studies should also test the credibility of the relative risk message, the warning message, 
as well as their credibility together on ST products. The results of this study found that the 
relative risk message had the opposite of its intended effect when in the presence of a picture 
warning. This finding was hypothesised to have resulted from a loss of credibility of the relative 
risk message, which communicated the lower risk of ST compared to cigarettes, when a picture 
warning simultaneously communicated that there are serious health risks associated with using 
ST. Further research could elucidate the issue of message credibility when using the novel 
approach of communicating relative risk on tobacco health warnings. Determining the perceived 
credibility of relative risk messages which are meant to communicate accurate information about 
health risk is important given the finding that picture warnings significantly increased 
misperceptions about the health risk of ST, and the political reality that picture warnings are 
likely to be mandated on ST packages in Canada in the near future. 
 
7.10 Implications and Conclusions 
 
Young adult Canadians‘ perceptions about ST, beliefs about the health risk of ST relative to 
smoking, and intentions to use ST have important public health implications given the potential 
for ST to reduce tobacco-related mortality. The impact of health warning labels on ST are of 
particular importance not only with respect to current Health Canada initiatives to revise and 
improve all tobacco warning labels, but also in light of the need to correct consumer 





In the current study, a number of important findings emerged. First, the findings confirm that 
many smokers are unaware of the low health risk of ST and NRT relative to smoking. 
Furthermore, the study found that picture health warnings increased misperceptions about ST 
health risk. In contrast, text warnings did not have the effect of increasing misperceptions about 
ST health risk. Evidence suggests that more users might use much less harmful ST, or NRT, to 
reduce or replace smoking cigarettes if not for misperceptions about these products and their 
health risk compared to cigarettes. This finding highlights the need to effectively communicate 
accurate information about the relative health risks of ST and cigarettes. 
 
Despite the fact that many smokers were unaware of the low health risk of ST relative to 
smoking, approximately half of young adult Canadian smokers were open to using ST for the 
times when they cannot smoke, for the times when they do not want to smoke around others, to 
help cut back smoking, to help quit smoking, and as a long-term replacement for cigarettes. 
Interestingly, there was no difference in the proportion of respondents who were open to trying 
NRT for the same five reasons. These findings indicate that young adult smokers might readily 
try ST for a variety of reasons, and do not distinguish between ST and NRT products in their 
potential for use. Further research is needed to determine if the high level of openness to trying 
ST found in this study will translate into actual use, and whether increased ST use will result in 
decreased cigarette consumption and reductions in tobacco-related illness. 
 
Furthermore, the current study found that health warning labels reduced young adult Canadian 
smokers‘ willingness to try ST. Picture warnings significantly decreased willingness to try ST, 
whereas the decrease resulting from text warnings was small. In other words, picture warnings 
significantly reduced young adult cigarette smokers‘ willingness to take up a much less harmful 
tobacco product, ST, whereas text warning labels did not. This finding may be used to guide 
Health Canada initiatives to revise all tobacco warning labels, including the current text warnings 
on ST. 
 
Finally, adding a relative health risk message to ST health warnings that communicated a 
favourable (reduced) health risk for ST compared to cigarettes increased willingness to try ST 
when added to text warning labels, but decreased willingness to try ST even further when placed 
143 
 
on picture warnings. This finding, taken together with the previous finding regarding the 
differential impact of text and picture warning labels on willingness to try ST, suggests that 







APPENDIX A: Screener & Demographic Information, Consent 
 
SCREENER & DEMOGRAPHIC INFO, CONSENT 
PROGRAMMER NOTE: Show the following script: Welcome! To get started, please answer a 
few questions to verify your eligibility to participate in this study.  
 
PROGRAMMER NOTE: Show the following script: 
Screen1. What is your age in years?   |__________| Number (e.g., 24) [1-99 limit] 
PROGRAMMER NOTE: If less than 18 or over 30, show the following script and end survey: 
Unfortunately, to be eligible for this study you must be between 18 and 30 years of 
age. Sorry about that. [END SURVEY] 
PROGRAMMER NOTE: If no age entered, show the following script: 
Unfortunately, we need to know your age to determine your eligibility for the study. Continue 
to age question. 
Otherwise, ask: 
 
Sex I am (select): 
01 – Female 
02 - Male 
Ethnicity People in Canada come from many racial and cultural groups. Are you . . . 
01 – White 
02 – Chinese 
03 – South Asian (for example, East Indian, Pakistani, Sri Lankan, etc.) 
04 – Black 
05 – Filipino 
06 – Latin American 
07 – Southeast Asian (for example, Cambodian, Indonesian, Laotian, 
Vietnamese, etc.) 
08 – Arab 
09 – West Asian (for example, Afghan, Iranian, etc.) 
10 – Japanese 
11 – Korean 
12 – Aboriginal (that is, North American Indian, Métis, or Inuit), or 
13 – Another group? 
Education What is the highest level of formal education that you have completed? 
01 – Grade school or some high school 
02 – Completed high school 
03 – Technical or trade school or community college (some or 
completed) 
04 – Some university (no degree) 
05 – Completed university degree 
06 – Post-graduate degree 
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Income Please be assured that your responses will be kept completely confidential. 
Which of the following categories best describes your annual household 
income, that is the total income before taxes, or gross income, of all persons in 
your household combined, for one year? 
01 – Under $10,000 
02 – $10,000 to $29,999 
03 – $30,000 to $44,999 
04 – $45,000 to $59,999 
05 – $60,000 to $74,999 
06 – $75,000 to $99,999 
07 – $100,000 to $149,999 
08 – $150,000 and over 
Employment Are you currently employed outside the home? 
01 – Yes 
02 – No 
 
PROGRAMMER NOTE: If between 18 and 30 (inclusive): 
Screen2a. Have you smoked 100 cigarettes or more in your lifetime? 
01 - Yes   
02 - No 
 
Screen2b. How often do you smoke? 
 
01 - Daily  
02 - Weekly  
03 - Monthly 
 
04 - Less than monthly   
05 - Not at all 
 
PROGRAMMER NOTE: If non-smoker, show the following script and end survey: 
Unfortunately, to be eligible for this study you must have smoked at least 100 
cigarettes in your lifetime and smoke at least monthly. [END SURVEY] 
Otherwise, ask: 
Screen3. Have you ever used any other tobacco product other than cigarettes? (Select any) 
       Cigars 
       Pipes 
       Roll-your-own cigarettes 
                   Smokeless tobacco (e.g., chewing) 
PROGRAMMER NOTE: If yes in Screen3, include response category in Screen4. 
Screen4. Have you used any of the following products in the last month? (Select any) 
       Cigars 
       Pipes 
       Roll-your-own cigarettes 









INFO / CONSENT 
PROGRAMMER NOTE: Show the following script: 
Great – thank you for your interest!  You are eligible to participate in this survey. The survey 
will take approximately 20 minutes. First, you’ll review an information letter. Once you have 
read and understand the details of the study you may choose to click “agree” to continue 
completing the survey or “decline” to end the survey. 
 
Department of Health Studies & Gerontology               University of Waterloo 
 Faculty of Applied Health Sciences             200 University Ave West 




Title of Project: Smokeless Labels Study 
 
 Student Investigator:    Faculty Supervisor:   
 William Callery, BSc, MSc (Candidate) Dr. David Hammond, PhD 
 Dept. of Health Studies & Gerontology Dept. of Health Studies & Gerontology 
 University of Waterloo   University of Waterloo 
 (519) 888-4567, ext. 36786   (519) 888-4567, ext. 36462 
 E-mail: wcallery@uwaterloo.ca  E-mail: dhammond@uwaterloo.ca 
 
1.PURPOSE OF THIS RESEARCH STUDY 
 
You are being asked to be part of a research study that examines people’s opinions about smokeless 
tobacco warning labels.  We are interested in people’s opinions about different forms of warning labels 




In total, approximately 500 people will take part in the study. Participation involves a 20 minute online 
survey, conducted at a computer terminal. The survey will be split up into three parts. 
 
During the first portion, you will be asked questions about demographics as well as questions about 
your smoking history, such as the number of cigarettes you have smoked in your lifetime. During the 
second portion of the interview, you will be shown pictures of different smokeless tobacco packages 
and warning labels and asked to rate them on, for example, how likely you would be to try them and 
how risky they are.  In the third portion of the interview, you will be asked questions about your opinion 
of smokeless tobacco in general. 
 
We are interested in participants who are 18-30 years of age who have smoked greater than 100 
cigarettes in their lifetime, and smoke at least monthly. Participation is voluntary and you may decline 
to answer particular questions if you wish. 
 
3.POSSIBLE RISKS OR DISCOMFORT 
 
There are no known or anticipated risks to your participation in this study.   
 
4.POSSIBLE BENEFITS  
 
Participation in the study is not expected to benefit you directly but you are taking part in an important 




packaging regulations in Canada and other countries. At the end of the interview session, we will be 
happy to answer any questions you may have. Information on smoking cessation resources will be 
available should these be of interest to you. If you want to quit at any time during this study, information 
about how to quit and a list of local organizations that provide services to help you quit will be available 
from the researcher, if you wish. Taking part in this study will not require you to consider quitting.  
However, as you may know, smoking causes lung cancer, heart disease, and emphysema and may 
complicate pregnancy.  Quitting smoking now greatly reduces serious risks to your health.  
You will also have the option of receiving the final results of the study, if you’re interested.  If you desire 
this information, we will keep your contact address in a separate file and mail out the results when the 




In appreciation for your time and any inconvenience, you will receive financial remuneration worth a 





There is always a concern about keeping your privacy when you provide information about yourself 
such as your smoking history and demographics. All information obtained will be kept confidential. For 
your protection, we will assign you a number that will be used to label all information.  Any personal 
information such as your name and contact information will be kept in a separate file that will be locked 
securely in our lab at the University of Waterloo and will be destroyed after the study is completed in 
approximately 1 year. Electronic copies of your data will not contain any personal identifiers and will be 
stored indefinitely on a password protected computer at the University of Waterloo. 
 
The results of the study may be published for scientific purposes but will not give your name or include 
information that will identify you.  
 
7.TERMINATION OF RESEARCH STUDY 
 
You are free to choose whether or not to take part in this study. You can choose to stop being a part of 
the study at any time.  If during the study you decide to withdraw, you will still receive partial 




This study has been reviewed and received ethics clearance through the Office of Research Ethics at 
the University of Waterloo. However, the final decision about participation is yours. Should you have 
any comments or concerns resulting from your involvement in this study, please contact Dr. Susan 
Sykes in the Office of Research Ethics at (519) 888-4567, x36005. 
 
9.AVAILABLE SOURCES OF INFORMATION 
 
If you have any questions later, or if you require additional information about the study, please feel free 
to contact the researchers listed at the beginning of this information letter. 
 






Department of Health Studies & Gerontology  University of Waterloo 
Faculty of Applied Health Sciences   200 University Ave West 
     Waterloo, ON, CANADA 




Title of Project: Smokeless Labels Study 
 
I agree to take part in this research study being conducted by William Callery, a Masters student 
of the Department of Health Studies at the University of Waterloo. 
 
I have made this decision based on the information I have read in the information letter. All the 
procedures and any risks and benefits relating to my participation have been explained to me. I 
have had the opportunity to ask any questions and to receive any additional details I wanted 
about the study. If I have questions later about the study, or would like the information and 
consent form sent to me, I can ask one of the following researchers: 
 
 Student Investigator:    Faculty Supervisor:   
 William Callery, BSc, MSc (Candidate) Dr. David Hammond, PhD 
 Dept. of Health Studies & Gerontology Dept. of Health Studies & Gerontology 
 University of Waterloo   University of Waterloo 
 (519) 888-4567, ext. 36786   (519) 888-4567, ext. 36462 
 E-mail: wcallery@uwaterloo.ca  E-mail: dhammond@uwaterloo.ca 
 
 
I understand that I may withdraw from the study at any time without penalty by contacting the 
researcher listed above. 
 
This project has been reviewed by, and received ethics clearance, through the Office of 
Research Ethics at the University of Waterloo. I am aware that I may contact Dr. Susan Sykes 
at this office (519-888-4567, x 36005) if I have any concerns or questions from my involvement 
in this study. 
 
I agree to participate in this study:  
 
   Agree 
   Decline 










APPENDIX B: Background 
 
SMOKING BEHAVIOUR & SMOKING CESSATION 
 
PROGRAMMER NOTE: Show the following script: 
To begin, please answer a few questions about your smoking. 
 
1 Programmer note: If Screen2b = 01 (daily smoker), ask: 
On average, how many cigarettes do you smoke each day, including both 
factory-made and roll-your own cigarettes? 
|__________| Number [enter number] 
Programmer note: If Screen2b = 02 (weekly smoker), ask: 
On average, how many cigarettes do you smoke each week, including both 
factory-made and roll-your own cigarettes? 
|__________| Number [enter number] 
Programmer note: If Screen2b = 03 (monthly smoker), ask: 
On average, how many cigarettes do you smoke each month, including both 
factory-made and roll-your own cigarettes? 
|__________| Number [enter number] 
2 Programmer note: If Screen2b = 01 (daily smoker) ask: 
How soon after waking do you usually have your first cigarette? 
01 – |__________| Minutes [enter number] 
02 – |__________| Hours [enter number] 
Programmer note: If Screen2b = 02, 03 (non-daily smoker) ask: 
On days that you smoke, how soon after waking do you usually have your first 
cigarette? 
01 – |__________| Minutes [enter number] 
02 – |__________| Hours [enter number] 
3 a. Have you tried to quit smoking in the past 2 years?  
01 – Yes 
02 – No 
03 – Don‘t know 
(CTUMS, 2007) 
4 a. Are you planning to quit smoking: 
01 – Within the next month?  
02 – Within the next 6 months?  
03 – Sometime in the future, beyond 6 months 
04 – Not planning to quit  
5 Have you ever heard the following brands? 
DuMaurier    (01 – YES, 02 – NO, 03 – DON‘T KNOW) 
Marlboro       (01 – YES, 02 – NO, 03 – DON‘T KNOW) 
Copenhagen  (01 – YES, 02 – NO, 03 – DON‘T KNOW) 






NICOTINE REPLACEMENT THERAPY 
 
PROGRAMMER NOTE: Show the following script: 
Now we would like to ask you a few questions about nicotine replacement therapy (e.g., gum, 
patch, etc.). 
 
6 Have you heard about medications to help people stop smoking such as 
nicotine replacement therapy (e.g., gum, patch), or pills such as 
Zyban or Champix? 
01 – Yes GO TO Q.7 
02 – No GO TO Q.10 
7 Have you ever used any stop-smoking medication such as nicotine replacement therapy 
(e.g., gum, patch, etc.)? 
01 – Yes GO TO Q.8 
02 – No GO TO Q.10 
03 – Can‘t remember GO TO Q.10 
8 Which medication did you use? (Select any) 
01 – Nicotine gum 
02 – Nicotine patch 
03 – Nicotine lozenges 
04 – Nicotine (sub-lingual) tablets 
05 – Nicotine inhaler 
06 – Nicotine nasal spray 
07 – Zyban (or bupropion) 
08 – Wellbutrin 
09 – Other (specify) 
9 What was the main reason you used these medications? 
(select only one) 
01 – To stop smoking completely 
02 – To reduce the amount you smoke 
03 – To cope with times when you could not or were not allowed to smoke 
04 – Or some other reason? Specify: _____________________________ 
 
WARNING LABELS 
PROGRAMMER NOTE: Show the following script: 
The next set of questions will ask you about cigarette package warning labels. Please think 
about the warning labels you have seen on cigarette packages. 
10 In the last month, how often, if at all, have you noticed the warning labels on cigarette 
packages? 
01 – Never 
02 – Rarely 
03 – Sometimes 
04 – Often 
05 – Very often 
11 In the past 6 months, has information about the health risks of smoking on warning 
labels led you to think about quitting? 
01 – Not at all 
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02 – Once 
03 – A few times 








PROGRAMMER NOTE: Show the following script: 
You are now going to view 4 different smokeless tobacco packages. Smokeless tobacco (e.g., 
chewing, snuff) is used by placing it in the mouth, not smoking. After looking at picture of each 
product you’ll be asked to answer several questions. 
   
PROGRAMMER NOTE: Participants will be randomly assigned one of six experimental 
conditions where they will view only packages with either no warning, no warning with a 
relative risk message, a text warning, a text warning with relative risk message, a picture 
warning, or a picture warning with relative risk message. Participants will then be assigned 
random package/warning combination, and presented images in random order (first 4 
tobaccos at random, then 4 nicotine replacement therapies at random – referred in text as 1. 
And 2.). 
 
Familiarity a) Have you ever heard of or seen this product? 
01 – Yes 
02 – No 
03 – Don‘t know 
Appeal  
 
b) Would THIS product appeal to people your age? 
01 – Not at all 
02 – Unlikely 
03 – Undecided 
04 – Somewhat 




c) Would you be willing to try this product for any of the following 
reasons: 
f. In places where you can‘t smoke cigarettes?  
    (01-YES, 02-NO, 03-MAYBE) 
g. For the times when you don‘t want to smoke around others?  
    (01-YES, 02-NO, 03-MAYBE) 
h. To help you cut back the amount you smoke?  
    (01-YES, 02-NO, 03-MAYBE) 
i. To help you while you are trying to quit smoking? 
    (01-YES, 02-NO, 03-MAYBE) 
j. As a long-term replacement instead of cigarettes?  






d) Overall, how likely would you be to try THIS product in the future? 
01 – Definitely not 
02 – Probably not 
03 – Undecided 
04 – Probably try 







PROGRAMMER NOTE: For first four smokeless products... 
e) In your opinion, how HARMFUL TO HEALTH is this product… 
       a.  Compared to regular cigarettes 
d. Compared to other types of smokeless tobaccos 
e. Compared to nicotine replacement therapy (e.g., gum, patch, etc.) 
01 – A lot less harmful than (a. Cigarettes b. other smokeless tobaccos, c. 
nicotine replacement therapy) 
02 – Somewhat less harmful 
03 – No difference  
04 – Somewhat more harmful 
05 – A lot more harmful than (a. Cigarettes b. other smokeless tobaccos, c. 
nicotine replacement therapy) 
PROGRAMMER NOTE: For last four nicotine replacement therapy products... 
5. In your opinion, how HARMFUL TO HEALTH is this product… 
       a.  Compared to regular cigarettes 
f. Compared to other types of nicotine replacement therapies (e.g., 
gum, patch, etc.) 
b. Compared to smokeless tobacco 
01 – A lot less harmful than (a. cigarettes b. smokeless tobacco, c. other nicotine 
replacement therapies) 
02 – Somewhat less harmful 
03 – No difference  
04 – Somewhat more harmful 
f) 05 – A lot more harmful than (a. cigarettes b. smokeless tobacco, c. other 
nicotine replacement therapies) 
 
PROGRAMMER NOTE: Add a screen after the last question of EACH product (e.g., in between 
the last question of product 1 and the first question of product 2, after the last question of 
product 2 but before the first question of product 3, etc.) that states: “Here comes the next 
product. Please take a moment to look at it.” 








PROGRAMMER NOTE: Show the following script: 
Next, you will be asked some general questions about smokeless tobacco and nicotine 
replacement therapy (e.g. gum, patch, etc.). When answering, please think about smokeless 






(Bansai et al., 
2004) 
 
3. OVERALL, How addictive are smokeless tobacco products compared 
to cigarettes? 
4. OVERALL, How addictive are smokeless tobacco products compared 
to NRT? 
5. OVERALL, How addictive are NRTs compared to cigarettes? 
01 – A lot less addictive than (1. cigarettes, 2. NRT, 3. cigarettes) 
02 – A little less addictive 
03 – No difference 
04 – A little more addictive 








6. Do you think smokeless tobacco products should have picture health 
warnings similar to cigarette packages? 
01 – Disapprove Strongly 
02 – Disapprove 
03 – Undecided 
04 – Approve 
05 – Approve Strongly 
 
7. Are you interested in more information that compares the health risks 
of using smokeless tobacco to the health risks of smoking cigarettes? 
01 – Not at all 
02 – Probably not 
03 – Undecided 
04 – Somewhat 




















PROGRAMMER NOTE: Show the following script: 
That’s everything for today! Thank you very much for your participation. You will be receiving 
“MarketPoints” in appreciation of your time, according to the e-mail offer you received from 
GlobalTestMarket. Click continue to view a summary of the study details and our 
contact information should you have any questions. 
 
 
Department of Health Studies & Gerontology  University of Waterloo 
 Faculty of Applied Health Sciences             200 University Ave West 
Waterloo, ON, CANADA 
                                                                        N2L 3G1 
 
 
SMOKELESS LABELS STUDY - FEEDBACK LETTER 
 
We appreciate your participation in our study, and thank you for spending the time helping us 
with our research. 
 
As we mentioned earlier, we are interested in people’s opinions about smokeless tobacco. 
For the current study, we were particularly interested in the impact of having picture, text, or 
no warning labels on packages and how they affect product appeal, intentions to use the 
product, how the product might be used, as well as perceptions of health risk. We were also 
interested in the impact and support for a relative risk message about the health risk of 
smokeless tobacco compared to that of regular cigarettes. Different groups of participants 
were shown different forms of smokeless tobacco warning labels: whereas some participants 
were shown packages with no warning, others were shown packages with text or picture 
warnings. We will compare responses from the different groups to see whether the different 
forms of warning labels affect their ratings and opinions.  
 
As a reminder, all the information you provided during the survey will be kept strictly 
confidential. This project has been reviewed by, and received ethics clearance through the 
Office of Research Ethics at the University of Waterloo. Should you have any questions or 
concerns about your participation in this study, please contact myself or Dr. Susan Sykes, 
Director, Office of Research Ethics at the University of Waterloo, at 519-888-4567, Ext. 36005 
or by e-mail at ssykes@uwaterloo.ca. 
 
If you would like any further information about the study, including a copy of our findings when 
they become available, please contact us at the number below. Also, we would be happy to 
provide you with a list of smoking cessation resources, should you wish. 
 




      
William Callery    
Dept. of Health Studies 
University of Waterloo 
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